Pubmed abstracts for Protein-Protein Interaction search result :

Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.59763032
The overexpression of c erbB 2 has shown a significant association with estrogen receptor status ( those tumors expressing c erbB 2 are usually estrogen receptor negative ) , presence of fibrosis and lymphoplasmacytoid infiltrates . 0.59763032^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.63601603
RESULTS : Stable or transient or natural HER 2 overexpression in ER positive breast cancer cells promoted the nucleus to cytoplasm relocalization of ER , enhanced interactions of ER with HER 2 , inhibited ER transactivation function , and induced resistance to tamoxifen mediated growth inhibition of breast cancer cells . 0.63601603^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Low grade breast cancers i . e . mucinous ( 17 cases 3 . 2 % ) , tubular ( 7 cases 1 . 3 % ) and invasive cribriform carcinomas ( 3 cases 0 . 5 % ) have been identified within a series of 524 breast cancers only by histotyping in hematoxylin eosin stained sections : the reactivities of immunohistochemical prognosticators as estrogen / progesterone receptors ( ER , PgR ) , growth fraction ( GF : Ki 67 ) , p 53 and c erbB 2 oncoproteins are in agreement with clinical behaviours . ^^^ Medullary carcinoma ( 13 cases 3 . 4 % ) has a paradoxical behaviour displaying a favourable clinical prognosis together with high grading and GF , absence of ER , PgR , high p 53 and c erbB 2 values , as compared with invasive ductal carcinomas : an extensive tissue immune response as suggested by a heavy lymphocyte infiltration may explain this behaviour . ^^^ Invasive lobular carcinoma ( 62 11 . 6 % ) shows an intermediate immunohistochemical pattern , paralleling an intermediate prognosis , when compared with low and high grade carcinomas : ER , PgR and GF positivities are nearly the same as in ductal carcinomas whereas grading , p 53 and c erbB 2 are less expressed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Coexpression of c erbB 2 reduced the response rate of ER positive patients from 48 % to 20 % and of ER negative cases from 27 % to 0 % ( P less than 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this investigation , 83 human mammary carcinomas were examined for the expression of oestrogen receptor ( ER ) , epidermal growth factor receptor ( EGF R ) , epidermal growth factor ( EGF ) , transforming growth factor alpha ( TGF alpha ) , c erbB 2 , histological grade , mitotic index and nodal status , all of which are reportedly prognostically significant factors ( Bloom and Richardson 1957 ; Baak et al . 1985 ; Wright et al . 1989 ) . ^^^ ER expression was biochemically recognized in 43 . 4 % of mammary carcinomas , and EGF R , EGF , TGF alpha and c erbB 2 were histochemically recognized in 25 . 3 , 14 . 5 , 27 . 7 and 18 . 0 % of mammary carcinomas examined respectively , using conventional sections of buffered formalin fixed , paraffin embedded tissue and monoclonal or polyclonal antibodies . ^^^ There were significant relationships between negative ER and positive EGF R or TGF alpha ; positive EGF R and TGF alpha ; positive EGF R and c erbB 2 ; and positive c erbB 2 and TGF alpha . ^^^ The single changes which were the negative ER and the positive c erbB 2 correlated with histological grade and mitotic index . ^^^ Therefore , the present investigation indicates that the negative ER , single expression of c erbB 2 and co expression of EGF R and TGF alpha are important markers which contribute indirectly to prognosis , which reconfirms previous findings on the former two while adding the new finding that immunohistochemical demonstration of expression of EGF R and TGF alpha may provide useful information for selecting the appropriate treatment . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In 42 invasive breast carcinomas , the expression of c myc , c erbB 2 , and Ki 67 proliferation marker were compared with lymph node status , estrogen receptor status , progesterone receptor status , and age of patients at diagnosis . c erbB 2 overexpression and Ki 67 overexpression were identified as the only factors associated with lymph node status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : High level p 53 protein overexpression , found in 41 of the 289 tumors , was most common in tumors with high histologic grade , negative estrogen receptor status , c erbB 2 protein overexpression , DNA index greater than 1 . 3 , or high S phase fraction . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We have previously reported that estrogens inhibit c erbB 2 expression at both the mRNA and protein level in estrogen receptor ( ER ) positive , but not in ER negative , breast cancer cell lines . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor , c erbB 2 and nm23 / NDP kinase expression in the intraductal and invasive components of human breast cancers . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This study showed a trend for an inverse relationship between c erbB 2 positive tumours and estrogen receptors ( ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor status and the expression of cancer associated antigens recognized by antibodies DF 3 , B73 . 2 , SP 1 , and c erbB 2 were compared to matched tumors from females . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , estrogen has been found to inhibit the expression of c erbB 2 through ER in breast cancer cell lines . ^^^ Thus patients with gastric cancers whose tumors were positive for both ER and c erbB 2 gene expression , may benefit from estrogen therapy rather than tamoxifen therapy . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
C erbB 2 and ras expression both correlated with ER levels and EGFR , but not with the Prognostic Index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The relationship between c erbB 2 gene expression ( assessed immunohistochemically ) , S phase fraction ( SPF ) and prognosis has been analysed in 172 women with primary breast cancer . c erbB 2 staining was independent of age , tumour size , number of nodes involved , tumour grade and DNA ploidy , but was more common in oestrogen receptor ( ER ) negative tumours ( P = 0 . 02 ) and progesterone receptor ( PgR ) negative tumours ( P = 0 . 03 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All patients had involvement of axillary lymph nodes and all were randomised onto one of the Ludwig Breast Cancer Trials 1 4 between July 1978 and August 1981 . c erbB 2 overexpression significantly correlated with high S phase fraction , four or more positive axillary nodes involved , estrogen receptor negative primaries , progesterone receptor negative primaries , high grade tumours and DNA aneuploidy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In breast cancer we studied the distribution of immunohistochemical positivity for EGFR , c erbB 2 , c myc , ras p 21 and Ki 67 , which was related to age , nodal status , ER and PgR receptor status , LI , DI and histopathological grading . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Prognostic significance of c erbB 2 and estrogen receptor status in human breast cancer . ^^^ There was no significant relationship between c erbB 2 positivity and ( a ) age at diagnosis , ( b ) menopausal status , ( c ) tumor size , ( d ) lymph node status , ( e ) estrogen receptor status , or ( f ) whether or not the patient had disseminated disease outside the axillary fields . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no significant correlation between expression of c erbB 2 oncoprotein and conventional prognostic factors , estrogen receptor ( ER ) , axillary lymph node metastasis and epidermal growth factor receptor ( EGFR ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The nuclear p 53 immunoreaction was closely associated with overexpression of c erbB 2 protein ( P less than 0 . 05 ) , high histologic grade ( P less than 0 . 01 ) , advanced clinical stage ( P less than 0 . 05 ) , and negative estrogen receptor status ( P less than 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Epidermal growth factor receptors ( EGFr ) and oestrogen receptors ( ER ) measured by ligand binding , c erbB 2 expression assessed by immunochemistry and lymph node status were compared with p 53 staining . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Surprisingly , c erbB 2 expression in the tamoxifen treated group was significantly diminished in the ER ( P = 0 . 02 ) and PR ( P = 0 . 01 ) populations . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Determination of c erbB 2 mRNA levels in the same series of tumours showed that high expression of c erbB 2 mRNA is significantly correlated with ER , inflammatory tumours and with lymph nodes involvement . ^^^ Moreover , a multivariate analysis showed that c erbB 2 mRNA overexpression was a significant predictor of early relapse ( P = 0 . 02 ) , as significant as ER negativity and ER+ ( R 2 ) . ^^^ However , in the case of ER patients , early relapses were strongly correlated with c erbB 2 overexpression . ^^^ The counterpart of this observation is that ER patients with no overexpression of c erbB 2 constitute a group with a relatively good prognosis . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical expression of c erbB 2 in human breast cancer by monoclonal antibody : correlation with lymph node and ER status . c erbB 2 Protein expression was investigated in a series of fifty primary breast cancers by means of a specific monoclonal antibody and immunocytochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An analysis by estrogen receptor ( ER ) status ( i . e . positive or negative ) and by c erbB 2 expression ( i . e . positive or negative ) revealed that patients with ER positive primaries and negative c erbB 2 have the longest disease free survival ( DFS ) and overall survival ( OS ) . ^^^ We conclude that c erbB 2 expression might be clinically useful only if other prognostic variables ( e . g . estrogen receptor content in the tumor ) are also considered . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a non parametric test ( Kruskal Wallis ) a strong negative association was found between high levels of c erbB 2 amplification and absence of estrogen receptor ( ER ) ( P = . 0009 ) or progesterone receptor ( PR ) ( P = . 011 ) expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
As factors regulating growth and differentiation of cervical squamous epithelium , immunohistochemical expression of estrogen receptor ( ER ) , progesterone receptor ( PR ) , epidermal growth factor receptor ( EGFR ) , c erbB 2 protein , adult T cell leukemia derived factor ( ADF ) , and HPV DNA was examined . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of the gene coding for a new breast tumor associated antigen , H 23 , was compared to expression of genes coding for pS 2 , c erbB 2 and estrogen receptor ( ER ) . ^^^ It is expressed in 92 % of breast tumors whereas 69 % , 62 % and 56 % of breast tumors demonstrate significant mRNA levels of c erbB 2 , ER and pS 2 , respectively . ^^^ Expression of genes coding for pS 2 , c erbB 2 , estrogen receptor and the H 23 breast tumor associated antigen . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Amplification of c erbB 2 was strongly correlated to the absence of either estrogen ( ER , P = 0 . 003 ) or progesterone ( PR , P = 0 . 004 ) receptors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This study was aimed at elucidating the immunohistochemical localization of oncogene products which are related to cell growth , c erbB 2 product , epidermal growth factor receptor ( EGFR ) , c myc protein and estrogen receptor ( ER ) , in benign and malignant lesions of the breast . ^^^ C erbB 2 product and EGFR were localized on the cell membrane whereas c myc protein and ER were observed in the nuclei . ^^^ In breast cancers , the incidence of immunoreactivity for c erbB 2 was higher in the cases with lymph node metastasis than cases without nodal metastasis ( p less than 0 . 05 ) and there was reciprocal correlation between the expressions of EGFR and ER ( p less than 0 . 05 ) . ^^^ Regarding the size of the primary tumour , there was no statistically significant correlation with the expressions of c erbB 2 , EGFR , c myc or ER . ^^^ Immunohistochemical studies on oncogene products ( c erbB 2 , EGFR , c myc ) and estrogen receptor in benign and malignant breast lesions . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We could also detect the c erbB 2 immunoreactivity in the cytosols prepared from the breast tumor tissue for estrogen and progesterone receptor ( ER & PgR ) measurements using the same commercial kit for serum studies , and the intact c erbB 2 oncoprotein ( p 185 ) in the extracts of the tissue membrane fractions with a different kit designed for tissue extract . ^^^ Most of the elevated cytosol c erbB 2 immunoreactivities were also found to associate with breast tumor specimens containing low concentrations of ER & PgR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Quantification of oestrogen receptor ( ER ) , epidermal growth factor receptor ( EGFR ) , c erbB 2 receptor levels and ploidy were examined on the total and cytokeratin positive cell populations . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A c erbB 2 expression vector was transfected into the estrogen receptor positive ( ER+ ) MCF 7 human breast cancer cell line to determine if overexpression of this transmembrane tyrosine kinase could increase the malignant phenotype of this cell line . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no significant difference between the two groups in age , clinical stage , lymph node status , estrogen receptor status , operation method or c erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The authors studied a consecutive series of 40 cases of DCIS and after its histologic categorization verified its relationship with ploidy using image analysis and analyzing estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 and c erbB 2 expression using immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a multivariate analysis including axillary lymph node status , histological grade , tumour size , ER status , c erbB 2 score , EGF ratio and hormonal treatment , c erbB 2 overexpression was the most powerful parameter ( P = 0 . 001 ) followed by EGF R overexpression ( P = 0 . 02 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PDGF B expression was analyzed with respect to the expression of the proliferating cell nuclear antigen , as well as tumor grade , p 53 overexpression , estrogen receptor , progesterone receptor , and c erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The responsiveness of estrogen receptor ( ER ) positive breast cancer to endocrine therapy is frequently reduced in cells over expressing c erbB 2 . ^^^ Stimulation of ER suppresses c erbB 2 , indicating that estrogen controls the activity of c erbB 2 . ^^^ Here we describe the effects of HRG on cell growth and on ER and c erbB 2 expression in breast cancer cell lines containing distinct levels of c erbB 2 and ER ( BT 474 : c erbB 2 , ER+ ; MDA MB 361 : c erbB 2++ , ER++ ; MCF 7 : c erbB 2+ , ER ) . ^^^ Proliferation of estrogen stimulated , c erbB 2 and ER positive cells is inhibited by HRG in a dose dependent manner . ^^^ The intensity of the mutual inhibition between the HRG / c erbB 2 and the estrogen / ER system depends on the relative levels of ER and c erbB 2 expression in the respective cell lines . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PATIENTS AND METHODS : Immunohistochemistry with antibodies recognizing ER , PGR , Ki 67 , and the p 53 , c erbB 2 , and bcl 2 encoded proteins was performed on 291 primary breast carcinomas . ^^^ RESULTS : P 53 , c erbB 2 , and bcl 2 gene products were detected , respectively , in 30 . 6 % , 31 . 6 % , and 85 . 9 % of the examined invasive breast carcinomas , revealing variable associations with cellular differentiation and proliferation as defined by ER / PGR status , Ki 67 , tumour mass and histologic and nuclear grading . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER negativity was significantly correlated with the expression of p 53 , epidermal growth factor receptor ( EGFR ) and c erbB 2 ( p < 0 . 05 each ) . ^^^ Thus , it was concluded that ER positive breast carcinomas , relatively small in size , preferentially expressed HSP 27 , HSP 70 and pS 2 and that ER negative tumors , relatively large in size , were predisposed to express p 53 , EGFR and c erbB 2 . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Epidermal growth factor receptor expression in breast cancer : association with response to endocrine therapy . 106 previously untreated breast cancer patients have been immunohistochemically analysed for EGF R , ER , Ki 67 , and c erbB 2 product . ^^^ The presence of c erbB 2 protein product did not influence endocrine sensitivity in any of the ER / EGF R sub groups . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We investigated the relation of c erbB 2 and int 2 gene amplification , expression , ER and EGFR with clinical characteristics . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
According to a Cox multivariate analysis for disease free survival , the two stronger factors in predicting a poor prognosis were c erbB 2 overexpression and ER . ^^^ Estrogen receptor , pS 2 , and c erbB 2 mRNA were measured by Northern blot analysis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A relationship of borderline significance was observed between c erbB 2 protein overexpression and negative or low estrogen receptor ( ER ) content . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The result of c erbB 2 gene amplification , overexpression , and ErbB 2 protein levels were significantly correlated with negative estrogen receptor ( ER ) and progesterone receptor ( PgR ) status in tissue cytosol fraction . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry showed that 81 % of the tumors were estrogen receptor positive and 73 % progesterone receptor positive . p 53 protein and c erbB 2 oncoprotein expression was identified in 40 % and 57 % of the cases , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A significant correlation was observed between tissue c erbB 2 protein concentration and estrogen receptor status or immunohistochemical determination . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The authors studied the role of 70 Kd heat shock protein ( HSP 70 ) in the progression of breast cancer by examining the correlation between the expression of HSP 70 and epidermal growth factor receptor , c erbB 2 , p 53 , and estrogen receptor in 124 cases of invasive primary human breast cancers . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of transforming growth factor alpha ( TGF alpha ) , epidermal growth factor receptor ( EGF R ) and oncogenes c erbB 2 , c H ras , c myc , as well as estrogen ( ER ) and progesterone ( PR ) receptors were studied immunohistochemically in the tissue of 21 benign and 58 malignant human breast lesions . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Overexpression of c erbB 2 was significantly more frequent in DNA aneuploid tumors than in DNA diploid ones and correlated with increasing S phase fraction and estrogen receptor negativity . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , high ER mRNA levels were associated with absence or minimal necrosis and vascular invasion together with absence or minimal level of tumor lymphocytic infiltration , but not with age , clinical stage , tumor size or overexpression of c myc or c erbB 2 mRNA . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of epidermal growth factor receptor ( EGF R ) , c erbB 2 proto oncogene , and estrogen receptor ( ER ) was studied immunohistochemically in a series of 97 human papillomavirus ( HPV ) lesions of the uterine cervix , with special emphasis on their association with the HPV type , grade of intraepithelial neoplasia ( CIN ) , and the natural history of the disease . ^^^ No clear cut associations were established between the EGF R , c erbB 2 , or ER expression and HPV type , nor in CIN or the clinical course of HPV infections . ^^^ This failure for EGF R , c erbB 2 , and ER to be associated with the specific HPV types , grade of CIN , or the clinical course of cervical HPV lesions suggests that the assessment of these factors is of limited value in explaining the development of HPV associated CIN and in predicting the prognosis of this disease . . ^^^ Epidermal growth factor receptor , c erbB 2 proto oncogene and estrogen receptor expression in human papillomavirus lesions of the uterine cervix . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was also a significant correlation between c erbB 2 staining and higher nuclear grade and estrogen receptor negativity . ^^^ According to this analysis , the strong correlation between c erbB 2 expression and degree of nodal involvement , higher grade disease , and estrogen receptor negativity suggests expression of this protooncogene product in a biologically more aggressive form of breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The authors studied 30 consecutive archival cases of pure breast carcinoma in situ ( CIS ) for estrogen receptor ( ER ) , progesterone receptor ( PR ) , and c erbB 2 oncogene product . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Significant associations of positive tumour ER immunoreactivity and non comedo architecture chi 2 = 6 . 76 ; ( d . f . = 1 ) : P < 0 . 001 , small cell size chi 2 = 4 . 49 ; ( d . f . = 1 ) : P = 0 . 034 , higher S phase fraction chi 2 = 4 . 71 ; ( d . f . = 1 ) : P = 0 . 03 and lack of c erbB 2 protein overexpression chi 2 = 7 . 96 ; ( d . f . = 1 ) : P < 0 . 01 were identified . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of c erbB 2 was positively correlated with a number of parameters analysed : ductal type , intraductal growth pattern , high tumour grade , density of tumour infiltrating lymphocytes ( TIL ) , DNA aneuploidy , steroid ( ER , PR ) receptor negativity , high S phase fraction , high mitotic frequency , high values of nuclear factors , and accumulation of p 53 protein . c erbB 2 expression showed a weak association with a low survival probability ( p = 0 . 07 ) and with a short recurrence free survival ( p = 0 . 1 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , expression of EGFR in addition to c erbB 2 protein was more frequently observed with advancing stage of disease and was inversely correlated with the grade of differentiation and with the expression of ER or PR of the tumor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The stimulation of tumour growth by oestradiol was always accompanied by a down regulation of c erbB 2 protein both in the ER positive mammary carcinomas and in the ER negative mammary carcinoma 4151 ES . ^^^ The inhibition of tumour growth by tamoxifen was correlated with a reversion of the oestradiol induced down regulation of c erbB 2 , also in the ER negative / oestradiol responsive mammary carcinoma 4151 ES . ^^^ From our results we hypothesize that the oestrogen dependent growth of ER negative breast carcinoma 4151 ES could also be correlated with the oestradiol regulated expression of c erbB 2 protein . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to investigate the prognostic significance of c erbB 2 , estrogen receptors ( ER ) and progesterone receptors ( PgR ) , an immunohistochemical staining was performed on 330 tissue sections from paraffin blocks of 50 fibrocystic diseases and 40 ductal adenocarcinomas N . ^^^ The positivity for c erbB 2 was considered only in the cytoplasmic membrane , while for ER and PgR in the nucleus of epithelial cells . ^^^ Our results suggest that c erbB 2 , ER and PgR , especially when combined with clinicopathological parameters , may show some prognostic usefulness in breast disease . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study , MT expression was examined immunohistochemically in 92 cases of invasive breast carcinoma and compared with immunohistochemically demonstrated estrogen receptor ( ER ) , c erbB 2 , Ki 67 status and clinicopathological characteristics . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To study changes induced by tamoxifen , core biopsies before treatment and surgical specimens after hormonal therapy were assayed by immunohistochemistry for oestrogen ( ER ) and progesterone receptors ( PR ) , pS 2 , GSTpi and c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Oncoproteins and tumor progression in papillary thyroid carcinoma : presence of epidermal growth factor receptor , c erbB 2 protein , estrogen receptor related protein , p 21 ras protein , and proliferation indicators in relation to tumor recurrences and patient survival . ^^^ Immunohistochemical expression of c erbB 2 protein , estrogen receptor related protein ( p 29 ) , which may be regarded as an indicator of hormone dependent growth , S phase , G2M phase , sex , age , histologic grade , and primary tumor extent were all of significant prognostic importance in univariate analyses of patient survival . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The latter included high tumor stage , lymph nodal involvement , high growth fraction ( as determined by labeling with the MoAb Ki 67 ) , negative results for estrogen receptor ( ER ) and progesterone receptor ( PR ) proteins , and amplification of the c erbB 2 oncogene product in the neoplastic cells . ^^^ Ninety nine of 640 ( 15 . 5 % ) cases of high grade , invasive , ductal breast carcinoma , however , showed an inverse relationship between expression of p 53 protein and positive results for ER / PR proteins and a direct correlation with large tumor size , Ki 67 determined growth fraction , and amplification of c erbB 2 oncopeptide . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tests for estrogen ( ER ) and progesterone ( PR ) receptors , c erbB 2 , p 53 and Bcl 2 were made on paraffin sections of thirty three cases of invasive micropapillary carcinoma ( MPCa ) of the breast . ^^^ Accordingly , ER ( 72 . 7 % ) , PR ( 45 . 4 % ) and Bcl 2 ( 69 . 6 % ) were directly interrelated and inversely related with nuclear grade , mitotic grade , c erbB 2 ( 36 . 3 % ) and p 53 ( 12 . 1 % ) . ^^^ The lack of discriminative power between MPCa and NOSCa of ER , PR , c erbB 2 , p 53 , and Bcl 2 reinforces the importance of recognizing this particular type of cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
By contrast , significantly higher c erbB 2 serum levels were found in ER or PgR tumors than in those ER+ or PgR+ tumors , in both locoregional or metastatic tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Univariate analysis shows that loss of bc 1 2 expression , nuclear accumulation of p 53 , overexpression of c erbB 2 , age at diagnosis , menstrual status , tumor size , histologic grade , number of lymph nodes involved , and estrogen receptor were all significantly associated with the survival rates . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of c erbB 2 oncoprotein , epidermal growth factor receptor ( EGFR ) and estrogen receptor ( ER ) was evaluated by the immunoperoxidase technique ( PAP ) in ductal breast carcinomas . ^^^ Stratifying of patients on the basis of c erbB 2 , EGFR and ER status indicated that the combination of c erbB 2 overexpression accompanied by high EGFR value and undetectable ER , identified poorly differentiated tumors and patients with high incidence of axillary lymph node metastases , while high EGFR expression and negative c erbB 2 staining was connected only with poor tumor grade . ^^^ Our results indicate that the comparison of c erbB 2 , EGFR and ER status seems to be a powerful tool in discriminating breast carcinomas with different biological phenotypes . . ^^^ Relationship between c erbB 2 oncoprotein , epidermal growth factor receptor , and estrogen receptor expression in patients with ductal breast carcinoma . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to obtain prognostic clinicopathological information , 49 cases of pure ductal carcinoma in situ of the breast ( DCIS ) , were evaluated for the immunohistochemical expression of potential predictor markers including c erbB 2 oncogene product , p 53 protein , oestrogen ( ER ) and progesterone ( PR ) receptors , oestrogen regulated proteins pS 2 and cathepsin D ( cath D ) , CD 44 protein and 67 kDa laminin receptor ( MLuC 5 ) . ^^^ When markers were matched to each other , statistical analyses provided a significant positive correlation between c erbB 2 overexpression and p 53 positivity ( P < 0 . 01 ) and between ER and PR ( P < 0 . 01 ) , ER , PR and pS 2 ( P < 0 . 01 ) , pS 2 and MLuC 5 ( P < 0 . 05 ) . ^^^ Significant negative correlations between c erbB 2 overexpression and ER ( P < 0 . 05 ) , PR ( P < 0 . 01 ) and pS 2 ( P < 0 . 01 ) positivity was also observed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of PRL , p 53 , nm 23 , and c erbB 2 was investigated by immunohistochemical ( IHC ) localization ; cathepsin D ( CD , Enzyme Linked Sorbant Assay ) and estrogen and progesterone receptors ( ER and PR , Dextran coated charcoal method ) were estimated in the tumor cytosols . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
By immunohistochemistry ( IHC ) , we studied tumour expression of ER , PR , pS 2 , c erbB 2 and glutathione S transferase pi ( GST pi ) on initial core biopsies of 208 post menopausal patients with a non metastatic invasive ductal carcinoma , treated by neoadjuvant tamoxifen therapy . ^^^ Relationship between response and age , tumour size , T , N , histological grade , ER and PR contents evaluated by radioimmunoassay , ER , PR , pS 2 , c erbB 2 and GST pi expression evaluated by IHC were studied . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , the overexpression of p 53 protein , c erbB 2 oncoprotein and estrogen receptor ( ER ) were immunohistochemically examined in order to discuss the relationship with histological subtype and histological grade . ^^^ High grade carcinoma demonstrated c erbB 2 more frequently and exhibited a low incidence of ER . ^^^ Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU : an immunohistochemical study including correlations with p 53 , c erbB 2 and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : As of November 30 , 1994 , the median follow up period was 12 years . c erbB 2 was overexpressed in 43 of 145 patients ( 29 . 7 % ) , which directly correlated with tumor size and inversely with estrogen receptor ( ER ) level . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
C erbB 2 oncoprotein concentrations were positively correlated with ER , pS 2 protein and cathepsin D . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The pattern and extent of reactivity has been correlated with clinicopathological data including tumour type , grade and lymph node status and with other prognostic parameters including oestrogen receptor ( ER ) status , expression of c erbB 2 , pS 2 protein and epidermal growth factor receptor ( EGFR ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The growth fraction ( MIB 1 ) , oestrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 mutant protein , c erbB 2 , epidermal growth factor receptor ( EGFR ) , NCRC11 / epithelial membrane antigen ( EMA ) and DNA plopidy were examined . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Overexpression of p 53 and c erbB 2 oncoprotein , presence of estrogen receptor ( ER ) and cellular localization of multidrug resistance gene product P glycoprotein ( P gp ) were immunohistochemically examined to investigate the relation with the proliferative activity and clinicopathologic characteristics . ^^^ Correlation with expression of p 53 , c erbB 2 , estrogen receptor and P glycoprotein . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Ki 67 labelling index , estrogen receptor ( ER ) , progesterone receptor ( PgR ) , and c erbB 2 oncoprotein expression were evaluated immunohistochemically in tumour biopsies obtained before and after chemotherapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was a strongly negative association between c erbB 2 protein overexpression and estrogen receptor status ( p < 0 . 001 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , the association of these proliferation markers with overexpression of p 53 protein , c erbB 2 oncoprotein , estrogen receptor ( ER ) status and clinicopathologic findings were also examined . ^^^ Proliferation marker MIB 1 correlates well with proliferative activity evaluated by BrdU in breast cancer : an immunohistochemical study including correlation with PCNA , p 53 , c erbB 2 and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this report , we investigate the association of altered cyclin expression with other prognostic indicators ( histological grade , lymph node status , estrogen receptor , p 53 , and c erbB 2 ) in the progression of human breast cancer . ^^^ The expression diversity and distribution of the localization of the protein products of the c erbB 2 , cyclins D 1 and D 3 , p 53 , and estrogen receptor were characterized immunohistochemically and the results in the original tumor ( T 0 ) were compared with those in the tumors that developed in nude mice ( T 1 ) xenografts . ^^^ In the T 1 tumors , both cyclins D 1 and D 3 , estrogen receptor , and p 53 were observed in 49 % to 86 % of the cells of the T 1 tumors examined ; the number of cells expressing c erbB 2 protein varied widely in these tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
On the same specimens steroid hormone receptors ( ER and PR ) were measured in the cytosol fraction using Abbott ELIZA assays , c erbB 2 and EGFR were determined in the membrane fraction and mutant p 53 protein in the nuclear fraction by Oncogene Science ELISA procedures . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Prior to BRCA 1 analysis , 79 breast and 19 ovarian tumours from 57 breast and breast ovarian cancer families , and 170 tumours from a comparison group of stage 2 breast cancers were studied with regard to histopathological features ; immunohistochemistry [ c erbB 2 , p 53 , oestrogen receptor ( ER ) and progesterone receptor ( PR ) ] , DNA flow cytometry and S phase fraction . ^^^ Additionally , as compared to BRCA 1 negative tumours , the BRCA 1 positive tumours were significantly more often ER , PgR and c erbB 2 negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The parameters studied were tumour size , histologic grade , nodal status , proliferative index ( with MIB 1 ) , ER expression , ploidy , c erbB 2 and p 53 expression . ^^^ The expression of STn was associated with axillary node metastasis , ER negativity and c erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
On examining the breast tumours , alpha JSB 1 showed a positive association with c erbB 2 ( P = 0 . 003 ) , c myc ( P = 0 . 0004 ) and c jun ( P = 0 . 02 ) but not ER or EGF R expression . alpha GSTpi showed a positive association with c erbB 2 ( P = 0 . 03 ) and c myc ( P = 0 . 0004 ) but not ER , EGF R or c jun . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The metastatic lesion showed positive expression of c erbB 2 , CD44E , AMFR , PR and ER expression , whereas no expression of MT MMP was detected . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
EMS 1 amplification ( > or = twofold increase in copy number ) was positively correlated with patient age > or = 50 years ( P = 0 . 025 ) , ER positivity ( P = 0 . 022 ) , PgR positivity ( P = 0 . 018 ) , and was negatively correlated with HER 2 / neu ( c erbB 2 ) amplification ( P = 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of bcl 2 , p 53 and c erbB 2 proteins in the primary tumors was examined immunohistochemically and their prognostic roles were also analyzed along with conventional clinicopathologic indicators . bcl 2 expression was correlated with positive estrogen receptor status and inversely correlated with p 53 , c erbB 2 and histologic grade . ^^^ Univariate analysis showed that bcl 2 , p 53 and c erbB 2 expression were prognostic indicators of the patient ' s group as well as node status , histologic grade , tumor size , age at diagnosis , menopausal status and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : We analyzed the medical records of 100 patients using univariate and multivariate analyses of nine factors as follows ; age , tumor size , nodal status , estrogen receptor , C erbB 2 , p 53 , microvessel density , DNA ploidy pattern , and S phase fraction . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In relation to lymph node involvement or estrogen receptor status , a significant difference in overall survival between the c erbB 2 positive and negative groups was found in patients with lymph node metastasis or in those with estrogen receptor negative tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We studied tumors from premenopausal patients with node negative breast cancer randomized in this trial to determine whether p 53 accumulation , c erbB 2 expression , percentage of Ki 67 positive cells , estrogen receptor ( ER immunoassay [ IA ] ) , progesterone receptor ( PR IA ) , and angiogenesis could be used as prognostic factors and predictors of responsiveness to adjuvant chemotherapy . ^^^ Paraffin sections from the tumors were analyzed for immunohistochemical expression of p 53 , c erbB 2 , Ki 67 , ER , PR , and angiogenesis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An investigation of the effects of phenotypic expression of estrogen receptors ( ER ) , the progesterone receptors , c erbB 2 oncoprotein and epidermal growth factor receptors ( EGFR ) on the capacity of HMEC cells to grow in vitro as monolayers showed that expression of ER and EGFR is required for controlling tumor proliferative activity in vitro . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunostaining of estrogen receptor , progesterone receptor , MIB 1 antigen , and c erbB 2 oncoprotein in cytologic specimens : a simplified method with formalin fixation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No association was found between angiogenesis and tumour size , histologic grade , estrogen receptor , MIB 1 index , ploidy and expression of p 53 and c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
On the same specimens steroid hormone receptors ( ER and PR ) were measured in cytosol fraction using Abbott ELIZA assays , c erbB 2 and EGFR were determined in the tissue homogenate and mutant p 53 protein in the nuclear fraction by Oncogene Science ELISA procedures . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BACKGROUND : The association between p 53 and c erbB 2 overexpression relation to ER status in ductal breast carcinoma is still unclear . ^^^ Our aim was investigate the prognostic importance of the overexpression of c erbB 2 , p 53 factor , and ER status in stage 2 of human ductal breast cancer . ^^^ Stratifying patients on the basis of c erbB 2 , p 53 and ER status revealed that the combination c erbB 2 and p 53 overexpression accompanied by undetectable ER , identified the population of poorly differentiated tumors and patients with a high incidence of axillary lymph node metastases and shorter relapse time . ^^^ CONCLUSIONS : Estimation of c erbB 2 , p 53 and ER status seems to be a powerful tool to discriminate between different phenotypes of breast carcinoma . c erbB 2 and p 53 oncoproteins have been recognized as independent molecular markers of aggressive tumor behaviour . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The predictive value of Topo IIalpha expression , c erbB 2 oncoprotein , p 53 tumour suppressor protein , oestrogen ( ER ) and progesterone receptor ( PR ) , S phase fraction and DNA ploidy were analysed from representative formalin fixed paraffin embedded primary tumour samples . ^^^ Although both negative ER status and c erbB 2 overexpression are associated with high Topo IIalpha expression in breast cancer , step wise logistic regression analysis showed that ER and c erbB 2 were associated with therapy response independent of Topo IIalpha expression . ^^^ Among the prognostic biomarkers , overexpression of c erbB 2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The up regulation of AGT was not directly linked to the expression of cyclins D 1 and D 3 , estrogen receptor , p 53 and c erbB 2 , genes involved in cell cycle regulation and tumor growth . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin sections of the CNB and excision specimens were immunostained for bcl 2 , estrogen receptor ( ER ) , c erbB 2 , and p 53 . ^^^ Immunostaining results for bcl 2 , ER , c erbB 2 , and p 53 on the CNB and the corresponding excision specimens were 100 % concordant . ^^^ In conclusion , in all of the cases studied , accurate results for the dichotomously scored markers bcl 2 , ER , c erbB 2 , and p 53 were obtained on CNB specimens . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , there was an inverse correlation in the group of stages 1 3 plus 4 breast cancer between c erbB 2 protein expression and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The upregulation of 8 oxo dGTPase was not directly linked to the expression of cyclins D 1 and D 3 , estrogen receptor , p 53 , Ki 67 and c erbB 2 , which are genes involved in cell cycle regulation and tumor growth . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A significant relationship ( p < 0 . 05 ) was observed between strong immunoreactivity of p 53 protein and absence of estrogen receptor , histological grade and c erbB 2 but not with lymph node metastases or age of patient . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We also surveyed the immunohistological distribution of cathepsin B , carcinoembryonic antigen , gross cystic disease fluid protein 15 , c erbB 2 , and estrogen receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Most of the IPC cases had low or intermediate nuclear grade , no necrosis , strongly expressed estrogen receptor , and was negative for c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
VLA 2 significantly correlated with ELAM , VCAM , VLA 3 and P glycoprotein ( P gp ) ( P < 0 . 01 ) and inversely correlated with cathepsin D ( P < 0 . 001 ) , but was independent of Ki67 / MIB1 , p 53 , bcl 2 , c erbB 2 , E cadherin , CD44v , CD 31 , oestrogen and progesterone receptors ' ( ER , PR ) antigenic sites and pS 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The prognostic significance of different factors ( ie , nodal status [ one to three 5 > three positive nodes ] , menopausal status [ pre 5 postmenopausal women ] , estrogen receptor [ ER ] status [ ER+ 5 ER ] , and pre and postchemotherapy c erbB 2 levels ) in predicting DFS was determined in all study patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In 74 in situ breast cancers an immunohistochemical study for estrogen ( ER ) and progesterone ( PR ) receptors , proliferation index ( PI ) , and c erbB 2 , p 53 , and bcl 2 overexpression was performed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , high bcl 2 expression has been shown to associate with a number of favorable prognostic factors including ER positivity , PgR positivity , low histological grade , well differentiated tumor , absence of c erbB 2 and p 53 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Significant associations were found between c erbB 2 values and oestrogen receptor ( ER ) ( P = 0 . 01 ) , progesterone receptor ( PgR ) ( P = 0 . 0001 ) and histological grading ( P = 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Ploidy and cell cycle were also studied by flow cytometry using propidium iodide labelling . p 53 , c erbB 2 and estrogen receptor expression as well as cell proliferation by Ki 67 staining were performed by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No significant differences were observed in the estrogen ( ER ) or progesterone receptor content , c erbB 2 oncogene overexpression , or axillary node involvement . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In 103 evaluable patients we performed a multivariate analysis of the tumour biological factors , i . e . histological grade , oestrogen receptor ( ER ) , progesterone receptor ( PR ) , S phase fraction ( SPF ) , ploidy , p 53 , c erbB 2 , Bcl 2 and Bax expression , which showed significance in the univariate analysis according to treatment response , time to progression ( TTP ) or overall survival ( OS ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fine needle aspiration was used to obtain samples from patients prior to therapy , and the following parameters were assessed : estrogen receptor ( ER ) , progesterone receptor ( PgR ) , p 53 , Ki 67 , Bcl 2 , and c erbB 2 measured by immunocytochemistry , and ploidy and S phase fraction ( SPF ) by flow cytometry . ^^^ Response rates for other parameters were as follows : ER positive , 82 % , and negative , 70 % ; PgR positive , 86 % , and negative , 71 % ; p 53 positive , 74 % , and negative , 81 % ; Bcl 2 positive , 85 % , and negative 61 % ; c erbB 2 positive , 57 % , and negative , 93 % ; Ki 67 high , 77 % , and low , 81 % ; SPF high , 77 % , and low , 77 % ; aneuploid , 71 % ; and diploid , 85 % . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Most of the cancer cell TN ( + ) / stromal TN ( + ) cases were c erbB 2 positive and estrogen receptor negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Moreover , in order to evaluate the significance of TP expression in mammary carcinomas , the relationship between vascular density and various clinicopathological factors , including age and menopausal status of patients with a mammary carcinoma , were compared with the size , nodal status , expression of estrogen receptor ( ER ) , progesterone receptor ( PgR ) , c erbB 2 , p 53 and TP of a mammary carcinoma . ^^^ In mammary tumors of 1 4 cm diameter , TP expression and vessel density were significantly high in tumors negative for ER or positive for c erbB 2 and in tumors positive for TP or c erbB 2 , respectively ; whereas tumors of 5 6 cm in diameter were not modified by any clinicopathological factors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
AIM : This study ( 1 ) investigates the incidence of bcl 2 protein expression in a series of 108 cases of ductal carcinoma in situ ( DCIS ) , including 25 with early invasive carcinoma , and ( 2 ) evaluates the relationship of bcl 2 expression to the histological grade of DCIS and to the expression of oestrogen receptor ( ER ) , c erbB 2 and p 53 proteins . ^^^ METHODS AND RESULTS : The expression of bcl 2 , oestrogen receptor ( ER ) , c erbB 2 and p 53 proteins was determined immunohistochemically . ^^^ CONCLUSIONS : Loss of bcl 2 expression occurs in poorly differentiated DCIS and is related to negative ER status and to positive p 53 and c erbB 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Higher percentages of Bcl 2 positive tumor cells were also associated with estrogen receptor positivity ( P = 0 . 03 ) , low histological tumor grade ( P = 0 . 03 ) , and low T stage ( P = 0 . 02 ) , whereas Bax immunostaining was associated only with c erbB 2 immunopositivity ( P = 0 . 02 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BRCA 1 expression was correlated with other prognostic parameters including p 53 , c erbB 2 , bcl 2 , oestrogen receptor ( ER ) , histological grade , tumour size , axillary lymph node status and age . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MMP 1 , MMP 3 protein , and MMP 3 mRNA detection were analyzed in parallel with clinicopathologic features ( menopausal status , histological type , nuclear and histological grade , stage ) and the immunohistochemical reactivity of estrogen ( ER ) , progesterone ( PR ) receptors , and c erbB 2 oncoprotein in breast carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Overexpression of c erbB 2 was found to be predictive for OS of node positive and negative patients ( P = 0 . 0048 and P = 0 . 0285 , respectively ) , but its predictive power was weak for ER ( P = 0 . 0456 ) and RFS ( P = 0 . 0455 ) of node negative patients and disappeared for node positive patients . c erbB 2 amplification offers minimal assistance to the prediction . ^^^ In conclusion , high CD concentration is indicative of ER of patients , and c erbB 2 overexpression correlates with OS of patients . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of the prognostic factors c erbB 2 , cyclin D 1 , and estrogen receptor was significantly less common in BRCA 1 mutation carriers . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Regarding the relationship between the degree of c erbB 2 amplification and clinicopathological factors , we found a greater degree of amplification of the c erbB 2 oncogene in estrogen receptor negative or progesterone receptor negative specimens than in positive ones and in lymph node metastasis positive specimens than in negative specimens , in stages 2 , 3 , and 4 of disease compared with stage 1 disease , and in samples with positive lymphatic vessel invasion than with no lymphatic vessel invasion . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunostains for gross cystic disease fluid protein 15 ( GCDFP 15 ) , carcinoembryonic antigen , S 100 protein , c erbB 2 oncoprotein , estrogen receptor protein , and progesterone receptor protein also showed largely overlapping phenotypes in each of the three tumor categories , with selected exceptions . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : Tubular and mucinous carcinomas were more likely to occur in older patients , be smaller in size ( tubular only ) , have substantially less nodal involvement , be estrogen receptor and progesterone receptor positive , have a lower S phase fraction , be diploid , and be c erbB 2 and epidermal growth factor receptor negative compared with NOS carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Possible relationships between risk factors , such as obesity and a family history of breast cancer , and prognostic factors of mammary carcinomas were investigated by examining the body mass index of patients and the expression of estrogen ( ER ) and progesterone receptors ( PgR ) , c erbB 2 and p 53 , grade of histology , size of tumors and nodal status of mammary carcinomas . ^^^ In premenopausal patients with or without a family history and in postmenopausal patients with a family history , there was no significant difference in the body mass index regardless of the mammary carcinoma prognostic factor , such as expression of ER , PgR , c erbB 2 and p 53 , grade of histology , size of tumors and nodal status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Unfortunately , there has been no agreement to date on whether c erbB 2 overexpression is of prognostic significance in patients with lymph node negative disease . c erbB 2 overexpression is correlated with the absence of estrogen receptor expression in a number of publications . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumour histology and immunohistochemical expression of Ki 67 , c erbB 2 , p 53 , oestrogen receptor ( ER ) , progesterone receptor ( PR ) , and Bcl 2 were compared . ^^^ Expression of Ki 67 , c erbB 2 and p 53 was generally low , and that of ER , PR and Bcl 2 high . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The objective of this study was to measure the expression of five markers of proven prognostic significance in symptomatic breast cancer ( estrogen receptor , progesterone receptor , p 53 , Ki 67 , and c erbB 2 ) in screen detected and interval breast cancers to identify biological markers that may be associated with the emergence of symptomatic breast cancer in the screening interval . ^^^ The expression of estrogen receptor , progesterone receptor , p 53 , Ki 67 , and c erbB 2 was assessed in a series of 51 true interval and 84 screened detected invasive tumors by immunohistochemistry . ^^^ Expression of estrogen receptor was 1 . 7 fold lower ( P < 0 . 001 ) , whereas expression of p 53 was 2 . 5 fold ( P < 0 . 01 ) , Ki 67 2 . 4 fold ( P < 0 . 001 ) , and c erbB 2 3 . 6 fold higher ( P < 0 . 01 ) in true interval cancers compared with screen detected invasive cancers . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of the ras and c erbB 2 oncoproteins ( p 21 and p 185 , respectively ) , together with estrogen receptor ( ER ) and progesterone receptor ( PgR ) determination , has been retrospectively analyzed in 68 primary breast carcinomas and in 19 normal breast tissue samples . ^^^ The aims of this study were : a ) to explore the association between ras and c erbB 2 expression ; b ) to evaluate the relationship between ras and c erbB 2 expression and both steroid receptor status and the classical clinical and pathological parameters ; and c ) to compare two different methods for p 185 determination . p 185 and p 21 were measured by enzyme immunoassay ( EIA ) ; p 185 was also determined by Western blotting ( WB ) ; ER and PgR were assayed by radioligand binding assay . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
OBJECTIVE : The aim of the study was to investigate a dose intensified , preoperative chemotherapy with 3 cycles ( cy ) of epirubicin 60 mg / m2 , ifosfamide 5 g / m2 with mesna 5 g / m2 , biweekly with G CSF 5 micrograms / kg ( filgrastim ) , in terms of toxicity , clinical and pathological remission rates and changes of immunohistochemical characteristics ( ER , PR , c erbB 2 , p 53 ) during chemotherapy of inoperable patients ( pt ) with poor prognosis ( locally advanced ( LABC , 9 pt ) , inflammatory breast cancer ( IBC , 12 pt ) and M 0 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Altered p 53 expression was found in 27 . 1 % of cases and was associated with negative estrogen receptor status . p 53 immunostaining was correlated weakly with histologically lymphatic vessel invasion of carcinoma . c erbB 2 protein overexpression was seen in 48 . 6 % of cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We investigated the expression of estrogen receptor , progesterone receptor , pS 2 , c erbB 2 and p 53 on both initial and recurrent specimens of the six patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor status , p 53 , and c erbB 2 were of minor significance . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a retrospective study of 62 formalin fixed paraffin embedded invasive EOBC ( diagnosed at 35 years or less ) , the amplification status of the c erbB 2 gene detected by fluorescence in situ hybridization ( FISH ) using a unique sequence probe was compared with p 53 protein accumulation measured by immunohistochemistry ( IHC ) and phenotypic features . p185erbB2 protein expression was also detected by immunohistochemistry , together with estrogen receptor ( ER ) and progesterone receptor ( PR ) expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fine needle aspiration cytology for estrogen receptor ( ER ) , progesterone receptor ( PgR ) , c erbB 2 , p 53 , bcl 2 , Ki 67 , S phase fraction ( SPF ) , and ploidy were performed pretreatment and repeated on day 10 or day 21 after the first cycle of treatment . ^^^ Tumor size , nodal disease , response , ER , PgR , c erbB 2 , p 53 , bcl 2 , Ki 67 , SPF , and ploidy were analyzed as predictors of survival . ^^^ ER expression ( P = . 03 ) , absence of c erbB 2 ( P = . 03 ) , and a decrease in Ki 67 on day 10 or day 21 of the first cycle ( P < . 05 ) significantly predicted for subsequent GCR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The other tumor variables that show significant association with survival time are nodal status ( P < 0 . 0001 ) , tumor size ( P = 0 . 0035 ) , histological grade ( P = 0 . 013 ) , staining for c erbB 2 ( P = 0 . 0015 ) , estrogen receptor ( P = 0 . 028 ) , and p 53 ( P = 0 . 032 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was a significant association of staining for S100A4 with tumours fixed to the chest wall , staining for c erbB 2 , c erbB 3 , pS 2 , cathepsin D and , inversely , at borderline levels with staining for estrogen receptor . ^^^ Using Wilcoxon statistics in univariate analyses , staining for S100A4 , nodal status , tumour class , histological grade and staining for c erbB 2 , p 53 were associated negatively and staining for estrogen receptor , progesterone receptor were associated positively with patient survival times . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Thus , the DF group of patients included 90 % of those having tumors with an associated colloid pattern , 73 . 3 % of the ER positive tumors , none of the C erbB 2 positive tumors , and 100 % of the tumors with no axillary metastasis , 77 . 8 % of those with metastasis to up to 3 nodes , and 47 . 2 % of those metastasizing to 4 or more nodes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Molecular interactions between retinoid receptors or estrogen receptors ( ER ) and c erbB 2 , and between ER and retinoic acid receptor ( RAR ) alpha have been reported . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Then the c erbB 2 protein , p 53 Protein , estrogen receptor ( ER ) , progesterone receptor ( PR ) and the S phase fraction ( SPF ) were measured in paraffin embedded breast cancer tissue . ^^^ The relative risk of other four factors was respectively , PR 3 . 58 ( P < 0 . 002 ) , ER 2 . 93 ( P < 0 . 05 ) , p 53 1 . 44 ( P > 0 . 3 ) , c erbB 2 1 . 38 ( P > 0 . 5 ) . ^^^ Prognosis prediction of S phase fraction and p 53 , c erbB 2 , estrogen receptor , progesterone receptor in axillary node negative breast cancer ] . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to understand the relationship of C erbB 2 oncogene overexpression to ER and PR in breast cancer and its prognostic significance , we examined overexpression of C erbB 2 oncogene in 106 breast carcinomas by using immunohistochemical techniques ( LSAB ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The tumor from a woman with both hMLH 1 mutations and a BRCA 1 mutation exhibited typical BRCA 1 histology , e . g . , grade 3 invasive ductal carcinoma with dense lymphocytic infiltration , and immunohistology , estrogen receptor ( ER ) negative , progesterone receptor ( PgR ) negative , strongly p 53 positive , c erbB 2 negative and highly Ki 67 positive ( > 50 % stained cells ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All neoplasms were ER negative and all but one were PR negative . p 53 expression was present in 71 % ; none expressed bcl 2 . c erbB 2 was detected in four ( 19 % ) node positive and in 0 ( 0 % ) node negative cases ( P = 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Eighty six infiltrating ductal carcinoma of breast were studied by the standard avidin biotin complex immunoperoxidase method on formalin fixed , paraffin embedded tissue sections , for oestrogen receptor ( ER ) protein and c erbB 2 oncoprotein expression . ^^^ They were categorized according to the modified Bloom and Richardson criteria into three histological grades . 21 % tumours were ER positive while 44 % were c erbB 2 positive . ^^^ Of ER positive tumours , 33 . 3 % were c erbB 2 positive whereas the c erbB 2 positivity rate was much higher ( 47 . 1 % ) in ER negative tumours . ^^^ Only 16 % of c erbB 2 positive tumours were ER positive while 25 % of c erbB 2 negative tumours were ER positive . ^^^ This negative relationship between ER and c erbB 2 expression was statistically significant ( Mc Nemar ' s test , p < 0 . 005 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunocytochemically , all cases were E cadherin and p 53 negative , and c ErbB 2 , GCDFP 15 and estrogen receptor positive . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : The patients in group A were older , and had larger tumors and a higher percentage of positive nodes than those in group B ; they also had significantly higher grade tumors , higher Ki 67 levels , and a higher percentage of ER and PgR negative and c erbB 2 positive tumors ( all of the P values were significant ) . ^^^ A logistic regression analysis adjusted for tumor diameter and age showed a reduction in the significance of each of the considered variables , but all of them remained significantly associated with the modality of diagnosis except ER , PgR and c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of p 53 , bcl 2 , Ki 67 , ER , progesterone receptor , c erbB 2 , and the multidrug resistance P glycoprotein ( gp 170 ) was evaluated in BC specimens obtained at diagnosis by incision biopsy and at postchemotherapy surgery . ^^^ In a multivariate regression analysis , after adjusting for treatment administered ( epirubicin versus CMF + / tamoxifen ) , menopausal status , tumor and node status , histology grade , ER , progesterone receptor , c erbB 2 , Ki 67 , bcl 2 , and gp 170 expression , the p 53 status maintained an independent predictive role for cCR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The possible prognostic value of LEA . 135 was also compared with some widely utilized prognostic biomarkers such as c erbB 2 , topoisomerase II . alpha ( TPII . alpha ) , MIB 1 , estrogen receptor ( ER ) and progesterone receptor ( PR ) , as well as age of the patients and clinicopathologic parameters . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a consecutive and unselected series of 178 cases of carcinoma in situ of the breast ( CIS ) , comprising both ductal ( DCIS ) and lobular type ( LCIS ) , and a series of 48 cases of invasive carcinoma ( IC ) with predominance of DCIS , the association between histopathology , immunohistochemical markers ( ER , PgR , MIB 1 , c erbB 2 , and p 53 ) , and DNA ploidy was investigated , in order to discriminate biologically different groups . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this mixture , not only is the histomorphology recreated , but well established clinical molecular markers including the estrogen receptor , c erbB 2 ( HER 2 / neu ) , and aberrant cell proliferation are maintained . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Increasing postoperative serum c erbB 2 concentrations were in good association with severity , progressiveness and relapse of breast cancer independently of other variables such as age , menopausal status , tumor size , axillary node invasion , ER or PR status . ^^^ Pretreatment serum c erbB 2 positivity was inversely correlated to ER status but relation to other prognostic parameters of breast cancer was not found . ^^^ Our data confirmed that in primary breast cancer patients , monitoring of circulating c erbB 2 protein levels after operation are useful for detecting the recurrence and / or metastasis of the disease especially in ER positive breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of TP , estrogen receptor , Bcl 2 , Bax , p 53 , c erbB 2 and MIB 1 was examined by immunohistochemical methods . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of c erbB 2 and estrogen receptor ( ER ) was inversely correlated in 67 % of breast cancer patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Decreased expression of ER ( 70 . 6 % vs . 25 . 0 % p = 0 . 006 ) and increased expression of c erbB 2 ( 65 . 0 % vs . 23 . 5 % , p = 0 . 012 ) were observed in the aneuploidy of metastatic nodes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Therefore , the patterns of expression of the receptors , epidermal growth factor receptor ( EGF R ) , c erbB 2 , c erbB 3 , c erbB 4 , and one of the erbB ligands , heregulin ( HRG ) , were examined in normal and malignant breast cell lines and compared with expression of oestrogen receptor ( ER ) , a classical indicator of good prognosis . ^^^ There was an inverse correlation between ER and EGF R mRNA levels , as previously described , but no correlation between either of these receptors and c erbB 2 . c erbB 3 expression was positively correlated with ER . ^^^ Expression of antisense ER resulted in increased EGF R mRNA , demonstrating a functional link between the expression of these 2 genes , however , there was no significant change in c erbB 2 or c erbB 3 mRNA , suggesting that ER is not directly involved in control of expression of these genes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no correlation between the ACD present group and the ACD absent group for immunohistochemical status of the estrogen receptor ( ER ) , progesterone receptor ( PgR ) , p 53 , or c erbB 2 ; Ki 67 labeling index of cancer tissues ; size of tumor , or lymph node metastases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Repeatedly or recently investigated prognostic markers ( tumor size , menopausal status , ER , PgR , 3H thymidine labeling index , c erbB 2 and p 27 expression ) were evaluated on a series of 286 prospectively recruited node negative breast cancer patients who underwent loco regional treatment alone and were closely followed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
On univariate analysis comparing tumor size , nodal status , Ki 67 , c erbB 2 , p 53 and estrogen receptor , low or absent p27kip1 is a strong predictor of reduced disease free survival . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The immunophenotype of the tumour was determined as : the expression of oestrogen ( ER ) and progesterone ( PR ) receptors , p 53 , and c erbB 2 . ^^^ No significant correlation was found between nodal positivity and ER , PR , p 53 , or c erbB 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
High levels of c erbB 2 ( > 500 IU / mg protein ) were associated with estrogen receptor ( ER ) and progesterone receptor negativity , high histoprognostic SBR grade and high levels of uPA and p 53 . ^^^ Univariate analyses showed shorter metastasis free survival ( MFS ) and overall survival ( OS ) in patients whose tumors overexpressed c erbB 2 in the overall population , in subgroups defined by ER and uPA status , and in patients with positive pathological nodal status , SBR grade 2 , progesterone receptor , and p 53 negative tumors . ^^^ Patients with ER positive , c erbB 2 positive tumors had a shorter MFS and OS than those patients with c erbB 2 negative tumors . ^^^ These results suggest that c erbB 2 overexpression in breast cancer may be a better predictor of the response to tamoxifen than is ER status alone . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This clone produced only undifferentiated carcinomas that , compared to tumors formed by the parental uncloned variant , had lost ER , DF 3 and c erbB 2 expression , but more strongly expressed p 53 . ^^^ Immunohistochemistry utilized antibodies against DF 3 , c erbB 2 , cyclin Dl , m keratin , p keratin , p 53 , B72 . 3 and estrogen receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tissues from 100 cases of breast cancer were analysed immunohistochemically for the presence of adrenocorticotropic hormone ( ACTH ) or ACTH like peptides and expression of c erbB 2 oncoprotein , epidermal growth factor receptor ( EGF R ) as well as oestrogen receptor ( ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
EGFR and c erbB 2 were inversely correlated to the presence of estradiol receptors ( ER ) and progesterone receptors ( PgR ) , and positively correlated to the histoprognostic grading ( HPG ) . ^^^ The expression level of EGFR and c erbB 2 was significantly higher in ER and PgR negative tumors compared with ER and PgR positive tumors ( Student ' s t test ) , and in tumors with higher grade compared with tumors with lower grade . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Oestrogen ( ER ) and progesterone receptor ( PR ) negativity , c erbB 2 overexpression , low bcl 2 expression , p 53 accumulation , DNA non diploidy and high Ki 67 , were strongly associated with high grade DCIS , and comedo type necrosis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining was conducted for p 53 , c erbB 2 , Ki 67 , ER , PR , bcl 2 and angiogenesis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunostaining for epidermal growth factor receptor ( EGFR ) , c erbB 2 , c erbB 3 , c erbB 4 , ER , and PR was performed in 107 cases of primary breast carcinomas from Anyang , China . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The predictivity of tumour size , oestrogen ( ER ) and progesterone ( PgR ) receptors , 3H thymidine labelling index ( TLI ) , c erbB 2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER positive , node positive tumours . ^^^ TLI , ER , c erbB 2 and p27kip1 were generally unrelated to each other . ^^^ PgR was directly related to ER and inversely to c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Data on 13 biological indicators ; ER , PR , P 53 , c erbB 2 , PCNA , CEA , Ki 67 , Vimentin , Ulex , Nm 23 , Cathepsin D , Factor 8 , PS 2 together with clinical and pathological factors were collected . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The following antibodies were used in immunohistochemical staining : Rabbit Anti Human c erbB 2 Oncoprotein , monoclonal Mouse Anti Human Estrogen Receptor ( IgG 1 , kappa ) , and monoclonal Mouse Anti Human Progesterone Receptor ( Clone PgR 636 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The objective of this study was to investigate the expression of c erbB 2 , p 53 , Ki 67 , Cyclin D 1 , Bcl 2 , estrogen receptors ( ER ) , and progesterone receptors ( PR ) in mammary Paget disease . ^^^ RESULTS : The majority of Paget cells were positive for c erbB 2 ( 92 . 9 % ) , Cyclin D 1 ( 100 % ) , and Ki 67 ( 85 . 7 % ) , but very few were positive for Bcl 2 ( 14 . 3 % ) . p 53 was overexpressed in 42 . 9 % of the cases , and only 28 . 6 % were positive for ER and PR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ERalpha negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c erbB 2 . ^^^ Similar studies performed with MCF 7 cells overexpressing epidermal growth factor receptor or c erbB 2 confirmed that hyperactivation of MAPK resulted in down regulation of ERalpha that was reversible by MEK inhibition or transfection with dominant negative ERK 1 and ERK 2 constructs . ^^^ These data suggest that the hyperactivation of MAPK in epidermal growth factor receptor or c erbB 2 overexpressing breast cancer cells is directly responsible for generation of an ERalpha negative phenotype and , more importantly , that this process may be abrogated by inhibiting these pathways , thus restoring ERalpha expression . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of axl was correlated with tumour characteristics ( lymph node involvement , stage , grade ) and immunohistochemical expression of ER , PR , Ki 67 and c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An overexpression of c erbB 2 was detected in 32 % of the tumors and was correlated with a negative estrogen receptor status , increasing tumor size as well as axillary lymph node involvement . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this first ever study , we investigated the role of nine prognostic markers ' expression ( estrogen receptor [ ER ] , progesterone receptor [ PR ] , p 53 , C erbB 2 , epidermal growth factor receptor [ EGFR ] , cathepsin D [ CD ] , proliferating cell nuclear antigen [ PCNA ] , DNA ploidy , and S phase fraction [ SPF ] ) and disease outcome in IBC cases compared with the control group . ^^^ The expression of nine prognostic markers , that is , ER , PR , p 53 , C erbB 2 , EGFR , CD , PCNA , SPF , and DNA ploidy , was studied by immunohistochemistry and flow cytometry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER , PR Ki 67 , p 53 and c erbB 2 had a significant correlation with ploidy and overall prognostic value in breast cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We also assessed the potential role of the ERalpha genotype in ER , PR , p 53 , c erbB 2 , and bcl 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CONCLUSIONS : The direct ICC detection of ITCs in BM correlated with primary tumor stage , nodal stage , vascular invasion , c erbB 2 expression , and ER / PgR status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining for AX 1 , c erbB 2 , p 53 protein , ER , PR , EGF and IGF were performed by LSAB . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Of the tumors 48 % were immunoreactive for EGFR , 63 % for c erbB 2 , 78 % for c erbB 3 , 95 % for c erbB 4 , 88 % for estrogen receptor ( ER ) and 80 % for progesterone receptor ( PR ) . ^^^ In addition , expression of c erbB 4 protein was associated with c erbB 2 ( p= . 004 ) , c erbB 3 ( p= . 058 ) , ER ( p= . 002 ) and PR ( p= . 004 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen ( ER ) and progesterone receptors ( PR ) and HER 2 / neu ( c erbB 2 ) protein overexpression are important prognostic factors for breast carcinoma . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
OBJECTIVE : To study the telomerase activity in samples of breast fine needle aspirates , its clinical implications , and possible association with expression of PR , ER , PCNA , c erbB 2 and p 53 . ^^^ In 35 breast cancer tissue specimens , expression of PR , ER , PCNA , c erbB 2 and p 53 were examined by immunohistochemical staining . ^^^ Telomerase activity of breast cancer aspirates did not correlate with histologic type , lymph node status , tumor size and clinical stage , nor did it correlate with PR , ER status and PCNA and c erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
TIMP 2 protein was analyzed in parallel with clinicopathologic features ( tumor size , histologic type , nuclear and histologic grade , stage ) , patients ' overall survival and ER , PR , Ki 67 , topo IIalpha , c erbB 2 , p 53 and bcl 2 proteins . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Other tumor variables that show a significant association with patient survival times in this group of patients include nodal status , tumor size , histological grade , staining for c erbB 2 , estrogen receptor alpha , or p 53 . ^^^ Multivariate regression analysis for 202 patients shows that staining for OPN is most highly correlated with patients ' deaths ( P < 0 . 0001 ) , but involved lymph nodes ( P = 0 . 0007 ) , fixed tumors ( P = 0 . 0008 ) , and staining for estrogen receptor alpha ( P = 0 . 008 ) are also significant independent prognostic variables with that for c erbB 2 being of borderline significance ( P = 0 . 060 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of this study was to analyse the relationships between the expression of c erbB 2 , estrogen receptor ( ER ) , progesterone receptor ( PR ) , Bcl 2 and PCNA in node negative breast cancer . ^^^ Expression of c erbB 2 in node negative breast cancer does not correlate with estrogen receptor status , predictors of hormone responsiveness , or PCNA expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Oestrogen receptor ( ER ) , progesterone receptor ( PR ) and c erbB 2 showed 54 % , 46 % and 63 % positivity , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The immunohistochemical panel induced oestrogen ( ER ) and progesterone ( PR ) receptors , c erbB 2 protein , p 53 , Ki 67 , CK MNF 116 , and vimentin . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BACKGROUND AND OBJECTIVES : An overexpression of c erbB 2 has been reported to be associated with a poor clinical outcome in breast cancer , however , its prognostic value remains controversial especially in patients with node negative breast cancer , and regarding the estrogen receptor ( ER ) status . ^^^ RESULTS : The c erbB 2 expression was positive in 120 ( 17 . 2 % ) of 698 cases , which inversely correlated with the ER status . ^^^ A univariate analysis also indicated a subgroup with the positive c erbB 2 and negative ER to have both a worse DFS and OS than the other subgroups . ^^^ In addition , the combination of c erbB 2 and ER made it possible to identify the subgroup with the worst clinical outcome . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The following variables thought to have prognostic significance were evaluated : grade , tumor size , estrogen ( ER ) and progesterone receptor ( PgR ) content ( absent ; low , 1 to 9 fmol / mg cytosol protein ; or positive , > or = 10 fmol / mg cytosol protein ) , c erbB 2 overexpression , menopausal status , and age . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The observed chromosome specific numerical abnormalities were evaluated along with the established clinicopathological parameters , the immunohistochemical expression of ER , PR , p 53 , c erbB 2 , Ki 67 and patients ' survival . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Current literature suggests two roles for c erbB 2 , either as a pure prognostic factor with no association with therapy or as a factor predictive of benefit from specific types of systemic treatments . c erbB 2 appears to be only a weak prognostic factor , although some individual studies suggest greater prognostic importance . c erbB 2 abnormalities appear to predict for relative , but not absolute , resistance to endocrine therapy in estrogen receptor ( ER ) positive women . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The immunohistochemical avidin biotin peroxidase method was performed on paraffin sections for the detection of Flk 1 , p 53 , Bcl 2 , c erbB 2 , Ki 67 , Topo IIalpha , ER , and PR . ^^^ It is interesting that Flk 1 expression demonstrated a significant correlation with 2 well established proliferation indices , Ki 67 ( P = 0 . 037 ) and topo IIalpha ( P = 0 . 009 ) , whereas there was no correlation with the expression of ER , PR , p 53 , Bcl 2 , and c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Also , ER protein was frequently positive in patients with a higher number of lymph node invasions , well to moderate nuclear differentiated tumor cells and negative c erbB 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Candidate prognostic biomarkers for breast cancer include elevated proliferation indices such as Ki 67 and proliferating cell nuclear antigen ( PCNA ) ; ER and PR overexpression ; markers of oncogene overexpression such as c erbB 2 , TGF a and EGFr ; indicators of apoptotic imbalance including overexpression of bcl 2 and an increased bax / bcl 2 ratio ; markers of disordered cell signaling such as p 53 nuclear protein accumulation ; alteration of differentiation signals such as overexpression of c myc and related proteins ; loss of differentiation markers such as TGF b 2 receptor and retinoic acid receptor ; and alteration of angiogenesis proteins such as VEGF overexpression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We also performed immunostaining analysis for estrogen receptor , p 53 , MIB 1 and c erbB 2 on all the tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of this study is to evaluate the expression patterns of estrogen receptor ( ER ) , progesterone receptor ( PR ) , MiB 1 ( Ki 67 ) , Her 2 / neu ( c erbB 2 ) , and p 53 and to correlate them with the prognosis , presentation , staging , management , and survival / outcome in male breast carcinoma identified through the Veterans Administration nationwide cancer registry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Pathologically , tumors with a papillotubular pattern , Estrogen receptor ( ER ) positivity , low nuclear grade and c erbB 2 negativity tended to show dendritic shrinkage . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Except for the small mean size of the tumors ( P < . 01 ) , no significant differences were identified among the prognostic parameters , including a nodal status , estrogen receptor status , growth fraction by Ki 67 or immunoreactivity for c erbB 2 , as compared with the other 123 cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Pathology data were reviewed : 81 % of tumors were estrogen receptor positive , 74 % were progesterone receptor positive , 37 % overexpressed c erbB 2 , 30 % overexpressed p 53 , 79 % overexpressed Bcl 2 , 51 % overexpressed cyclin D 1 , and 39 % overexpressed epidermal growth factor receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using the tissue microarray technique , 166 breast cancer cases , all characterized by comparative genomic hybridization , were evaluated by immunohistochemistry , using 15 different antibodies ( estrogen receptor , progesterone receptor , p 53 , Ki 67 , c erbB 2 , epidermal growth factor receptor , cyclins A , D 1 , and E , bcl 2 , p 21 , p 27 , Ck 5 / 6 , Ck 8 / 18 , and smooth muscle actin ) and chromogenic in situ hybridization for c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
McCarthy et al . , microvessel density , expression of estrogen receptor alpha , MIB 1 , p 53 and c erbB 2 in inflammatory breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The results were compared with p 53 and c erbB 2 protein expression , estrogen ( ER ) and progesterone ( PR ) receptors ' status and with clinicopathological prognostic factors . pRb was expressed in normal , hyperplastic and neoplastic epithelium . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunostaining of tissue microarray sections and conventional full sections of each tumor were performed using well characterized prognostic markers ( estrogen receptor ER , progesterone receptor PR and c erbB 2 ) . ^^^ The full section versus tissue microarray concordance for these stains was 97 % for ER , 98 % for PR , and 97 % for c erbB 2 , respectively , with a strong statistical association ( kappa value more than 0 . 90 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Traditional prognostic indicators ( age , tumor size , number of involved lymph nodes , sites of recurrence , disease free interval [ DFI ] , adjuvant treatments , estrogen receptor [ ER ] expression , progesterone receptor [ PgR ] expression , S phase fraction [ SPF ] , and DNA ploidy ) , together with three newer biologic markers ( c erbB 2 , p 53 , and bcl 2 ) were assessed . ^^^ In addition , the molecular phenotype of the primary breast tumor was significant , with primary tumors that showed ER negativity and PgR negativity , high SPF , aneuploidy , accumulation of p 53 protein , and lower bcl 2 expression , together with c erbB 2 overexpression , all associated with a poorer clinical outcome ( P < 0 . 05 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We evaluated docetaxel ' s efficacy and safety and analyzed correlations between response and the expression of c erbB 2 , ER status , and Ki 67 labeling index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to evaluate the prognostic value of cyclin D 1 and other prognostic variables in human breast cancers , we have assessed estrogen receptor ( ER ) status , cyclin D 1 , c erbB 2 and p 53 overexpression in 175 primary breast carcinomas , and investigated the relationships of prognostic variables to the patient clinical outcome and the association between cyclin D 1 overexpression and other prognostic variables . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An inverse association of MVD with estrogen receptor ( ER ) expression was noted ( p=0 . 0007 ) , while high MVD was directly related to c erbB 2 overexpression ( p=0 . 04 ) and high MIB 1 proliferation index ( p=0 . 02 ) . ^^^ Angiogenesis relates to estrogen receptor negativity , c erbB 2 overexpression and early relapse in node negative ductal carcinoma of the breast . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumor size in the lymph node negative cohort and estrogen receptor status , progesterone receptor status , and c erbB 2 expression in the lymph node positive cohort also were correlated significantly with NKG . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Biomarkers , including estrogen receptor status , tumor proliferation rate as determined by Ki 67 , and gene expressions of c erbB 2 , p 53 , bcl 2 , and BRCA 1 , were determined by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
P cadherin positive and ER negative tumors were related to a higher histologic grade , a high proliferation rate , and expression of c erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER , PR , p 53 , C erbB 2 , EGFR , Cathepsin D , PCNA , DNA ploidy and S phase fraction , were studied by immunohistochemistry and flow cytometry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS AND RESULTS : Sections of 64 cases of in situ carcinoma of the breast were stained for ER , progesterone receptors ( PgR ) , androgen receptors ( AR ) , c erbB 2 and p 53 , using the immunoperoxidase technique . ^^^ ER negativity was significantly associated with high nuclear grade ( 88 % versus 27 % for ER positive cases , P < 0 . 001 ) , PgR negativity ( 100 % versus 25 % , P < 0 . 001 ) , c erbB 2 positivity ( 79 % versus 14 % , P < 0 . 001 ) and p 53 positivity ( 58 % versus 6 % , P < 0 . 001 ) . ^^^ Of the four cases of DCIS with microinvasion , three were ER and PgR negative , all four were c erbB 2 positive and AR positive and one was p 53 positive . ^^^ None of the four LCIS was ER , PgR or AR negative and none was c erbB 2 or p 53 positive . ^^^ CONCLUSIONS : There is a highly significant direct relationship between ER negativity in DCIS and high nuclear grade , PgR negativity and c erbB 2 and p 53 positivity . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CEA was also related to menopausal status , c erbB 2 overexpression in tissue and ER . ^^^ Multivariate analysis in DFS and in OS showed that nodal involvement CEA and ER but not tumor size , menopausal status , histological grade , histology , CA 15 . 3 , c erbB 2 , PgR , adjuvant treatment , p 53 ( 345 patients ) or c erbB 2 in tissue are independent prognostic factors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BACKGROUND : We recently confirmed , in a series of 365 human breast cancers , that EGFR and c erbB 2 were associated with estradiol receptors ( ER ) and / or progesterone receptors ( PgR ) negative tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Low molecular weight cytokeratins , cytokeratin 20 , vimentin , S 100 , p 63 , estrogen receptor , progesterone receptor , p 53 and c erbB 2 were negative in tumoral cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Specimens from 254 consecutive breast carcinoma ( BC ) cases ( 110 N 0 , 144 N1 / 2 ) with long term follow up ( median , 95 months ) were immunostained for syndecan 1 , estrogen receptor ( ER ) , progesterone receptor ( PgR ) , and p 53 ; in 154 cases , c erbB 2 status was known . ^^^ High syndecan 1 expression was associated with high histologic grade , large tumor size , high mitotic count , c erbB 2 overexpression , and ER and PgR negative status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of this study was to determine VEGF C protein expression in a series of breast carcinomas and correlate this with axillary lymph node ( LN ) metastases , the presence of lympho vascular invasion ( LVI ) , bone marrow micro metastases ( BMM ) and other clinico pathological data including oestrogen receptor ( ER ) and c erbB 2 status . ^^^ ER and c erbB 2 were also assessed by IHC . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Analyses of the primary tumor included histologic grading , vascular invasion , and immunohistochemical detection of c erbB 2 , cathepsin D , p 53 , and estrogen receptor ( ER ) / progesterone receptor ( PgR ) expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The status of estrogen receptor , progesterone receptor , proliferating cell nuclear antigen , and C erBb 2 was also analyzed by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE AND EXPERIMENTAL DESIGN : The purpose is to define intratumoral microvessel density ( MVD ) and potential biological markers that correlate with inflammatory breast cancer ( IBC ) , we examined MVD , estrogen receptor a ( ER ) status , MIB 1 proliferation index , p 53 , and c erbB 2 by immunohistochemistry in archival specimens from 67 women diagnosed with breast cancer with or without the inflammatory phenotype at the Institut Salah Azaiz ( Tunis , Tunisia ) . ^^^ Microvessel density , expression of estrogen receptor alpha , MIB 1 , p 53 , and c erbB 2 in inflammatory breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Four biomarkers , c erbB 2 , Cox 2 , p 53 and VEGF , were significantly overexpressed in tumors with the ER negative ( ER ) phenotype . ^^^ The malignant potential of the ER / VEGF+ subgroup was associated with the strong correlations of Cox 2 and c erbB 2 with VEGF . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There were significant differences in the presence of CK+ cells according to estrogen receptor expression ( p = 0 . 049 ) , and lymph node status ( p = 0 . 033 ) , but not to the age , menopausal status , type of patient ( neoadjuvant , adjuvant or metastatic ) , TNM stage , histological type , progesterone receptor expression , c erbB 2 expression , p 53 expression or Ki 67 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
OBJECTIVE : To correlate histologic and cytologic specimens of breast cancer by the expression of prognostic factors , such as estrogen receptor ( ER ) , progesterone receptor ( PR ) and c erbB 2 , with immunochemical staining . ^^^ STUDY DESIGN : Cytologic and histologic specimens from 83 patients were analyzed for expression of ER and PR , and 30 cases were analyzed for overexpression of c erbB 2 using a standard immunochemical method . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
FVD was correlated significantly with lymph node metastasis ( P < 0 . 0001 ) , VEGF D expression ( P = 0 . 0019 ) , tumor size ( P = 0 . 0015 ) , estrogen receptor ( P = 0 . 0211 ) , progesterone receptor ( P = 0 . 0462 ) , and c erbB 2 ( P = 0 . 0326 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The MR characteristics were correlated with classical pathologic prognostic factors ( tumor size , histologic type , grade and lymph node status ) and immunohistochemically detected biomarkers [ c erbB 2 , p 53 , Ki 67 , and estrogen receptor ( ER ) ] . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Western blot analysis revealed that beta HCH induced transformation related biochemical changes in MCF 7 cells , such as a decline in the levels of ERalpha and p44 / 42 MAP kinase and a significant increase in expression of c ErbB 2 and MMP 9 levels . ^^^ In contrast , long term E ( 2 ) treatment resulted in the downregulation of ERalpha and p44 / 42 MAP kinase and upregulation of MMP 9 only , but no changes in c ErbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tissue samples were prospectively collected and analyzed for estrogen ( ER ) and progesterone ( PgR ) receptor , c erbB 2 overexpression , mutant p 53 and bcl 2 protein accumulation , proliferation index and microvessel density ( MVD ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Prognostic markers such as ER , PR , p 53 , and c erbB 2 failed to provide new criteria to allow discrimination of these tumours from other breast cancers . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to evaluate the biological differences between ILC and IDC patients and their implication with regard to tumour chemosensitivity , additional immunohistochemical stainings ( oestrogen receptor ( ER ) , Bcl 2 , p 53 , c erbB 2 and Ki 67 ) were performed on 129 pretherapeutical specimens . 38 ( 8 . 3 % ) ILC were diagnosed by core needle biopsy before CT . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In 18 cases , an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89 % of cases , PR in 61 % , pS 2 in 44 % , CathD in 72 % , p 53 in 56 % , c erbB 2 in 50 % , Ki 67 and PCNA in 100 % and bcl 2 in 78 % . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
INTRODUCTION : The aim of the present study was to identify the relationships between the uptake of radiotracers namely pentavalent dimercaptosuccinic acid [ ( 5 ) DMSA ] and sestamibi ( MIBI ) and the following parameters in primary breast cancer : steroid receptor concentrations ( i . e . estrogen receptor [ ER ] and progesterone receptor [ PR ] ) , Ki 67 expression , tumor size , tumor grade , age , and levels of expression of p 53 and c erbB 2 . ^^^ The tumor to background ratio was calculated and correlated with the presence of ER , PR , Ki 67 , tumor size , tumor grade , p 53 , and c erbB 2 . ^^^ ER , PR , p 53 , and c erbB 2 were determined immunohistochemically . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The methylation status of caveolin 1 gene had no clear relationship with age , cell grade , stage of tumor , and status of estrogen receptor , p 53 and c erbB 2 in the breast cancer tissues . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The results were correlated with the estrogen receptor alpha ( ER alpha ) and beta ( ER beta ) , progesterone receptor , Ki 67 , and c erbB 2 expressions analyzed by immunohistochemical techniques and with the Tumor Node Metastasis classification , tumor grade , disease free interval , and survival of the patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PCDGF expression was independent of c erbB 2 overexpression and of ER and PR status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Association between estrogen receptor ( ER ) , progesterone receptor ( PgR ) , p 53 and c erbB 2 expression and clinicopathologic variables were assessed by the chi square test for qualitative parameters . ^^^ CONCLUSION : We concluded that expressions of c erbB 2 , p 53 , ER , and PgR may be used in the evaluation of breast carcinoma . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Hormone receptor ( estrogen receptor and progesterone receptor ) status and c erbB 2 status were also studied . ^^^ RESULTS : Significantly reduced estrogen receptor ( P < 0 . 001 ) and progesterone receptor ( P = 0 . 001 ) expression was seen in effusions compared with primary tumors , with opposite findings for c erbB 2 ( P = 0 . 003 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There were no relations between the MT 1 MMP protein or mRNA expression and ER , PR or C erbB 2 ( P > 0 . 05 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIAL / METHODS : We compared the immunohistochemical expressions of the tumor suppressor protein p 53 , estrogen receptor ( ER ) , c erbB 2 , and E cadherin in 57 primary invasive breast cancers and in their respective LRs . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We also observed high level amplifications in ER negative infiltrating ductal carcinoma in regions of 8q24 and 17q12 encompassing the c myc and c erbB 2 genes and apparent homozygous deletions in 3p21 , 5q33 , 8p23 , 8p21 , 9q34 , 16q24 , and 19q13 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To evaluate reliability of data , results of ER , PR , MIB 1 , p 53 and c erbB 2 on core biopsy were compared with those on surgical specimens . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this case control study , tissue VEGF was retrospectively determined by immunohistochemistry and related to T , N , ER , PgR , c erbB 2 , p 53 , MIB 1 and cyclin D 1 in 129 breast cancer patients . ^^^ In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease free patients , whereas there were significant differences in N , ER , PgR , c erbB 2 , p 53 , MIB 1 and cyclin D 1 ( p ranging from 0 . 001 to 0 . 0001 ) . ^^^ In multivariate analysis VEGF showed less significance than N , ER , c erbB 2 , MIB 1 and cyclin D 1 ( p = 0 . 012 , p = 0 . 007 , p = 0 . 005 , p = 0 . 005 , p = 0 . 002 and p = 0 . 001 , respectively ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Specimen pairs from 39 patients were tissue arrayed and stained for ER , progesterone receptor ( PgR ) , Bcl 2 , c ErbB 2 ( HER 2 ) , and phosphorylated ( p ) p 38 mitogen activated protein kinase ( MAPK ) , p ERK1 / 2 MAPK , and p Akt . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This study evaluated 59 cases of LCIS ( 29 pure , 30 with synchronous IBC ) for five biomarkers known to be important in IBC ( ER , PgR , c erbB 2 , p 53 and Ki 67 proliferation rate ) by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
AIMS AND BACKGROUND : p 53 , c erbB 2 and Ki 67 protein expression and microvessel density ( MVD ) determined by CD 34 antibody were evaluated by immunohistochemistry and their correlation with clinicopathological parameters including estrogen ( ER ) and progesterone ( PR ) receptor status and survival were investigated in patients with axillary lymph node negative infiltrating ductal breast carcinoma . ^^^ There were no statistically significant differences in the distribution of p 53 , Ki 67 and c erbB 2 protein expression in relation to the age of the patients or to the size , histological grade or ER and PR status of the tumors . p 53 protein expression correlated positively with c erbB 2 and Ki 67 protein expression ( P < 0 . 05 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Axillary lymph node status , T stage , histological grade , c erbB 2 expression and estrogen receptor status did not differ significantly between the two age groups . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : We performed immunohistochemistry to detect COX 2 , estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 , c erbB 2 , topoIIalpha and PPARgamma proteins in 175 cases of invasive breast carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Hormone dependence and C ERBB 2 : relationship between estrogen receptor expression , estrogen regulated proteins , and C ERBB 2 in breast carcinoma ] . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of ER , PgR , c erbB 2 , CD44v6 , and p 53 in the primary and the locoregional tumor was analyzed in 70 patients with recurrent breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The biopathologic profile ( ER , PR , MIB 1 , p 53 , c erbB 2 ) as well as the follow up was also investigated . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry was applied on 141 paraffin embedded breast tissue specimens for the detection of phospho beta catenin , ER , PR , c erbB 2 , p 53 , Ki 67 , bcl 2 , uPAR and TIMP 1 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Sections of tissue of 114 consecutive breast cancer cases were studied immunohistochemically , using antibodies against oestrogen receptor ( ER ) , progesterone receptor ( PR ) , androgen receptor , c erbB 2 , cathepsin D , and cyclin D . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
EXPERIMENTAL DESIGN : Using a series of invasive breast carcinomas , P cadherin expression was evaluated and correlated with histologic grade , estrogen receptor , MIB 1 , and p 53 and c erbB 2 expression . ^^^ RESULTS : P cadherin expression showed a strong correlation with high histologic grade , increased proliferation , c erbB 2 and p 53 expression , lack of estrogen receptor , and poor patient survival . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical expression of different biomarkers such as hormone receptor status ( ER , PR ) , proliferation associated indices ( PCNA , MIB 1 ) , oncogene ( c erbB 2 ) , tumour suppressor gene products ( pRb , p 53 protein ) , cell cycle related proteins ( cyclin D 1 , cyclin E , p21 / WAF1 ) , anti apoptotic protein ( bcl 2 ) , adhesion molecule ( CD44s ) , proteolytic enzyme ( cathepsin D ) , heat shock protein ( hsp 27 ) and metallothionein ( MT ) has shown the contribution of these molecules to endometrial carcinogenesis in a hormone dependent or independent manner as an early or late event . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expressions of ER , PR , c erbB 2 and p 53 were immunostained in tumor tissues and serum p 53 Abs were assayed using ELISA method . ^^^ Among 144 patients , 31 ( 21 . 5 % ) had positive p 53 Abs , which was associated with several poor prognostic parameters including higher clinical stage ( p = 0 . 0233 ) , lymph nodes metastasis ( p = 0 . 0033 ) , negative ER expression ( p = 0 . 0250 ) and positive c erbB 2 status ( p = 0 . 0227 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Co expression of steroid hormone receptors ( estrogen receptor alpha and / or progesterone receptors ) and Her2 / neu ( c erbB 2 ) in breast cancer : clinical outcome following tamoxifen based adjuvant therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Among the hypermethylated cancers , 50 % were tumor grade 2 3 , 44 . 44 % were positive in lymph node involvement ( LN ) , 36 . 11 % were positive in lymphovascular permeation ( LVP ) ; 44 . 44 % , 22 . 22 % and 47 . 22 % for the overexpressions in estrogen receptor ( ER ) , progesterone receptor ( PR ) and c erbB 2 , respectively . ^^^ CONCLUSION : The result demonstrated that hypermethylation of TIMP 3 in IDC might be associated with high tumor grading and lymph nodes metastasis , and overexpression of ER , PR and c erbB 2 , respectively . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In ER negative , c ErbB 2 overexpressing SK BR 3 cells , the expression of c ErbB 2 and its downstream extracellular signal regulated kinase pathway were down regulated by LJ 529 . ^^^ In conclusion , our novel findings open the possibility of LJ 529 as an effective therapeutic agent against both ER positive and ER negative breast cancers , particularly against the more aggressive ER negative , c ErbB 2 overexpressing types . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In ERalpha tumors , overexpression of epidermal growth factor receptor ( EGFR ) or c erbB 2 , leading to increased growth factor signaling , is observed such that mitogen activated protein ( MAP ) kinase ( MAPK ) is significantly hyperactivated compared with ERalpha+ breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical studies for AE1 / AE3 , CEA , EMA , CK 7 , 34betaE12 , NSE , synaptophysin , chromogranin A , Leu 7 , vimentin , S 100 , SMA , calponin , estrogen receptor , progesterone receptor , c erbB 2 , E cadherin , Ki 67 and p 53 were also carried out . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The presence of oestrogen alpha receptor ( ER ) , progesterone receptor ( PR ) , and HER 2 / neu ( c erbB 2 ) oncoprotein in the uterine walls of 10 healthy cats and 20 subjects with cystic endometrial hyperplasia pyometra ( CEH P ) were evaluated . ^^^ The ER , PR and c erbB 2 expression in the endometrium , glandular epithelium , stromal fibroblasts and myometrial smooth muscle cells was quantified by immunohistochemistry . ^^^ The ER , PR and c erbB 2 staining patterns differed between normal uteri and uteri with CEH P . ^^^ As a conclusion , we suggest that c erbB 2 oncoprotein may play a role in the pathogenesis of the CEH together with the ER and PR in cats , and that ER does not have a role in the mechanism of pyometra , whereas PR plays a role in the pathogenesis of both CEH and pyometra . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Oestrogen and progesterone receptors ( ER , PR ) were positive in 51 ( 61 . 4 % ) and 43 ( 51 . 8 % ) cases , respectively , out of 83 ( 91 . 2 % ) cases in which they were evaluated . c erbB 2 immunostaining , carried out in 54 ( 59 . 3 % ) invasive cancers , showed positivity in 16 ( 29 . 6 % ) cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to evaluate its prognostic value , hMAM was correlated with age of patients , type and size of tumor , nodal stage , histologic grade , c erbB 2 over expression , Ki 67 labelling index , estrogen receptor ( ER ) status and progesterone receptor ( PGR ) status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIALS AND METHODS : Operable breast cancers in Yogyakarta were studied clinically , pathologically and immunohistochemically for tumor size , lymph node status , histological grade , mitotic index , ER , PR , c erbB 2 , p 53 and MIB 1 proliferation index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Telomerase activity , ER and c erbB 2 expression were analyzed by standardized immunohistochemistry techniques . ^^^ RESULTS : Aneuploidy significantly correlated with high SPF and lack of ER , while high SPF showed significant correlations with high telomerase activity , c erbB 2 overexpression and absence of ER . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Also , amplification of c erb B 2 showed a significantly negative association with both progesterone and estrogen receptor presence . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Microvessel counts did not correlate with other prognostic features , ie , grade , size , estrogen receptor status , c erb B 2 or accumulated P 53 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of estrogen receptor , progestin receptor , epidermal growth factor receptor , HER 2 / neu ( c erb B 2 ) oncoprotein , and cathepsin D were determined . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Having established prolactin to be an indicator of disease progression and hyperprolactinemia as an independent predictor of short term prognostication , we have in this report compared plasma prolactin with the expression of c erb B 2 oncoprotein , ER and PR . c erb B 2 oncoprotein , ER and PR are determinants of breast cancer biology . ^^^ The expression of c erb B 2 , ER and PR did not differ in these two sub groups . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Microvessel quantitations were related to flow cytometric DNA ploidy , c erb B 2 overexpression , and estrogen receptor status of the tumor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All examples tested were found to be c erb B 2 negative , universally diploid with normoproliferative DNA content , and estrogen receptor and progesterone receptor positive . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The association between TS and disease free survival ( DFS ) and overall survival ( OS ) was independent of other prognostic factors such as tumor size , tumor grade , nodal status , vessel invasion , estrogen receptor ( ER ) / progestin receptor ( PR ) status , c erb B 2 , or Ki 67 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
OBJECTIVE : To examine the association between expression of osteopontin ( OPN ) , p 53 , other molecular markers ( Ki 67 , c erb B 2 , and estrogen receptor protein ) and tumor progression in a case of synchronous , bilateral , invasive mammary carcinomas of the same histology . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The median of pO 2 values and the percentage of hypoxic areas ( pO 2 < 10 mmHg ) were calculated and correlated with the histological type , grading , ER , PR , and the expression of Ki 67 , p 53 , EGFR , pS 2 , and c erb B 2 . ^^^ Also tumors with negative nodes or positive ER had significantly higher pO 2 values , as did tumors with an overexpression of c erb B 2 , p 53 , and cathepsin D . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using immunocytochemistry , tumors were immunostained for overexpression of p 53 , c erb B 2 , and epidermal growth factor receptor and were evaluated quantitatively for expression of estrogen receptor , progesterone receptor , and Ki 67 antigen , a marker of cellular proliferation . ^^^ Epidermal growth factor receptor , c erb B 2 , estrogen receptor , and progesterone receptor statuses did not differ significantly between the two groups . ^^^ CONCLUSION : Markers that did not correlate with survival included the hormone receptors , estrogen receptor and progesterone receptor , and the oncogenes , c erb B 2 and epidermal growth factor receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using immunocytochemistry , tumors were immunostained for overexpression of c erb B 2 , epidermal growth factor receptor ( EGFR ) , p 53 , and expression of the Ki 67 defined antigen ( a marker of cellular proliferation ) , tumor necrosis factor alpha ( TNFalpha ) , estrogen receptor ( ER ) , progesterone receptor ( PR ) , and P glycoprotein ( P 170 , a marker of multidrug resistance ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIAL AND METHODS : The expression of nuclear estrogen receptor ( RE ) , nuclear progesterone receptor ( PGR ) , p 53 and c erb B 2 proteins was analyzed in 382 cases of infiltrating ductal carcinoma of the breast . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BRCA 1 associated HBCs were significantly more estrogen receptor negative ( P < 0 . 01 ) , c erb B 2 negative ( P < 0 . 05 ) , and p 53 positive ( P < 0 . 01 ) , and they also showed a significant increase in MIB 1 staining grades ( P < 0 . 01 ) as well as microvessel counts ( P < 0 . 05 ) compared with the control group . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Two large series of a total of 613 lymph node negative breast carcinoma patients from a single institution were analyzed with respect to tumor size , histologic grade , and immunohistochemical staining for p 53 , c erb B 2 , estrogen receptor ( ER ) , and progesterone receptor ( PgR ) . ^^^ RESULTS : Immunoreactivities for p 53 , c erb B 2 , ER , and PgR did not differ significantly in the two series . p 53 immunostaining was present in 187 of 613 tumors ( 29 % ) , and c erb B 2 immunoreactivity was present in 58 of the tumors ( 10 % ) . ^^^ No significant differences in survival were found when comparing p 53 , c erb B 2 , ER , and PgR positive and negative cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was a statistically significant inverse correlation between c erb B 2 expression and ER status . ^^^ There was also a significant inverse correlation between c erb B 2 expression and tumour free interval . c erb B 2 expression had no influence on response to treatment with tamoxifen among patients co expressing both c erb B 2 and estrogen receptor ( ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , CD44std , Ki 67 , c erb B 2 , p 53 , ER and PR expression were studied on the same tissue samples by the same method . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Histopathology and case notes of metaplastic carcinomas with predominant spindle cell differentiation were analysed for patient demographics , tumour pathology , c erb B 2 oestrogen ( ER ) and progesterone ( PR ) receptor status and radiology . ^^^ Negative ER , PR and c erb B 2 status limits treatment options . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , the following parameters were determined in all tumors : DNA ploidy by means of flow cytometry ; hormone receptor ( ER & PR ) , Ki 67 , c erb B 2 and p 53 expression by means of immunohistochemistry ; and h MAM ( mammaglobin ) expression by means of RT PCR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical studies of MIB 1 ( Ki 67 ) , estrogen receptors ( ER ) , progesterone receptors ( PR ) , p 53 , and c erb B 2 were performed in 55 cases of primary breast carcinoma on cell blocks ( cytoblock technique ) and on their corresponding tissue samples ( 46 mastectomy specimens and 9 Trucut biopsies ) and in 38 cases on cell blocks from fine needle cytopunctures of both the primary breast tumors and their concurrent lymph node metastases . ^^^ A good correlation was observed between immunostaining assessment on cell blocks and on the corresponding tumor tissues as follows : Ki 67 ( 85 % ) , ER ( 96 % ) , PR ( 82 % ) , p 53 ( 76 % ) , and c erb B 2 ( 84 % ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Strong expression of estrogen receptor , weak expression of progesterone receptor , and lack of expression of androgen receptor by both tumors were demonstrated by immunohistochemistry , as well as lack of expression of p 53 and C ERB B 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Core biopsies were performed in all cases prior to treatment for histological diagnosis which allowed for the determination of the following parameters by means of immunohistochemistry : hormone receptors ( ER and PR ) , oncogenes and tumor suppressor genes ( c erb B 2 and p 53 ) and the proliferation marker Ki 67 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To evaluate the effect of formalin fixation on breast tumor markers , multitumor blocks of tissue fixed in formalin for varying time intervals from 33 different infiltrating breast carcinomas were analyzed for the expression of estrogen receptor ( ER ) , progesterone receptor ( PR ) , c erb B 2 , Ki 67 , p 27 , and vimentin . ^^^ The loss of antigen preservation is not accompanied by a loss of vimentin immunoreactivity , making vimentin a suboptimal marker for ER , PR , or c erb B 2 preservation . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor status , progesterone receptor status , c Erb B 2 expression , p 53 expression , and Bcl 2 expression were evaluated by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin blocks corresponding to the same tumors were used for immunohistochemistry , to study the expression of hormone receptors ( ER and PR ) , p 53 , c erb B 2 and the Ki 67 labelling index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Histopathological grade , estrogen receptor status or expression of the c erb B 2 protein of the original tumours did not significantly correlate with the resistance of cultures . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We compared the MSI incidence with the expression of prognostic markers , such as p 53 , c erb B 2 , estrogen receptor , and progesterone receptor , and found no significant correlation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : We conducted a cross sectional analysis in 546 women diagnosed with invasive breast cancer to evaluate the associations between breast density and tumor size , lymph node status , lymphatic or vascular invasion , histologic grade , nuclear grade , tumor differentiation , mitotic index , tumor necrosis , Ki 67 proliferation , estrogen receptor , progesterone receptor , p 53 , p 27 , cyclin E , Bcl 2 , and C erb B 2 invasion . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All tumors were studied after surgery for hormone receptor ( ER and PR ) , Ki 67 , c erb B 2 and p 53 expression by means of immunohistochemistry , and for DNA ploidy by means of flow cytometry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
DESIGN : We constructed a tissue microarray from 38 cases of IMC and performed immunohistochemical stainings for cytokeratin ( CK ) 7 , CK 20 , estrogen receptor , progesterone receptor , p 53 , c Erb B 2 , CD 34 , CK 5 , epidermal growth factor receptor , and c Kit in both MC and non MC components . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Furthermore , hormone receptor ( estrogen receptor , ER ; progesterone receptor , PR ) , c erb B 2 and p 53 expressions were studied using the same method . ^^^ RESULTS : A DNA index > 1 ( aneuploidy ) correlated significantly with histological grade 3 ( p = 0 . 01 ) , nuclear grade 3 ( p < 0 . 0001 ) , nodal invasion ( p = 0 . 007 ) , absence of ER ( p = 0 . 006 ) and of PR ( p = 0 . 002 ) , c erb B 2 expression ( p = 0 . 008 ) , p 53 expression ( p = 0 . 007 ) and tumor size ( p = 0 . 01 ) . ^^^ An expression of Ki 67 in 20 % or more of tumor cell nuclei , on the other hand , correlated significantly with histological grade 3 ( p < 0 . 0001 ) , nuclear grade 3 ( p < 0 . 0001 ) , absence of ER ( p < 0 . 0001 ) and of PR ( p < 0 . 0001 ) , c erb B 2 expression ( p < 0 . 0001 ) , p 53 expression ( p < 0 . 0001 ) and tumor size ( p = 0 . 0005 ) , but not with nodal invasion . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Other clinical / pathological markers ( ER , PR , c erb B 2 , LN status ) were not significantly different between patients with CaR positive or CaR negative tumours . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen ( ER ) and progesterone receptors ( PR ) and c erb B 2 were negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
These results were correlated with the estrogen receptor alpha ( ERalpha ) and beta ( ERbeta ) , progesterone receptor , androgen receptor , CDC 47 and c erb B 2 expressions and with the tumor stages . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ErbB 2 amplification significantly occurs in tumors whose estrogen receptor and progesterone receptor were below the cut off value or absent and tumors with dissociated estrogen receptor and progesterone receptor status were revealed as entities similar to both estrogen receptor and progesterone receptor negative tumors . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumor specimens have also been analyzed for the presence of mRNAs for the estrogen receptor and for the ERBB 2 oncogene . ^^^ No evidence for the presence of truncated forms of estrogen receptor mRNA has been found , and overexpression of the ERBB 2 oncogene did not correlate with the steroid receptor status or pS 2 gene expression . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of an endoplasmic reticulum ( ER ) form of the anti erbB 2 sFv resulted in a profound down regulation of cell surface erbB 2 in an erbB 2 overexpressing ovarian carcinoma cell line . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We studied the expressions of aberrant epidermal growth factor receptor ( EGFR ) gene or erbB 2 , which is highly homologous to EGFR gene , and erbA or estrogen receptor ( ER ) gene , which is highly homologous to erbA , as a preliminary study , to know which oncogene expressions are associated with the development of endometrial cancers . ^^^ The behavior of aberrant erbB 2 and ER gene co expressions is considered of similar to that of erbA and erbB co expressions in the chicken introduced by the avian erythroblastosis virus , which leads to the development of erythroblastosis in the chick , and seems to be associated with the development of endometrial cancer . . ^^^ Aberrant estrogen receptor gene and erbB 2 expressions . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Such high levels of protein expression were exclusively observed in invasive ductal carcinomas and were prevalent in those showing a significant in situ component . 2 ) `` Intermediate ' ' levels of expression ( 3 10 U / micrograms ) were rarely observed in tumors exhibiting gene amplification ( 9 % ) , but were preferentially found in cancers of more favorable prognosis ( only 49 % were aneuploid and 9 % estrogen receptor negative ) . 3 ) Levels of p185 / ERBB2 below 3 U / micrograms were detected in benign mastopathies and , thus , carcinomas presenting such levels were scored ERBB 2 negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Similarly , a significant association was observed between amplification of ERBB 2 and the absence of either ER or PgR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Strikingly , we have recently observed that the erbB 2 signalling pathway can be modulated by estrogen acting through the estrogen receptor ( ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Accumulation of p 53 was significantly correlated to tumour size over 20 mm , negative oestrogen receptor ( ER ) status , DNA aneuploidy , high S phase fraction and positive erbB 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Since ST 3 mRNA expression was independent of the EGFR , ER and erbB 2 protein expression , ST 3 may be a new potent prognostic guide for breast carcinomas , which can detect highly malignant subpopulations . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression of mRNAs for epidermal growth factor ( EGF ) , transforming growth factor alpha ( TGF alpha ) , EGFR , platelet derived growth factor ( PDGF ) A and B chain , PDGF receptor ( PDGFR ) , transforming growth factor beta ( TGF beta ) , erbB 2 and estrogen receptor ( ER ) genes was first examined in 6 human esophageal carcinoma cell lines , 6 xenoplanted and 15 surgically resected esophageal carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To investigate how the expressed UDPGT was retained in the ER , we constructed chimeric plasmids of cDNAs of UDPGT and ErbB 2 which is a receptor protein localized in the cell membranes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Within the 100 IBC , expression of erbB 2 significantly correlated with high histologic and nuclear grading , with high growth fraction , and with estrogen receptor ( ER ) and progesterone receptor ( PgR ) negative tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
As a first consequence , the modulation of erbB 2 expression level by antiestrogen may represent a point to consider when selecting breast cancer patients for hormonal therapy , in those ( few ) cases where estrogen receptor positivity accompanies erbB 2 amplification . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The data presented here suggest a close cross regulation between the erbB 2 / 4 receptors and ER and provide new insights into the mechanism by which breast cancer cells acquire a hormone independent phenotype . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The scFvs were provided with a signal peptide which directs them to the secretory pathway of the cell . scFv 225 , which competes with EGF for binding , functions in an autocrine fashion to inhibit EGF dependent cell growth . scFv FRP 5 was also provided with an endoplasmic reticulum ( ER ) retention signal and inactivates ErbB 2 in an intracrine fashion , by preventing its appearance on the cell surface . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study , the effects of a putative erbB / HER ligand , gp 30 , on estrogen receptor ( ER ) concentration and activity was investigated in the estrogen receptor positive human breast cancer cells , BT 474 and MCF 7 , which express either high or low levels of erbB 2 and erbB 4 , respectively . ^^^ The effects of gp 30 on estrogen receptor concentration and activity were independent of the level of erbB 2 and erbB 4 in the cell . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Recombinant adenoviruses encoding either a reporter gene ( AdCMVLacZ ) or the endoplasmic reticulum ( ER ) directed anti erbB 2 sFv ( Ad 21 ) were delivered to various breast cancer cell lines . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Oestrogen receptor ( ER ) positive tumour derived cell lines are known to express relatively low levels of ERBB 2 protein under oestrogenic conditions , but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen . ^^^ A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB 2 promoter in two types of transient transfection assay . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Total protein kinase C ( PKC ) activity and the expression of 9 isoforms were determined in the estrogen receptor ( ER ) positive MCF 7 human breast cancer cell line , this line transfected to overexpress either PKC  or erbB 2 , and in 3 ER negative breast cancer cell lines . ^^^ Transfection to overexpress erbB 2 , with ER retention and slowed growth , produced a decrease in PKC alpha and gamma . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , by several assays , this sFv was shown to be unable to retain the erbB 2 protein within the ER . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We have developed plasmid and adenoviral vectors expressing an anti erbB 2 single chain antibody ( sFv ) , directed to the endoplasmic reticulum ( ER ) of target cells , that is cytotoxic to tumor cells overexpressing erbB 2 through induction of apoptosis . ^^^ METHODS AND MATERIALS : To test our hypothesis , we established subcutaneous ( s . c . ) tumors in the flanks of nude mice with SKOV3 . ip1 human ovarian cancer cells and SKOV 3 cells stably expressing the ER directed anti erbB 2 sFv ( SKOV3 / pGT21 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The AP 2 genes are expressed in many human breast cancer cell lines , and critical AP 2 binding sites are present in both the ERBB 2 ( HER2 / neu ) and estrogen receptor promoters . ^^^ There was also a significant correlation between the presence of the AP 2alpha protein and estrogen receptor expression ( P = 0 . 018 ) and between specimens containing both AP 2alpha / AP 2gamma proteins and ERBB 2 expression ( P = 0 . 003 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The most representative tumor samples were derived to a single laboratory for immunohistochemical evaluation of the following molecular markers : ER , PR , proliferating cell nuclear antigen ( PCNA ) , p 53 protein product , erbB 2 ( HER 2 / neu ) oncoprotein , and P 170 glycoprotein ( mdrl gen product ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To direct recombinant ErbB 2 to the cytoplasm where major histocompatibility complex ( MHC ) 1 peptide processing takes place , the endoplasmic reticulum ( ER ) signal sequence was deleted in cyt ErbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Both the primary tumor and LN metastasis were positive for estrogen receptor ( ER ) and progesterone receptor ( PgR ) , but lacked erbB 2 expression . ^^^ Approximately one year later , the patient presented with a 0 . 8 cm comedo type intraductal mammary adenocarcinoma in the left breast that was negative for ER and PgR , but positive for erbB 2 . ^^^ The bone metastasis was a poorly differentiated adenocarcinoma lacking ER , PgR , and erbB 2 , characteristics shared by the LCC 15 MB cells , although ER can be re expressed by treatment of the LCC 15 MB cells for 5 days with 75 microM 5 aza 2 ' deoxycytidine . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Thus , expression of AP 2alpha / beta was found to correlate significantly with expression of both ER ( p=0 . 036 * ) and the universal cell cycle inhibitor p 21 ( cip ) ( p=0 . 03 * ) , but was inversely related to levels of the proto oncogene ErbB 2 ( p=0 . 008 * ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In human breast cancer , lack of response to endocrine therapy is often associated with decreased expression of the estrogen receptor and increased expression of epidermal growth factor receptor ( EGFR ) and / or HER 2 / neu ( ErbB 2 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen induced erbB 2 tyrosine kinase activity in human breast epithelial cells irrespective of estrogen receptor expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , expression of genes was differential in tumors with lymph node metastasis and according to the estrogen receptor status ; ERBB 2 expression was strongly correlated with the lymph node status ( P < 0 . 0001 ) and that of GATA 3 with the presence of estrogen receptors ( P < 0 . 001 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
TCDD elevates erbB 2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity , independent of estrogen levels and enhanced ER down regulation . 2 , 3 , 7 , 8 Tetrachlorodibenzo p dioxin ( TCDD ) induced erbB 2 and erbB 3 in estrogen receptor ( ER ) positive T47D ( T47D+ ) cells , but substantially slower than the direct induction of CYP1A1 or CYP1B1 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ErbB 2 status was significantly associated with recurrence and death in Cox multivariate analysis , adjusting for nodal status , tumour size and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
For carcinoma of the breast , these approaches have been applied in the context of the disease linked oncogenes erbB 2 and cyclin D 1 , as well as the estrogen receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In order to study the association of histological grade ( HG ) with specific clinical and biological parameters which may influence the clinical behavior of infiltrating ductal carcinomas of the breast ( IDC ) , we analyzed in 229 tissue samples the cytosolic concentrations of estrogen receptor ( ER ) , progesterone receptor ( PR ) , pS 2 , cathepsin D , hyaluronic acid ( HA ) and tissue type plasminogen activator ( t PA ) , as well as those of the erbB 2 oncoprotein , epidermal growth factor receptor ( EGFR ) , HA , CD44v5 and CD44v6 in the cell membrane fraction . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In oestrogen receptor ( ER ) positive breast epithelial cells oestrogens reduce ERBB 2 mRNA and protein levels , an effect that is reversed in the presence of anti oestrogens such as tamoxifen and ICI 182780 . ^^^ Our previous studies have shown that the major effect of oestrogen on ERBB 2 expression is at the level of transcription and that this is mediated through a region within the ERBB 2 first intron which can act as an oestrogen suppressible enhancer in ER positive breast cells . ^^^ Indeed , the essential domain of the ER responsible for repression of the ERBB 2 enhancer is a region termed AF 2 which is required for the ligand dependent association of non DNA binding cofactors . ^^^ We further demonstrate that one of these ER cofactors , SRC 1 , can relieve oestrogen repression of the ERBB 2 enhancer and conclude that these data fit with a model whereby the ER and the ERBB 2 enhancer compete for this limiting , non DNA binding cofactor . ^^^ Thus , in oestrogenic conditions SRC 1 preferentially binds to the ER which effectively sequesters it thereby reducing enhancer activity , but in antioestrogenic media the cofactor is released from the ER and is therefore available to activate the ERBB 2 enhancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The presence of the 10 allele of ER gene significantly correlated with the overexpression of the erbB 2 and EGFR oncogenes . ^^^ The XXbb allelic combination of the ER / VDR genes was associated with a significantly lower erbB 2 expression , whereas in the other genotypes significantly higher oncogene expression was seen . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
When comparing p 53 positivity and other clinicopathological parameters , significant differences were found with younger age ( p = 0 . 017 ) , premenopausal status ( p = 0 . 003 ) , increasing tumor size ( p = 0 . 026 ) , negative estrogen receptor ( p = 0 . 003 ) and negative progesterone receptor ( p = 0 . 047 ) , but not with histologic grade , axillary lymph node status , stage or erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Differences in response rates between letrozole and tamoxifen were most marked for tumors that were positive for ErbB 1 and / or ErbB 2 and ER ( 88 % 5 21 % , P = . 0004 ) . ^^^ This suggests that ErbB 1 and ErbB 2 signaling through ER is ligand dependent and that the growth promoting effects of these receptor tyrosine kinases on ER+ breast cancer can be inhibited by potent estrogen deprivation therapy . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The tumors also display extensive genetic / molecular alterations , including overexpression of ErbB 2 , c Myc , p 27 and Cyclin D 1 in the majority of tumors , while they were virtually ERalpha and p 16 negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We observed a negative correlation between ERalpha and ERbeta expression . ' ERalpha negative ' tumors ( containing very low ERalpha mRNA levels ) were associated with SBR histopathological grade 3 , RB 1 underexpression and ERBB 2 overexpression , confirming that ERalpha negativity delineates poorly differentiated tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Full length ErbB 2 is efficiently processed via the endoplasmic reticulum ( ER ) and Golgi network , so that at steady state most of the detectable protein is plasma membrane associated . ^^^ Drug sensitivity of nascent ErbB 2 is distinguished by 2 characteristics protein instability and inability to traverse the ER . ^^^ As nascent ErbB 2 can associate with both cytoplasmic Hsp 90 and its ER luminal homolog Grp 94 , also a GA binding protein , the purpose of this study was to examine the relative contributions of the cytoplasmic and ER luminal domains of ErbB 2 to the GA sensitivity of the nascent kinase . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We have examined whether signaling by HER2 / neu ( erbB 2 ) receptor tyrosine kinase , which can induce antiestrogen resistance , can also disrupt the tamoxifen induced interaction of ER with transcriptional corepressors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The biopsy specimens were used for CD DST and immunohistological examination of 6 biological markers ( P gp , erbB 2 , p 53 , BCL 2 , MIB 1 and ER alpha ) . ^^^ Expressions of other biological markers ( erbB 2 , p 53 , BCL 2 , MIB 1 and ER alpha ) were not significantly associated with response to CE or DOC therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor ( ER ) , progesterone receptor , epidermal growth factor receptor , erbB 2 , and HSP 27 were measured by immunohistochemistry in paraffin fixed material obtained from the primary tumors at initial surgery . ^^^ Using CA 125 criteria , comparison of the CA 125 stable / responding disease with progressive disease indicated that tumors with higher ER ( P = 0 . 013 ) , lower erbB 2 ( P = 0 . 026 ) , and higher epidermal growth factor receptor ( P = 0 . 009 ) were associated with CA 125 stable / responsive disease . ^^^ Estrogen receptor ( ER ) , progesterone receptor , epidermal growth factor receptor , erbB 2 , and HSP 27 were measured by immunohistochemistry in paraffin fixed material obtained from the primary tumors at initial surgery . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The prognostic biomarkers chosen for comparison represented surrogate measures of tumor : ( 1 ) . proliferation , growth and genetic instability ( mitotic and apoptotic indices , Ki 67 / MIB 1 positivity , nuclear grade , p 53 positivity ) , ( 2 ) . endocrine dependence ( estrogen receptor ( ER ) , progesterone receptors ( PR ) , pS 2 , Bcl 2 ) , ( 3 ) . growth factor receptor dependence ( ErbB 2 , EGFR / ErbB1 ) , and ( 4 ) . angiogenic , invasive and proteolytic potential ( uPA , PAI 1 , Cathepsin D , VEGF ) . ^^^ In particular , breast tumors arising in older patients have slower growth rates , are more likely to be ER positive , and are less likely to be p 53 positive , EGFR positive or ErbB 2 positive . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All specimens were analysed by standard immunohistochemistry for ERa , PR , cyclin D 1 , bcl 2 , p 53 and erbB 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using real time quantitative PCR assays , mRNA levels of ERalpha , ERbeta , epidermal growth factor receptor , ErbB 2 , ErbB 3 , ErbB 4 , ERRalpha , ERRbeta , and ERRgamma were determined in unselected primary breast tumors ( n = 38 ) and normal mammary epithelial cells enriched from reduction mammoplasties ( n = 9 ) . ^^^ Thus , ERRalpha was the most abundant nuclear receptor in a subset of tumors that tended to lack functional ERalpha and expressed ErbB 2 at high levels . ^^^ Consequently , ERRalpha may potentiate constitutive transcription of estrogen response element containing genes independently of ERalpha and antiestrogens in ErbB 2 positive tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To evaluate the role of the phosphatidylinositol 3 kinase ( PI3K ) / Akt pathway in breast cancer cell survival and therapeutic resistance , we analyzed a panel of six breast cancer cell lines that varied in erbB 2 and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It has been reported that overexpression of the epidermal growth factor receptor ( erbB 1 ) or its homologous receptor , HER 2 ( erbB 2 ) , can confer antiestrogen resistance to estrogen receptor ( ER ) positive human breast cancer cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Finally , expression of the oncogenic activated ErbB 2 / Neu protein specifically enhanced ERalpha but not ERbeta interactions with SRC RIDs to an extent similar to E 2 stimulated interactions . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor ( ER ) , progesterone receptor , erbB 2 , p 53 , and Ki 67 expression was determined from tumor tissue microarrays using immunohistochemistry , and the erbB 2 ( HER 2 ) amplification status was determined using chromogenic in situ hybridization . ^^^ ER and progesterone receptor values obtained from the hospital case records or tumor microarrays showed weaker association with outcome than the erbB 2 status . ^^^ The erbB 2 status was superior to ER as a prognostic factor in these tumors . . ^^^ Amplification of erbB 2 and erbB 2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer : a nationwide population based study . ^^^ Estrogen receptor ( ER ) , progesterone receptor , erbB 2 , p 53 , and Ki 67 expression was determined from tumor tissue microarrays using immunohistochemistry , and the erbB 2 ( HER 2 ) amplification status was determined using chromogenic in situ hybridization . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We sought relationships between mRNA levels of the coregulators and those of molecular markers , including ERalpha , ERbeta , CCND 1 , and ERBB 2 . ^^^ The relationship between mRNA expression of the coregulators , and ERalpha and beta only showed a significant positive correlation between GCN5L2 and ERalpha ( P = 0 . 015 ) . mRNA levels of CCND 1 correlated with those of all of the coregulators studied ( P < 0 . 05 or trend ) , whereas ERBB 2 mRNA levels only correlated with AIB 1 mRNA levels ( P = 0 . 011 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Enhanced estrogen receptor ( ER ) alpha , ERBB 2 , and MAPK signal transduction pathways operate during the adaptation of MCF 7 cells to long term estrogen deprivation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To investigate the significance of these mechanisms on an early stage of human breast tumour growth , we studied the expression of EGFR ( ErbB 1 ) , HER 2 / neu ( ErbB 2 ) , cyclin D 1 , p 21 and p 53 as well as oestrogen ( ER ) and progesterone receptor ( PgR ) in paraffin sections of 45 ductal carcinoma in situ ( DCIS ) by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on ER alpha expression and activity is mediated by ErbB 2 and not by EGFR . ^^^ Taken together , our results suggest that estradiol treatment results in binding to membrane ER alpha and interaction with a heterodimer containing ErbB 2 , leading to tyrosine phosphorylation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ERBB 2 positivity and bcl 2 , oestrogen receptor ( ER ) and progesterone receptor ( PR ) negativity were individually associated with the risk of clinical recurrence . ^^^ ERBB 2 , bcl 2 , ER and PR expression were conserved in the recurrent lesions , including subsequent invasive cancers . p 21 positive DCIS was also associated with clinical recurrence , independently of the associations with ERBB2 / bcl 2 / ER / PR expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The gene expression levels in the two model systems were found to be quite similar in relation to ERalpha , AIB 1 ( amplified in breast cancer 1 ) , breast cancer antiestrogen resistance gene 1 ( BCAR 1 ) and ErbB 2 mRNA expression , whereas significant differences were observed on the expression of ERbeta , multidrug resistance gene 1 ( MDR 1 ) , PR and EGFR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
These paired specimens were simultaneously analyzed for Ki 67 , ER , progesterone receptor ( PgR ) , trefoil factor 1 ( PS 2 ) , HER 1 ( epidermal growth factor receptor ) , and HER 2 ( ErbB 2 or neu ) by semiquantitative immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Although ERBB 2 signaling has been proposed to inhibit the transcriptional activity of ER , a large proportion of the perturbed genes in the ' low confidence ' / ERBB2+ samples are not known to be estrogen responsive , and a recently described bioinformatic algorithm ( DEREF ) was used to demonstrate the absence of potential estrogen response elements ( EREs ) in their promoters . ^^^ We propose that a significant portion of ERBB 2 ' s effects on ER+ breast tumors may involve ER independent mechanisms of gene activation , which may contribute to the clinically aggressive behavior of the ' low confidence ' breast tumor subtype . . ^^^ Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB 2 receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We also observed positive links between the expression of PEA 3 and those of MKI 67 and ERBB 2 ( P = 0 . 034 and P = 0 . 045 , respectively ) and an inverse relationship with ERalpha ( P = 0 . 0016 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Thus , signal transduction via EGFR and erbB 2 could be related to the estrogen induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF like growth factors , leading to ERalpha activation that may result in cancerous lesions in vaginae from neonatally DES exposed mice later in life . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry revealed that the sarcomatous cells were positive for alpha smooth muscle actin ( alpha SMA ) , vimentin , calponin , S 100 protein , epithelial membranous antigen ( EMA ) , cytokeratin ( large spectrum ) and cytokeratin 14 ( CK 14 ) in the cytoplasm , and p 53 , erbB 2 and progesterone receptor in the nuclei , but negative for desmin and estrogen receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No relationship was found between nuclear localized Stat5a and menopausal status , tumor size , ploidy , percentage of cells in S phase , lymph node metastases , ER , ErbB 2 , nuclear localized p 21 or nuclear localized Stat5b / Stat3 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This ERBB 2 specific gene expression signature ( GES ) contained 29 overexpressed genes including the ERBB 2 gene itself , five genes located in its immediate vicinity on 17q12 , non 17q genes such as GATA 4 and eight downregulated genes including oestrogen receptor alpha ( ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The importance of oestrogen receptor alpha ( gene ESR 1 ) and Her 2 / neu ( ERBB 2 ) as classifiers for cell lines and tumours is underlined . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHOD : mRNA transcripts for aromatase ( CYP 19 ) , 17 beta hydroxysteroid dehydrogenase 1 , 17 beta hydroxysteroid dehydrogenase 2 , ERalpha , ERbeta , steroid sulfatase ( STS ) , oestradiol sulfotransferase ( EST ) , cyclin D 1 ( CYCLD 1 ) and ERBB 2 were fluorometrically quantified by competitive RT PCR using an internal standard in 155 breast carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tissue microarrays ( TMAs ) were used to determine the immunohistochemical profile of eight proteins including E cadherin , EGFR , oestrogen and progesterone receptor ( ER and PR ) , MIB 1 , ERBB 2 , MUC 1 , and P 53 . ^^^ The five variables that were significantly associated with IBC in multivariate analysis were E cadherin > or = 300 [ HR = 5 . 64 ( 2 . 92 10 . 87 ) ] , ER negative [ HR = 3 . 00 ( 1 . 67 5 . 51 ) ] , MIB 1 > 20 [ HR = 3 . 54 ( 1 . 87 6 . 71 ) ] , MUC 1 cytoplasmic staining [ HR = 2 . 72 ( 1 . 49 4 . 96 ) ] , and ERBB 2 positive 2+ or 3+ [ HR = 2 . 46 ( 1 . 26 4 . 78 ) ] . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry data ( ER , PR , ERBB 2 , P 53 ) on pre chemotherapy specimens suggested strong differences between IBC and non IBC . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Microarray studies have shown that this phenotype is associated with breast cancers that express neither estrogen receptor ( ER ) nor erbB 2 ( HER2 / neu ) ( i . e . , ER / erbB 2 negative tumors ) . ^^^ The ER / erbB 2 negative phenotype is also found in breast cancers occurring in BRCA 1 mutation carriers ( i . e . , BRCA 1 related breast cancers ) . ^^^ Among 292 breast cancer specimens previously analyzed for ER , erbB 2 , p 53 , and germline mutations in BRCA 1 and BRCA 2 , we identified 76 that did not overexpress ER or erbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Akt activation was blocked by wortmannin and LY 294 , 002 , two inhibitors of PI 3 K ; by genistein , a protein tyrosine kinase inhibitor and an ER agonist ; by AG 825 , a selective ErbB 2 inhibitor ; and by the antiestrogens ICI 182 , 780 and 4 hydroxy tamoxifen ; but not by rapamycin , an inhibitor of the ribosomal protein kinase p70S6K ; nor by AG 30 , a selective epidermal growth factor receptor inhibitor . ^^^ Taken together , our data suggest that estradiol , bound to membrane ERalpha , interacts with and activates an ErbB dimer containing ErbB 2 , inducing activation of PI 3 K / Akt . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
They were , like breast tumors in general , mainly ErbB 2 low ( 11 of 13 were low ) and estrogen receptor positive ( 11 of 13 positive ) . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Although transcription factors AP 2alpha and AP 2gamma have been implicated in the control of estrogen receptor ( ER ) and ErbB 2 , their impact for breast cancer is still controversial . ^^^ A total of 51 specimens of female breast cancer patients and a tissue microarray containing 93 additional female breast cancer cases were immunohistochemically stained for AP 2alpha , AP 2gamma , ER and ErbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : The retrovirus pBabe 5R , which encodes an erbB 2 single chain antibody with an endoplasmic reticulum ( ER ) targeting sequence , and control pBabe puro were used to infect THCE cells ( an SV 40 immortalized HCEC line ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To test this hypothesis , we examined whether ER alpha positive and Ki 67 positive tumors showed differences in ( 1 ) pathological grade , ( 2 ) three indices of tumor grade ( tubule formation , nuclear pleomorphism , and mitotic number ) , and ( 3 ) expression of important proteins implicated in breast tumorigenesis ( cyclin D 1 , ErbB 2 , ATM , BRCA 1 , Rb , p 53 , and p 21 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Greater letrozole responses were associated with high and low levels of estrogen receptor expression and with coexpression of ErbB 1 and / or ErbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This study examines whether the serine / threonine protein kinase , Akt , is involved in the crosstalk between the ErbB 2 and estrogen receptor alpha ( ER alpha ) pathways . ^^^ Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG beta 1 on ER alpha expression and activity is also mediated by ErbB 2 and not by EGFR , demonstrating that ErbB 2 is the primary mediator of the effects of HRG beta 1 on ER alpha regulation . ^^^ Taken together , our data suggest that HRG beta 1 , bound to the ErbB 2 ErbB3 heterodimer , in the presence of membrane ER alpha , interacts with and activates PI 3 K / Akt . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : Comparing cases and controls , there were no differences in expression of ERalpha ; progesterone receptor , ErbB 2 ; or tumor grade . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Deregulated signaling of ErbB 2 receptor tyrosine kinase is often associated with hormone resistance in estrogen receptor alpha ( ERalpha ) positive breast cancers , establishing a relationship between ErbB 2 and ERalpha pathways . ^^^ Although ERalpha and ERbeta are expressed in many breast cancer cells , the response of ERbeta to ErbB 2 signaling is less well defined . ^^^ The estrogen dependent transcriptional activity of ERbeta was altered in a manner similar to ERalpha by either activation of ErbB2 / ErbB3 signaling by growth factor heregulin beta or expression of a constitutively active mutant of ErbB 2 . ^^^ However , as opposed to ERalpha , the p 38 MAPK pathway was found to be involved in liganded ERbeta repression activity by ErbB 2 signaling and in regulating estrogen responsive promoter occupancy by ERbeta . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In xenografts , combined treatment with ER down regulator fulvestrant and letrozole , prevented increases in erbB 2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment . ^^^ In cells isolated from tumors after 56 weeks and maintained as a cell line ( LTLT Ca ) in 1 micromol / L letrozole , ERalpha was also decreased whereas erbB 2 , adapter proteins ( p Shc and Grb 2 ) , and the signaling proteins in the mitogen activated protein kinase ( MAPK ) cascade were increased compared with MCF 7Ca cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIALS AND METHODS : Three hundred and twenty four samples of invasive breast cancer were immunohistochemically stained for ER and PgR , bcl 2 and erbB 2 . ^^^ The correlation between immunohistochemistry results of ER , PgR , bcl 2 and erbB 2 as well as SMI ( standardized mitotic index ) , patient age , tumor size and axillary lymph node status were tested . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining of sections from paraffin wax embedded tissues from these cases for the expression of oestrogen receptor ( ER ) , progesterone receptor ( PGR ) , Human ERBB 2 ( or HER2 / neu ) , p 53 and cyclin D 1 ( CCND 1 ) was carried out using the avidin biotin complex ( ABC ) procedure . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
These results suggest that NASBA is well suited for assessing ER , PR and ERBB 2 status in breast tumor samples . ^^^ In human breast cancer , estrogen receptor alpha ( ERalpha ) , progesterone receptor ( PR ) and human epidermal growth factor receptor ( ERBB 2 ) status are currently determined using different techniques . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We found increased expression levels for estrogen receptor ( ER ) and ERBB 2 in PIK3Ca mutant lines . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Phosphorylated ERBB 2 correlated with EGFR and ERBB 2 , and inversely with oestrogen receptor ( ER ) , progesterone receptor ( PgR ) and ERBB 4 expression levels . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Transfection of PI3K siRNA in breast cancer cells resulted in a significant decrease in cell viability and induction of apoptosis irrespective of their estrogen receptor alpha ( ERalpha ) or ErbB 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aggregation of ErbB 2 and herstatin was found in endoplasmic reticulum ( ER ) . ^^^ The decrease of ErbB 2 on the cell surface was accompanied with the increased colocalization of ErbB 2 and herstatin in the cytoplasm , suggesting that the formation of ErbB2 / herstatin complex may prevent transit from ER to cell surface of ErbB 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : On a univariate basis , the following features were significantly associated with worse survival : high pathologic tumor or nodal class , histologic grade , epidermal growth factor receptor , ERBB 2 , MYC , or TP 53 ; absent estrogen receptor ( ER ) or progesterone receptor ; and low BCL 2 . ^^^ However , the benefit of ER positive status was moderated by BCL 2 , ERBB 2 , and progesterone receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using the same culture conditions , we tested the blocking action of growth factor antibodies for erbB 2 ( 9G6 ) and insulin like growth factor ( IGF Ab ) receptors and discovered they inhibited BG 1 proliferation ( 9G6 : HE and beta HCH / IGF Ab : Endo . ) This experiment confirms the existence of a possible cross talk between ER and growth factor receptors in OC ligand dependent activation and also validates this sensitive method for determining both ligand dependent and independent estrogenic activity of selected pesticides . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : The distribution of initial clinical stage , tumor size , estrogen receptor or progesterone receptor status , menopausal status , or erbB 2 expression was not significantly different among the polymorphic variants . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using gene interference , we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB 2 alone to codependence upon ER and ErbB 2 rather than loss of ErbB 2 expression or insensitivity of ErbB 2 signaling to lapatinib . ^^^ Importantly , we confirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB 2 overexpressing breast cancers receiving lapatinib therapy . ^^^ These findings provided the rationale for preventing the development of acquired resistance by simultaneously inhibiting both ER and ErbB 2 signaling pathways . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this review we propose that , through a complex mechanism involving the regulation of MAPK / ER cross talk as well as critical E 2 related proteins including the Her 2 / neu ( erbB 2 ) oncogene and the cyclin dependent kinase inhibitors p 21 ( WAF1 / CIP1 ) and p 27 ( Kip 1 ) , a previously unrevealed connection exists between FASN and the genomic and nongenomic ER activities in breast and endometrial cancer cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The estrogen receptor alpha ( ERalpha ) , progesterone receptor ( PR ) , and erbB 2 ( Her 2 in humans ) are important prognostic markers of human breast cancer , and they are variably expressed in different subtypes of breast cancer . ^^^ Thus , mouse mammary stem cells were negative for ERalpha , PR , and ErbB 2 and appeared to share common properties with poor prognosis basal breast cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Moreover , activation of the HER 2 receptor in breast cancer cells by the peptide growth factor , heregulin , leads to direct and rapid phosphorylation of ER on tyrosine residues . ^^^ In addition , overexpression of HER 2 receptor in estrogen dependent tumor cells promotes ligand independent down regulation of ER and a delayed autoregulatory suppression of ER transcripts . ^^^ HER 2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells . ^^^ Clinical data indicate that overexpression of the HER 2 gene is associated with an estrogen receptor negative phenotype . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Since the poor prognosis associated with HER 2 amplified breast cancers might be explained by a mechanistic association between p185HER2 overexpression and therapeutic resistance , we assessed the chemo endocrine sensitivity of estrogen receptor ( ER ) containing MCF 7 breast cancer cells transfected with full length HER 2 cDNA . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The results of multiple linear regression analysis , with HER 2 as the dependent variable , showed that family history of breast cancer was significantly associated with elevated HER 2 levels in the tumors ( p = 0 . 0038 ) , after controlling for the effects of age , tumor estrogen receptor , and DNA index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HER 2 overexpression , patient age , estrogen receptor status , progesterone receptor status , and previous hormone treatment were assessed by univariate and multivariate analysis . ^^^ Decreased overall survival correlated significantly with HER 2 overexpression ( P = 0 . 004 ) and decreased expression of both estrogen receptor ( P = 0 . 032 ) and progesterone receptor ( P = 0 . 039 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In the present study , we investigated the effect of combined treatment with a humanized anti HER 2 monoclonal antibody , rhumAbHER 2 ( trastuzumab ) , and an anti oestrogen , ICI 182 , 780 , on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER 2 . ^^^ The combined treatment enhanced the growth inhibitory effect on ML 20 cells , which express a high level of ER and a moderate level of HER 2 , but showed no additive effect on either KPL 4 cells , which express no ER and a moderate level of HER 2 , or MDA MB 231 cells , which express no ER and a low level of HER 2 . ^^^ These findings indicate that combined treatment with anti HER 2 antibody and anti oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2 . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Therefore , to test the hypothesis that HER 2 / neu expression is associated with a poorer response to tamoxifen , a shorter time to treatment failure ( TTF ) , and worse survival in estrogen receptor ( ER ) positive metastatic breast cancer , we examined 205 paraffin embedded blocks of tumors from patients enrolled on Southwest Oncology Group 8228 for HER 2 / neu expression . ^^^ HER 2 / neu positivity was associated with lower ER values ( P = 0 . 04 ) and low bcl 2 ( P = 0 . 01 ) . ^^^ HER 2 / neu expression in ER positive metastatic breast cancer is not significantly associated with a poorer response to tamoxifen or a more aggressive clinical course . ^^^ Earlier suggestions to the contrary may have been due to failure to rigorously exclude ER negative tumors , which are much less likely to respond to tamoxifen and more likely to have high HER 2 / neu levels . . ^^^ HER 2 expression and response to tamoxifen in estrogen receptor positive breast cancer : a Southwest Oncology Group Study . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Overexpression of HER 2 in estrogen receptor ( ER ) positive human breast tumors has been associated with resistance to endocrine therapy . ^^^ Here we investigated the effects of HER 2 on expression of apoptotic pathways and modulation of tamoxifen induced apoptosis in ER positive MCF 7 breast cancer cells . ^^^ In addition , human tumor cell lines that are both ER positive and overexpress HER 2 also express enhanced levels of Bcl 2 compared to cells that are either ER positive or overexpress HER 2 alone . ^^^ Our findings suggest that possible deregulation of antiapoptotic Bcl 2 and Bcl XL may be associated with the enhanced survival of HER 2 overexpressing and ER positive breast cancer cells treated with antiestrogens . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The hybrid compounds are active and more selective than the parent causing degradation of ER and HER 2 , but not other GDM targets . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , ER positive breast tumors overexpressing EGF R and / or HER 2 ( Erb B 2 ) are resistant to endocrine therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Recent studies in the neoadjuvant context have shown a significant antiproliferative effect of endocrine therapy in HER 2 positive / ER positive tumours but this is much less than in HER 2 negative / ER positive tumours . ^^^ It is concluded that incomplete hormonal resistance results from co expression of HER 2 and ER and that this may differ between different hormonal agents . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Taken together , they uphold the emerging concern that women with ER ( + ) cancers may not benefit significantly from endocrine treatment if the tumors also overexpress HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Inhibition of HER 2 and MAPKs with AG 1478 and U 0126 , respectively , as well as dominant negative MEK 1 / 2 constructs restored the inhibitory effect of tamoxifen on estrogen receptor ( ER ) mediated transcription and cell proliferation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CONCLUSIONS : Our findings indicate that p 53 and HER 2 expression levels in the second tumors might be the same as those of the first tumors in metachronous bilateral breast carcinoma ; however , loss of ER was more frequently observed in the second primary tumors than in the first tumors . . ^^^ Differences in estrogen receptor status , HER 2 , and p 53 comparing metachronous bilateral breast carcinoma . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin embedded tumor tissues were examined for protein expression of estrogen receptor ( ER ) , PR , Ki 67 , cyclin D 1 , TP 53 , HER 2 , beta catenin , and cyclin E using immunohistochemical approaches . ^^^ After age stratification , we found a significant difference in the frequency of tumors of BRCA 1 mutation carriers diagnosed before 50 years of age compared with age matched controls that stained positive for ER ( P = 0 . 01 ) , PR ( P = 0 . 03 ) , Ki 67 ( P = 0 . 008 ) , cyclin D 1 ( P < 0 . 001 ) , HER 2 ( P = 0 . 04 ) , and beta catenin ( P = 0 . 05 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry was used to determine the status of estrogen receptors ( ER ) , progesterone receptors ( PR ) , the expression of cell proliferation marker Ki 67 , and the overexpression of HER 2 / neu and p 53 protein . ^^^ The significantly different immunohistochemical expression of ER , PR , Ki 67 , and HER 2 in PPSPCs compared with OSPCs suggests that different molecular events may lead to tumorigenesis in these two cancers . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study we describe detailed immunohistochemical analysis of nuclear and cytoplasmic STATs 1 and 3 expression in primary breast carcinomas and correlate this with EGFR , HER 2 , p 53 , ER , PR , p21 / waf1 , Bcl XL and Ki 67 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In experimental models , human epidermal growth factor receptor 2 ( HER 2 ) amplification leads to estrogen independence and tamoxifen resistance in estrogen receptor ( ER ) positive human breast cancer cells . ^^^ This study aimed to evaluate the antiproliferative effects of endocrine therapy in HER 2 positive / ER positive primary human breast cancer . ^^^ Mean ER levels were lower in the HER 2 positive patients ( P = 0 . 06 ) but the change in Ki 67 was impeded even in those with high ER . ^^^ It is concluded that ER positive / HER 2 positive primary breast carcinomas show an impeded antiproliferative response to endocrine therapy that nonetheless may vary between individual treatments . ^^^ HER 2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor positive primary breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The treatment for PSCP was similar to that for advanced EOC and immunohistochemical studies were performed using archival material for PSCP and EC in order to determine p 53 , Bcl 2 , HER 2 , and estrogen and progesterone receptor ( ER , PR ) status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Almost all HER 2 positive patients had a negative estrogen receptor status ( 14 / 15 [ 93 . 3 % ] ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Interestingly , association with the unfavorable outcome was especially apparent in the subgroups defined by estrogen receptor positivity , low p 53 expression , and no HER 2 amplification ( P < 0 . 0001 for all comparisons ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER status is an important predictor of response to endocrine manipulation , but its independent prognostic significance , and that of micrometastatic disease , circulating carcinoma cells and other molecular factors , even well studied ones such as HER 2 status , are less clear . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The positivity rates for p 53 , HER 2 , estrogen receptor ( ER ) and progesterone receptor ( PR ) were 9 % ( 14 / 148 ) , 18 % ( 26 / 148 ) , 64 % ( 95 / 148 ) and 64 % ( 95 / 148 ) , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Furthermore , the interrelationship of HIF 1alpha with p 53 and HER 2 protein expression , estrogen receptor density , and survival was analyzed . ^^^ No correlation of HIF 1alpha and HER 2 expression or estrogen receptor density was observed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Some of the subclasses can be predicted by current molecular tests : estrogen receptor status , p 53 staining , and HER 2 overexpression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical analysis of 24 normal human breast samples and 124 consecutive breast carcinomas was correlated with tumor characteristics ( stage , histology , grade , lymph node involvement ) and the expression of ER , PR , Ki 67 , p 53 and HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining for p 53 , HER 2 , MIB 1 , bcl 2 , estrogen receptor ( ER ) and progesterone receptor ( PR ) was carried out on formalin fixed , paraffin embedded specimens . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no apparent association between NO2Y levels and the differentiation of the tumors , tumor aneuploidy , estrogen receptor status , HER 2 expression , lymph node status , or infiltration of the tumors by neutrophils or eosinophils . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor ( ER ) expression and Her 2 amplification define specific subsets of breast tumors for which specific therapies exist . ^^^ Interestingly , the subset of ER negative breast carcinomas overexpressing Skp 2 are also characterized by high tumor grade , negativity for Her 2 , basal like phenotype , high expression of certain cell cycle regulatory genes , and low levels of p 27 protein . ^^^ We conclude that Skp 2 has oncogenic potential in breast epithelial cells and is overexpressed in a subset of breast carcinomas ( ER and Her 2 negative ) for which Skp 2 inhibitors may represent a valid therapeutic option . . ^^^ Estrogen receptor ( ER ) expression and Her 2 amplification define specific subsets of breast tumors for which specific therapies exist . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Numerous biological markers such as p 53 , bcl 2 , oestrogen receptor ( ER ) and HER 2 have been assessed for their possible role in chemoresistance / response , but the data are not clear at this stage . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Histologic features of the primary tumor and immunohistochemical staining for estrogen receptor , progesterone receptor , Her 2 , and p 53 were also evaluated . ^^^ Estrogen receptor , progesterone receptor , Her 2 , and p 53 status did not predict the presence of metastases or survival when all tumor types were considered together . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HER 2 represents a successful therapeutic target of the biotechnology era as exemplified by the drug Herceptin ( trastuzumab ) , which has clinical activity in a subset of breast cancer patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The sections were also histologically graded and their oestrogen receptor ( ER ) , progesterone receptor ( PgR ) and HER 2 oncogene status was recorded . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
End points included : ( a ) . clinical and pathological response ; ( b ) . serial apoptotic [ terminal deoxynucleotidyl transferase ( Tdt ) mediated nick end labeling ] and proliferation ( immunohistochemistry , IHC ) rates ; and ( c ) . expression ( IHC ) of estrogen receptor , HER 2 , bcl 2 , and p 53 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Additionally , positive Phospho Stat 3 ( Tyr 705 ) nuclear expression is an independent prognostic marker of better overall survival node negative breast cancer by multivariate analyses that included the variables of nuclear grade , Ki 67 , estrogen receptor staining , progesterone receptor staining , Her 2 staining , age , and tumor size . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Role of the estrogen receptor coactivator AIB 1 ( SRC 3 ) and HER 2 / neu in tamoxifen resistance in breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The comparison related to patients ' characteristics and immunohistochemical expression of estrogen and progesterone receptors ( ER , PR ) , bcl 2 , HER 2 / neu , p 53 , and cell proliferation marker Ki 67 in endometrial and ovarian tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This review describes the roles of HER 2 , epidermal growth factor receptor ( EGFR ) , oestrogen receptor ( ER ) / progesterone receptor ( PgR ) , Ki 67 , Bcl 2 , p 53 and gene expression profiling in predicting responses to endocrine , cytotoxic and biological therapies . ^^^ ER and PgR remain the only well established predictive markers of responses to endocrine therapy , although HER 2 / neu has an emerging role in this area and in choice of adjuvant chemotherapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Sporadic breast tumors with a `` BRCA 1 like ' ' histopathological phenotype also demonstrated significantly lower frequency of HIN 1 promoter methylation ( P = 0 . 01 ) compared with other cancer types , and there was also a difference among tumors based on their estrogen receptor and HER 2 status ( P = 0 . 006 ) , suggesting that HIN 1 methylation patterns are associated with specific breast cancer subtypes . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry showed that , for HER 2 , p 53 , ER and PgR , discordance rates between primary and recurrent tumor were 2 ( 4 . 5 % ) , 1 ( 2 . 3 % ) , 7 ( 15 . 9 % ) and 10 ( 22 . 7 % ) , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We studied expression of SBR grade , estrogen ( ER ) and progesterone ( PR ) receptors , HER 2 , Ki 67 and P 53 on core biopsies before and after chemotherapy in a series of 115 patients , who received anthracycline based induction chemotherapy for primary breast cancer . ^^^ HER 2 , ER and PR status were stable during treatment . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Our data suggest that combinations of trastuzumab with anti oestrogens may be effective in the treatment of endometrial cancers with a positive ER and HER 2 receptor status . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
All of the latter cases expressed ER , whereas no case that overexpressed HER 2 expressed ER . ^^^ Moreover , all of the cases negative for HER 2 overexpression expressed ER , whereas those positive for HER 2 did not . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining for the estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 , Ki 67 , and HER 2 were performed . ^^^ The positive expression of ER and PR strongly related to low grade nuclei and non comedo subtype ; however , the positive expression of HER 2 and P 53 related to high grade nuclei and comedo subtype ( P < 0 . 01 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This paper reports the results of a study assessing the potential prognostic or predictive value of HER 2 , p 53 , cyclinD 1 , MIB 1 , ER and PgR expression by immunohistochemistry from patients included in an EORTC NCIC SAKK trial . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using the first 18 cases as the discovery set , we established a cutoff of 2 . 0 and 18 . 0 for ER and HER 2 mRNA levels , respectively , to distinguish clinically negative from positive cases . ^^^ TPs reliably measure conventional single gene prognostic markers such as ER and HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Our most successful therapies to date inhibit proliferation via the oestrogen receptor ( ER ) and HER 2 pathways . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Based on these data , we distinguish two subtypes of HER 2 / neu adenocarcinomas in mice : ER+ , PR and ER , PR , which can be used for the development of new approaches to the treatment of receptor negative mammary gland tumors . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The resulting tissue was analysed for apoptosis , Ki 67 , ER and HER 2 using immunohistochemical techniques . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor ( ER ) , progesterone receptor ( PgR ) , HER 2 , p 53 , and cathepsin D were determined by immunohistochemistry ( IHC ) before and after PCT . ^^^ Invasive ductal carcinoma ( IDC ) was more frequently ER negative and HER 2 positive than invasive lobular carcinoma ( ILC ) . ^^^ Estrogen receptor ( ER ) , progesterone receptor ( PgR ) , HER 2 , p 53 , and cathepsin D were determined by immunohistochemistry ( IHC ) before and after PCT . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To address this issue , we performed a comparative study of amplification and overexpression of HER 2 / neu and expression of several other important biochemical markers ( p 53 , MIB 1 , and estrogen receptor [ ER ] / progesterone receptor [ PR ] ) in these 3 cancer groups . ^^^ OBJECTIVE : To evaluate HER 2 / neu , p 53 , MIB 1 , and ER / PR as markers in the differential diagnosis of MC , AMC , and HGIDC . ^^^ Expression of HER 2 / neu , p 53 , MIB 1 , and ER / PR was detected by immunohistochemistry . chi 2 and Student t tests were applied for statistical analyses . ^^^ Differential amplification and overexpression of HER 2 / neu , p 53 , MIB 1 , and estrogen receptor / progesterone receptor among medullary carcinoma , atypical medullary carcinoma , and high grade invasive ductal carcinoma of breast . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The only significant correlations observed were between VEGF and estrogen receptor ( ER ) status ( p = 0 . 013 ) and between MVD and HER 2 overexpression ( p = 0 . 023 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Experimental Design : We performed immunohistochemical analysis of a set of 86 breast tumors for COX 2 , estrogen receptor ( ER ) , progesterone receptor ( PGR ) , HER 2 , Ki 67 ( a marker of proliferation ) , and CD 31 ( an endothelial cell marker of angiogenesis ) . ^^^ RESULTS : COX 2 protein expression was detected in 79 % of all tumors studied , ER was detected in 79 % of all tumors studied , PGR was detected in 73 % of all tumors studied , and HER 2 was detected in 16 % of all tumors studied . ^^^ No significant correlations were observed between COX 2 and ER , PGR , or HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical double staining with estrogen receptor ( ER ) and epidermal growth factor receptor 2 ( HER 2 ) was conducted in tissue sample of 125 women with invasive breast cancer . ^^^ HER 2 expression was inversely correlated with ER expression . ^^^ When evaluated even in ER positive patients , HER 2 overexpression was associated with lower ER levels . ^^^ In this study , we conducted immunohistochemical double staining with ER and HER 2 , and demonstrated that low ER levels might be one factor in the relative resistance of HER 2 positive and ER positive tumors to hormonal therapy . . ^^^ Immunohistochemical double staining with estrogen receptor and HER 2 on primary breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Correlation of MM with HER 2 , c met , nm 23 , p 53 and estrogen receptor ( ER ) were studied . ^^^ The presence of MM was correlated with HER 2 , nm 23 and p 53 positivity and with low frequency of nm 23 and ER . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Interestingly letrozole was more effective at all levels of ER expression and was particularly more efficacious than tamoxifen for tumors that expressed HER 1 and / or HER 2 ( with ER ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Recent data have suggested that HER 2 overexpression is associated with resistance to hormonal therapy and there is considerable preclinical evidence to support the existence of interaction or ' cross talk ' between HER 2 and estrogen receptor ( ER ) signalling pathways in breast cancer . ^^^ The existence of an inverse relationship between ER expression and HER 2 overexpression has also been well established clinically . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
TOP2A amplification in the absence of HER 2 amplification may be associated with lower histological grade and ER positivity . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Signaling via the EGF receptor and HER 2 / neu can activate both ER and the important ER coactivator AIB 1 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Because neoadjuvant trials permit temporal sampling of breast tissue , substudies in the phase 3 trial with letrozole have examined the impact of such biomarkers as estrogen receptor , progesterone receptor and epidermal growth factor receptor family members , HER 1 and HER 2 , on patient response . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The results were substantially concordant when estrogen receptor , progesterone receptor , and HER 2 receptor status determined by RT PCR was compared with immunohistochemistry assays for these receptors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This study aimed to determine COX 2 expression in ductal carcinoma in situ ( DCIS ) in comparison to invasive breast cancer ( IBC ) and normal breast , and also to investigate the relationship of COX 2 expression with HER 2 expression , oestrogen receptor ( ER ) , tumour grade and cellular proliferation ( Ki 67 ) in DCIS . ^^^ Cyclooxygenase type 2 , HER 2 , ER and Ki 67 expression were determined by immunohistochemistry on paraffin tissue sections of DCIS ( n=187 ) , IBC ( n=65 ) and normal breast reduction tissue ( n=60 ) . ^^^ In DCIS , COX 2 expression was associated with higher cellular proliferation rates ( P < 0 . 0001 ) , nuclear grade ( P=0 . 003 ) , with ER negativity ( P=0 . 003 ) and with HER 2 positivity ( P < 0 . 0001 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This investigation is beginning to elucidate the influence of growth factor pathways that interact with the ER , especially HER 1 ( epidermal growth factor receptor [ EGFR ] ) and HER 2 . ^^^ The results indicate that the distinct mechanisms by which tamoxifen and letrozole inhibit ER signaling may produce quite marked differences in clinical and biomarker outcomes in the subset of tumors that coexpress HER 1 and / or HER 2 with ER , favoring estrogen deprivation therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tissue microarrays containing 348 cases of invasive breast carcinoma were studied by immunohistochemical staining for CD 117 , CD 3 , CD 20 , CD 68 , Her 2 , estrogen receptor protein , and progesterone receptor protein , and results were correlated with patient outcome . ^^^ Hormone receptor status ( both estrogen receptor and progesterone receptor ) correlated with a good outcome while Her 2 overexpression was associated with a poor outcome . ^^^ When the multivariate analysis was expanded to include tumor grade , estrogen receptor status and Her 2 status , as well as tumor size and nodal status , the presence of stromal mast cells approached significance as an independent prognostic indicator . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To evaluate this concern , we prepared a single TMA block from 125 invasive breast carcinomas collected in a population based case control study conducted in Poland and compared estrogen receptor ( ER alpha ) , progesterone receptor ( PR ) , and human epidermal growth factor receptor 2 ( HER 2 ) expression in sections cut and stored for 6 months at room temperature with sections cut from the same TMA block and stained on the same day . ^^^ Percentage of positive cases for stored versus fresh sections was similar for ER ( 59 . 0 % ) but significantly higher in fresh sections for PR ( 56 . 3 % versus 64 . 1 % , P = 0 . 01 ) and HER 2 ( 45 . 5 % versus 64 . 4 % , P < 0 . 001 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A separate prognostic tumor tissue microarray containing 553 human breast tissue specimens annotated with clinicopathological parameters was assayed for ANX 7 , HER 2 , estrogen receptor , progesterone receptor , and p 53 protein . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The estrogen receptor ( ER ) and the human epithelial growth factor receptor 2 ( HER 2 ) genes have been implicated in the development and prognosis of breast cancer . ^^^ When allelic frequencies of the ER codon 594 and HER 2 codon 655 gene were compared , no significant differences were observed between the patient and control groups . ( P = 0 . 063 , OR = 1 . 55 , 95 % CI = 0 . 25 9 . 41 and P = 0 . 949 , OR = 1 . 01 , 95 % CI = 0 . 55 1 . 88 , respectively ) . ^^^ In conclusion , our results support the view that both the ER codon 594 and HER 2 codon 655 polymorphisms are not associated with increased risk of breast cancer . . ^^^ Estrogen receptor codon 594 and HER 2 codon 655 polymorphisms and breast cancer risk . ^^^ We have investigated the association between the estrogen receptor codon 594 ( ACA to ACG ) and HER 2 codon 655 ( ATC to GTC ) polymorphisms and breast cancer risk . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No significant correlation was established between ER and PR , on the one hand , and HER 2 expression , on the other . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
BACKGROUND : Patients receiving adjuvant tamoxifen whose tumors express high levels of both HER2 / neu ( HER 2 ) and the estrogen receptor ( ER ) coactivator AIB 1 often develop tamoxifen resistance . ^^^ Molecular cross talk between the ER and HER 2 pathways was increased in the MCF 7 / HER 2 cells compared with MCF 7 cells , with cross phosphorylation and activation of both the ER and the EGFR / HER2 receptors , the signaling molecules AKT and ERK 1 , 2 mitogen activated protein kinase ( MAPK ) , and AIB 1 itself with both estrogen and tamoxifen treatment . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor , progesterone receptor , and p 27 negativity ; HER 2 overexpression ; and p 53 positivity also predicted early failure . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Archival paraffin embedded tumor samples were retrieved to determine the expression level of estrogen ( ER ) and progesterone receptor ( PgR ) , p 53 , HER 2 , bcl 2 and PTEN protein , and phosphorylation status of protein kinase B ( PKB / Akt ) . ^^^ Amongst 22 patients who had tumor blocks available , the proportion showing positive expression of the following markers includes : PgR ( 86 % ) , ER ( 86 % ) , PTEN ( 82 % ) , phosphorylated PKB / Akt ( 59 % ) , bcl 2 ( 45 % ) , p 53 ( 32 % ) , and HER 2 ( 0 % ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We used the breast cancer cell lines that are estrogen receptor ( ER ) positive and HER 2 positive . ^^^ We also analyzed the molecular changes on the HER 2 and ( ER ) signaling pathways that are induced by trastuzumab plus tamoxifen . ^^^ The molecular effects of the combined treatment with trastuzumab plus tamoxifen on the levels of HER 2 and ER signaling showed that , with respect to HER 2 protein levels , trastuzumab downregulated HER 2 by 27 % , tamoxifen upregulated HER 2 by 40 % , and the combination of trastuzumab plus tamoxifen did not induce changes in HER 2 respect to control . ^^^ Taken together , our results show that in ER positive breast cancer cells overexpressing HER 2 , trastuzumab plus tamoxifen have antagonistic interactions when used in combination , and that this antagonism may be related with an increase in HER 2 signaling pathways that occurs when tamoxifen is added to trastuzumab . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : Expression profiling studies classified breast carcinomas into estrogen receptor ( ER ) + / luminal , normal breast like , HER 2 overexpressing , and basal like groups , with the latter two associated with poor outcomes . ^^^ CONCLUSIONS : A panel of four antibodies ( ER , HER 1 , HER 2 , and cytokeratin 5 / 6 ) can accurately identify basal like tumors using standard available clinical tools and shows high specificity . ^^^ RESULTS : Using a panel of 21 basal like tumors , which was determined using gene expression profiles , we saw that this subtype was typically immunohistochemically negative for estrogen receptor and HER 2 but positive for basal cytokeratins , HER 1 , and / or c KIT . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumor size , histology , grade , lymph node status , estrogen ( ER ) and progesterone receptor ( PgR ) status , HER 2 expression , peritumoral vascular invasion ( PVI ) , Ki 67 expression , extensive in situ component ( EIC ) , and multifocality between the two groups were analyzed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIALS AND METHODS : Using immunohistochemistry , we analysed archival specimens of human breast cancer ( n=29 ) using antibodies to COX 2 , ER , PgR and HER 2 and , from medical records , obtained clinicopathological data . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : HER 2 amplification was correlated with lower ER ( P = 0 . 02 ) , HER 1 positivity ( P = 0 . 004 ) , and HER 2 protein overexpression ( P < 0 . 00001 ) . ^^^ CONCLUSION : Patients with HER 2 amplification and HER 1 expression had lower ER levels and were modestly less responsive to tamoxifen , suggesting that molecular events in addition to those involving the ErbB receptors are important in determining the endocrine resistant phenotype . . ^^^ HER 2 amplification , HER 1 expression , and tamoxifen response in estrogen receptor positive metastatic breast cancer : a southwest oncology group study . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Characteristics of the patients associated with serum levels of tumor markers like CEA , CA 15 3 and receptor markers like ER , PR with P 53 , Cathepsin D and HER 2 were evaluated . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Immunohistochemical staining was undertaken for estrogen ( ER ) and progesterone ( PR ) receptors , epidermal growth factor receptor 2 ( Her 2 ) , p 53 , vascular endothelial factor ( VEGF ) , and hypoxia inducible factor 1alpha ( HIF 1alpha ) and the levels of these markers was compared to e cadherin expression in a high risk African American patient population . ^^^ RESULTS : E cadherin expression persisted into the later stagers of the disease , and was strongly associated with Her 2 and HIF 1alpha expression , but not p 53 , ER / PR or VEGF . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
At present , this includes diagnostic tests to identify single tumor markers for which specific therapies are available , such as estrogen receptor and HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In patients with operable breast cancer , there was a positive correlation between serum concentrations of HER 2 and the size of primary tumor ( P < 0 . 05 ) , whereas there was no correlation between serum concentration and axillary lymph node or estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Compound 1 also potently inhibited an ER , HER 2 overexpressing breast cancer cell line . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , hormonal receptor status ( ER and PR ) and HER 2 protein overexpression by IHC were also studied , and results were compared with whole tissue sections . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Positive stromal MMP 9 expression was related to HER 2 overexpression in estrogen receptor ( ER ) positive disease . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There were no statistically significant differences in age , grade , and percentage of average positive cells for ERa , PR , Ki 67 , cyclin D 1 , Bcl 2 , and HER 2 , between MMTV like positive and negative breast cancer specimens . ^^^ These included estrogen receptor , progesterone receptor , Ki 67 , Cyclin D 1 , Bcl 2 and HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A 43 year old woman underwent breast conserving therapy for right breast cancer with multiple liver metastases ( pT3N3aM1 , stage 4 , ER ( ) , PgR ( ) , HER 2 ( 3+ ) ) , in November , 2002 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Enhancement of estrogen receptor expression was accompanied with lower rate of HER 2 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
As expected , our studies showed identification of peptides from HER 2 in BT 474 while estrogen receptor peptides were detected in the MCF 7 line . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Discordance of estrogen receptor ( ER ) , progestin receptor ( PR ) , and HER 2 receptor statuses between primary and metastatic focuses of breast cancer . ] . ^^^ BACKGROUND & OBJECTIVE : Hormone and Herceptin therapy for metastatic breast cancer is commonly based on expression of estrogen receptor ( ER ) and progestin receptor ( PR ) , and over expression of HER 2 in primary breast cancer , but studies comparing receptor statuses in primary and metastatic focuses of the same patient are limited . ^^^ This study was designed to investigate discordance of ER , PR , and HER 2 statuses between primary and metastatic focuses of breast cancer . ^^^ METHODS : Immunohistochemistry assay was used to detect expression of ER , PR , and HER 2 receptor in primary and metastatic focuses of 65 cases of breast cancer . ^^^ RESULTS : Positive rate of ER in primary focuses was 56 . 9 % ( 37 / 65 ) , significantly higher than that in metastatic focuses ( 33 . 8 % , 22 / 65 ) ( P < 0 . 01 ) ; while positive rates of PR and HER 2 receptor have no significant difference between primary and metastatic focuses . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Evaluation of ER , PgR , HER 2 and Ki 67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer . ^^^ Diagnostic biopsies and postchemotherapy surgical specimens were stained for oestrogen ( ER ) and progesterone ( PgR ) receptor , HER 2 and cell proliferation ( Ki 67 ) . ^^^ In all , 10 tumours changed hormone receptor classification after chemotherapy ( three ER , seven PgR ) ; HER 2 staining changed in nine cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CONCLUSIONS : Currently , the only recommended predictive markers in oncology are ER and PR for selecting endocrine sensitive breast cancers and HER 2 for identifying breast cancer patients with metastatic disease who may benefit from trastuzumab . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Thus , there are two distinct major pathways to the evolution of low and high grade invasive carcinomas : whilst the former consistently show oestrogen receptor ( ER ) and progesterone receptor ( PgR ) positivity and 16q loss , the latter are usually ER / PgR negative and show Her 2 overexpression / amplification and complex karyotypes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Positive IGFBP 3 expression showed a possible trend in association with increased proliferation ( P = 0 . 096 ) , oestrogen receptor ( ER ) negativity ( P = 0 . 06 ) and HER 2 overexpression ( P = 0 . 065 ) in invasive tumours and a strong association with ER negativity ( P = 0 . 037 ) in DCIS . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fascin expression was compared with hormone receptor ( ER / PR ) status , HER 2 status , cancer grade , cancer stage , metastasis pattern , disease free survival , and overall survival . ^^^ Patients whose tumors were positive for fascin showed both a decreased mean disease free survival ( 74 . 44 versus 100 . 52 months , P = 0 . 002 ) and mean overall survival ( 77 . 58 versus 98 . 98 months , P = 0 . 002 ) , independent of tumor stage and HER 2 status , but not independent of ER / PR status or cancer grade . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Unsupervised cluster data analysis of both hereditary and sporadic cases using the complete set of immunohistochemical markers demonstrated that most BRCA 1 associated carcinomas grouped in a branch of ER , HER 2 negative tumors that expressed basal cell markers and / or p 53 and had higher expression of activated caspase 3 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
However , it is currently not known if HER 2 protein overexpression might be associated with reduced tamoxifen benefit in patients with ER positive DCIS , as has been suggested in patients with ER positive invasive breast cancer and in preclinical models . ^^^ Moreover , the frequency of HER 2 overexpression in ER positive ductal carcinoma in situ has not been previously evaluated in detail . ^^^ To address this issue , we studied ER expression and HER 2 overexpression in 148 cases of DCIS using a sensitive double immunostaining technique and assessed the frequency of ER expression and HER 2 overexpression in relation to each other and in relation to DCIS grade . ^^^ Overall , ER expression was seen in 114 cases ( 77 % ) and HER 2 protein overexpression was seen in 42 cases ( 28 % ) . ^^^ Of 114 ER positive ductal carcinoma in situ , 14 ( 12 % ) showed concurrent HER 2 protein overexpression , and all 14 of these DCIS lesions were of high nuclear grade . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Because treatments designed to deprive the ER of its ligand estrogen will reduce signaling from both nuclear and membrane ER , aromatase inhibitors might be expected to be superior to tamoxifen in tumors with high growth factor receptor content , such as those overexpressing HER 2 . ^^^ On the other hand , in tumors overexpressing HER 2 , acquired resistance to estrogen deprivation therapy involves the loss of ER and ER regulated genes and further up regulation of growth factor signaling rendering the tumor hormonal therapy resistant . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
With recent advances in endocrine therapy , and rapid and routine assessment of predictive factors of response such as estrogen ( ER ) , progesterone ( PR ) and Her 2 nu receptor status , endocrine therapy has come to the forefront of research investigating a neoadjuvant alternative to chemotherapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Further experiments to examine expression changes of the receptor tyrosine kinases EGFR , HER 2 and estrogen receptor alpha did not reveal any alterations in BG 1 ( LT ) if compared to wild type cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We studied the inverse relationship between HER 2 and estrogen ( ER ) and progesterone ( PR ) receptors using HER 2 testing and correlated HER 2 status with histologic features in 3 , 655 unselected invasive breast carcinomas . ^^^ Immunohistochemical analysis for ER , PR , and HER 2 and fluorescence in situ hybridization for HER 2 were performed . ^^^ ER and PR expression were decreased significantly in HER 2+ tumors compared with HER 2 tumors ( ER , 49 . 1 % vs 78 . 17 % ; PR , 24 . 3 % vs 53 . 13 % ) . ^^^ HER 2 overexpression or amplification essentially was limited to grades 2 and 3 ductal carcinomas and correlated inversely with ER or PR expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Primary tumors were compared for HER 2 , HER 3 , and HER 4 , estrogen receptor , and Ki 67 by immunohistochemistry . ^^^ Dually expressing HER2 / 4 DCIS was more likely to be estrogen receptor positive than HER 2 only expressing DCIS ( 73 % versus 53 % ; P = 0 . 05 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of the present study was to examine the relationship between the intensity of expression of oestrogen receptors ( ER ) , progesterone receptors ( PgR ) , HER 2 , p 53 and Ki 67 in cells of ductal breast cancer of G 1 , G 2 or G 3 differentiation grade . ^^^ In paraffin sections of 60 ductal breast cancers ( 20 cases in G 1 , 20 in G 2 and 20 in G 3 ) , immunocytochemical reactions were performed to detect the expression of ER , PgR , HER 2 , p 53 and Ki 67 . ^^^ We noted significant positive correlations between ER and PgR ( the entire group studied , G 1 3 , and the G 1 group ) , HER 2 and p 53 ( G 2 ) and between p 53 and Ki 67 expression ( G 2 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
TGF beta 1 could be a missing link in the interplay between ER and HER 2 in breast cancer . ^^^ However , most important biomarkers in a clinical setting are ER ( estrogen receptors ) and HER 2 ( human epidermal growth factor receptor 2 ) , but still only as predictive markers for tamoxifen and trastuzumab therapy . ^^^ TGF beta 1 is ER regulated biomarker which act synergistically with HER 2 . ^^^ Aim of this study is to show that clinical significance of determination ER and HER 2 status could be improved , when they are related with TGF beta 1 as additional biomarker . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Most BRCA 1 carcinomas have the basal cell phenotype , a subtype of high grade , highly proliferating , estrogen receptor and HER 2 negative breast carcinomas , characterized by the expression of basal or myoepithelial markers such as basal keratins , P cadherin , epidermal growth factor receptor , etc . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical profile of endometrioid adenocarcinoma of the uterus : ER , PR , HER 2 , Ki 67 and their prognostic value ] . 76 endometrioid adenocarcinomas of the uterine body were studied . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The relationship between the expression of all six membrane proteins and a variety of pathologic and biological variables , including estrogen receptor , HER 2 , and epidermal growth factor receptor status , was also examined . ^^^ CONCLUSIONS : We have confirmed the expression of three new membrane markers that had previously not been implicated in human breast cancer , and one of them ( NET 6 ) was correlated with HER 2 and estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Prolonged endocrine therapy can be associated with an acquired increase in peptide growth factor signaling ( EGFR , HER 2 ) , together with cross talk activation of ER dependent gene transcription and cell growth that leads to endocrine resistance . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : Experimental data suggest a complex cross talk between HER 2 and estrogen receptor , and it has been hypothesized that HER 2 positive tumors may be less responsive to certain endocrine treatments . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor ( ER ) and human epidermal growth factor 2 ( HER 2 ) are well investigated molecules and the focus of many breast cancer therapies . ^^^ There is a group of breast cancers lacking ER and HER 2 , but it is not fully understood . ^^^ Estrogen receptor ( ER ) and human epidermal growth factor 2 ( HER 2 ) are well investigated molecules and the focus of many breast cancer therapies . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Breast tumors were classified into four different subtypes depending on estrogen receptor ( ER ) and HER 2 expression . ^^^ Basal type tumors expressed neither of these proteins and represented 7 . 6 % of our series ; basal like HER 2 overexpressing tumors did not express ER and represented 17 . 7 % ; luminal type tumors expressed ER and represented 72 . 8 % of this series ( luminal A 56 . 3 % , luminal B 16 . 5 % ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It was found that NCOR 1 mRNA was expressed at significantly higher levels in patients over 50 years of age , without axillary lymph node involvement , with tumor size less than 2 cm , with low or intermediate histological grade , with ERalpha / PgR positive and with HER 2 negative tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study , we used a tissue microarray ( TMA ) approach to investigate the influence of slide age on comparisons between the results of IHC analyses for estrogen receptor ( ER ) , progesterone receptor ( PR ) , cyclin D 1 , HER 2 ( HercepTest ) , and E cadherin and clinical outcome in a series of 522 breast cancer patients . ^^^ As compared to results obtained on freshly cut sections , the frequency of positivity on old sections decreased from 65 to 46 % for ER ( P < 0 . 0001 ) , from 33 to 18 . 5 % for PR ( P < 0 . 0001 ) , from 16 . 3 to 9 . 6 % for HER 2 ( P=0 . 0047 ) , from 45 . 1 to 37 . 7 % for cyclin D 1 ( P=0 . 10 ) , and from 58 . 9 to 32 . 9 % for E cadherin ( P < 0 . 0001 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor , progesterone receptor , and HER 2 protein expression in tumor samples of premenopausal breast cancer patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Simultaneous bilateral breast carcinomas : a category with frequent coexpression of HER 2 and ER alpha , high Ki 67 and bcl 2 , and low p 53 . ^^^ The phenotype of the primary tumors and corresponding metastatic tumors was similar for the expression of ER alpha ( p=0 . 001 ) , PR ( p=0 . 03 ) , and HER 2 ( p=0 . 018 ) . ^^^ While strong coexpression of HER 2 and ER alpha is exceptional in hereditary breast carcinoma and sporadic breast carcinoma , 6 / 8 ( 75 % ) patients in this study had tumors with strong coexpression of HER 2 and ER alpha . ^^^ Characteristically , the tumors showed high levels of expression of ER alpha and Her 2 amplification , were bcl 2 positive , and had high Ki 67 fraction . ^^^ However , in patients with atypical medullary carcinoma there was no expression of ER alpha or amplification of Her 2 . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Finally , activation of AKT , via phosphorylation , was linked to activation of both HER 2 and ERalpha in this patient cohort . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Gallen consensus panel are that : adequately dosed anthracycline based CT regimens remain an acceptable standard for many women ; a lower threshold for using taxanes in sequence or combination with anthracyclines ( A ) is justified in the presence of an ER negative or low ER tumour status , other aggressive biologic features ( such as HER 2 overexpression ) , fear about A induced cardiotoxicity ; no recommendation can yet be made as far as the optimal taxane A regimen , the best taxane or the best taxane schedule . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A 51 year old woman underwent pectoralis preserving mastectomy for right breast cancer ( squamous cell cancer , f , T1c , ly 0 , v 0 , N 2 ( 18 / 33 ) , p 53 ( 3+ ) , HER 2 ( 2+ ) , ER ( ) , PgR ( ) , T1cN2M0 ( Stage IIIA ) in March 2001 , and received systemic chemotherapy using doxorubicin combined with cyclophosphamide , followed by paclitaxel . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Extensive interactions between estrogen receptor alpha ( ERalpha ) and HER 2 signaling pathways have been described . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The same cases were studied immunocytochemically using monoclonal antibodies to telomerase , estradiol receptors ( ER ) and HER 2 ( CB 11 ) and a standard alkaline phosphatase ( APAAP ) method . ^^^ An association was found between telomerase activity , ER receptors and HER 2 expression ( p < 0 . 005 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Our aims in this study are to evaluate the expression of estrogen receptor ( ER ) and progesterone receptor ( PR ) and Her 2 / neu overexpression in BC in Jordan , and to compare the expression of these with other prognostic parameters for BC such as histological type , histological grade , tumor size , patients ' age , and number of lymph node metastases . ^^^ We used immunohistochemistry to evaluate the expression of ER , PR , and Her 2 . ^^^ Her 2 expression was inversely related to ER and PR expression . ^^^ Her 2 overexpression was associated with young age at presentation , larger tumor size , and was inversely related to ER and PR expression . ^^^ One fifth of the carcinomas were Her 2 positive and ER negative . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : Phosphorylation of ER alpha Ser 118 , but not Ser 167 , was positively associated with overexpression of HER 2 , and HER 2 positive tumors showed resistance to endocrine therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It was found that HDAC 1 mRNA was expressed at significantly higher levels in tumors from patients over 50 years of age and in those tumors without axillary lymph node involvement , that are less than 2 cm , that are of a non high histological grade , that are HER 2 negative and that are ERalpha / PgR positive . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Overexpression of the RhoC GTPase and of HER 2 , and decreased ER expression are involved in IBC . ^^^ Exclusion of ER related or HER 2 related genes did not alter this discriminatory accuracy , indicating that the expression of other genes in addition to ER and HER 2 characterize the IBC phenotype . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To date , the only widely accepted markers for routine use in breast cancer are the oestrogen receptor ( ER ) , progesterone receptor ( PR ) and human epidermal growth factor receptor , HER 2 ( c erbB2 / neu ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Co expressed type of ER and HER 2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER positive and HER 2 positive breast cancer . ^^^ The purpose of this study was to analyze whether inter site variation types on estrogen receptor ( ER ) and HER 2 expression may be a predictive factor for evaluating the effectiveness of endocrine therapy in patients with ER positive and HER 2 positive breast cancer . ^^^ ER status was evaluated using the Allred score and HER 2 status was evaluated according to the HercepTest . ^^^ In ER positive and HER 2 positive tumors , the expression of ER and HER 2 was described as the co expressed type or the differently expressed type using double staining with ER and HER 2 . ^^^ Of the 366 patients , 249 ( 68 . 1 % ) were positive for ER and 74 ( 20 . 2 % ) were positive for HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Ten of 12 patients with a PR had HER 2 negative tumours , and 9 / 12 had ER positive and progesterone receptor ( PgR ) positive disease ( two patients had unknown HER 2 status and one had unknown ER and PgR status ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The finding that PR loss may not correlate with resistance to aromatase inhibition may be related to crosstalk between ER and PR and growth factor receptor pathways such as HER 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Recent biological studies have classified breast carcinomas into HER 2 overexpressing , estrogen receptor positive / luminal , basal and normal like groups . ^^^ All cases were estrogen receptor , progesterone receptor and HER 2 negative . ^^^ Our study shows that adenoid cystic carcinoma of the breast is a special , estrogen receptor , progesterone receptor , HER 2 negative and highly KIT positive , basal like breast carcinoma , associated with an excellent prognosis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Well known predictors for response to systemic therapy include estrogen receptor status HER 2 status , c kit mutation , and epidermal growth factor receptor mutation . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Our previous studies have indicated that combined treatment with an antiestrogen , fulvestrant , and an inhibitor of the HER 2 signaling pathway , trastuzumab , or an inhibitor of the HER 1 signaling pathway , gefitinib , leads to an additive antitumor effect in breast cancer cells expressing ER and HER 2 or HER 1 , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Protein expression profiles were generated for Ki 67 , Mcm 2 , geminin , HER 2 , ER and PR in a series of reduction mammoplasty ( n=18 ) and breast cancer specimens ( n=120 ) , and compared to clinicopathological parameters . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
New sections , with core and surgical specimens on the same slides , were stained for estrogen receptor ( ER ) , progesterone receptor ( PR ) , and human epidermal growth factor receptor 2 ( HER 2 ) immunohistochemistry ( IHC ) . ^^^ RESULTS : Concordance for ER , PR , overall hormone receptor ( HR ) , and HER 2 status was seen in 86 % , 83 % , 90 % , and 80 % of patients , respectively . ^^^ Using a log linear model , differences in ER , PR , and HER 2 staining were all in the direction of stronger staining in the cores , and were statistically significant . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We have analyzed a breast cancer TMA containing 2 , 517 breast tissues , including 2 , 222 neoplastic and 295 normal or premalignant samples , for Ki 67 labeling index ( Ki 67 LI ) and additional markers with a known relationship to Ki 67 LI by immunohistochemistry ( ER , PR , Bcl 2 , Egfr , p 16 , p 53 ) and Fluorescence in situ hybridization ( HER 2 , MDM 2 , CCND 1 , MYC ) . ^^^ A high Ki 67 LI was linked to tumor phenotype including grade ( p < 0 . 0001 ) , stage ( p < 0 . 0001 ) , nodal stage ( p = 0 . 0018 ) , and patient prognosis ( p < 0 . 0001 ) , elevated protein levels of p 53 , p 16 and Egfr , reduced levels of Bcl 2 , ER , and PR ( p < 0 . 0001 each ) , as well as amplifications of HER 2 , MYC , CCND 1 and MDM 2 ( p < 0 . 0001 each ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumors with no ER expression could be divided into three subgroups : `` basal like ' ' subtype , HER 2 positive subtype , and `` normal breast like ' ' . `` Basal like ' ' subtype was characterized by high expression of keratins 5 and 17 , laminin and fatty acid binding protein 7 . ^^^ A consecutive series of 195 primary operable invasive breast carcinomas was immunostained for HER 2 , ER , PGR , CK5 / 6 and CK 17 . ^^^ CK5 / 6 or CK 17 were expressed in 72 cases ( 36 . 9 % ) , and 41 cases ( 21 % ) presented expression of CK5 / 6 or CK 17 without ER / PGR or HER 2 . ^^^ ER / PGR was present in 109 cases ( 55 . 9 % ) , but in this group there were 8 cases with HER 2 overexpression and 17 cases with basal cytokeratin positivity . ^^^ Similarly , in 17 out of 72 `` basal like ' ' tumors there was ER / PGR positivity , and also in 17 of them there was HER 2 overexpression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry for estrogen receptor ( ER ) , HER 2 , EGFR , smooth muscle actin ( SMA ) , p 63 , CD 10 , cytokeratin 5 / 6 , cytokeratin 8 / 18 , and vimentin was performed on 18 basal like , 16 luminal , and 12 HER2+ tumors . ^^^ All basal like tumors tested were ER and HER 2 . ^^^ The most consistent immunophenotype seen in the basal like tumors was negativity for ER and HER 2 , and positivity for vimentin , EGFR , cytokeratin 8 / 18 , and cytokeratin 5 / 6 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Targets were chosen to assess the ability of EnzMet to specifically localize encoded antigens in the nucleus ( estrogen receptor ) , cytoplasm ( cytokeratins ) , and cytoplasmic membrane ( HER 2 ) in TMAs . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical stainings for estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 , p 53 , and Ki 67 were performed on paraffin tumor sections . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CXCR 4 positivity in the cytoplasm but not the nucleus was associated with HER 2 expression and amplification as well as with hormone receptor negativity ( both ER and PR ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : We used the automated quantitative analysis ( AQUA ) system and various concentrations of antibodies against HER 2 ( 1 : 500 to 1 : 8000 dilutions ) , p 53 ( 1 : 50 to 1 : 800 dilutions ) , and estrogen receptor ( ER ; 1 : 100 and 1 : 1000 dilutions ) to assess expression of HER 2 and p 53 in a tissue microarray containing specimens from 250 breast cancer patients with long term survival data available . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The histological type and grade ( hematoxylin and eosin staining ) and membrane receptor status ( semiquantitative immunohistochemistry for estrogen [ ER ] and progesterone [ PR ] receptors , as well as Her 2 antigen expression ) were assigned by the DCB before surgery . ^^^ RESULTS : DCB correctly ascribed tumor type and grade and ER , PR , and Her 2 receptor status in most cases ( correlating exactly in 97 . 5 % , 77 % , 68 % , 71 % , and 60 % , respectively ) with at least moderate concordance ( weighted kappa , > . 41 ) . ^^^ When miscategorized , DCB consistently tended to upscore the receptor stain intensity compared with the surgical specimen ( 22 % , 19 % , and 27 % had higher ER , PR , and Her 2 categorical scores , respectively ) . ^^^ DCB accurately identified all tumors with clinically important ER and Her 2 expression . ^^^ Furthermore , it promoted three patients into the therapeutically significant range of ER ( n = 1 ) or Her 2 ( n = 2 ) expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HIF 1alpha was scored as positive in 24 % of the tumours and correlated positively to tumour size , Nottingham histological grade ( NHG ) , Ki 67 , Her 2 and cyclin E expression and negatively to lymph node status , cyclin D 1 , ER and PR ( progesterone receptor ) expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER , including full length 66 kDa ER and a 46 kDa ER splice variant , are enriched in lipid rafts from MCF 7 cells with ( MCF 7 / HER 2 ) or without ( MCF 7 / PAR ) HER 2 gene overexpression and co localize with HER 1 and HER 2 growth factor receptors , as well as with lipid raft marker flotillin 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The basal like phenotype as defined by basal cytokeratin expression , lack of estrogen receptor ( ER ) and absence of HER 2 overexpression was found in 48 ( 25 % ) cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Ten patients with advanced breast cancer whose tumors overexpressed HER 2 , but not ER or PgR , were treated with weekly trastuzumab at standard doses with or without chemotherapy . ^^^ Reverting estrogen receptor negative phenotype in HER 2 overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study , we analyzed the protein expression and the mutational status of c KIT in ductal carcinoma in situ ( DCIS ) of the breast and correlated these findings with nuclear grade , architectural pattern , and expression of HER 2 , estrogen receptor ( ER ) alpha , and progesterone receptor ( PR ) . ^^^ C KIT , HER 2 , ER , and PR expression were analyzed immunohistochemically in 106 cases of paraffin embedded DCIS ( 85 pure DCIS and 21 DCIS with concurrent carcinoma ) . ^^^ Furthermore , c KIT expression was strongly associated with HER 2 positivity ( P < . 0001 ) and was significantly lower in ER or PR positive cases ( P = . 001 and P = . 006 , respectively ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
OBJECTIVE : In breast cancer , 2 molecular targets are well established ( ER / PR and HER 2 ) , and therapies directed to these proteins have demonstrated to be clinically useful . ^^^ RESULTS : To improve survival of metastatic breast cancer patients with ER / PR positive and HER 2 positive is critical to elucidate the mechanism of resistance or sensitivity of these tumors for a better selection depending on biologic molecular alterations . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MCF 7 / CA cells overexpressing HER 2 showed a > 2 fold increase in estrogen receptor ( ER ) mediated transcriptional reporter activity upon treatment with androstenedione compared with vector only control MCF 7 / CA cells . ^^^ Chromatin immunoprecipitation assays using cross linked protein DNA from MCF 7 / CA / HER 2 cells indicated ligand independent association of the ERalpha coactivators AIB 1 and CBP to the promoter region of the estrogen responsive pS 2 gene . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Although HER receptors can lower ER levels , one study showed that loss of PR correlated with high HER 2 levels in a multivariate analysis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Predictive markers of response like the estrogen receptor ( ER ) and the human epidermal growth factor receptor 2 ( HER 2 ) help identify those most likely to derive a survival benefit from adjuvant therapy with anti estrogens and trastuzumab therapy , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The peptides are linear stretches based on the native protein sequence , containing antibody epitopes of HER 2 , estrogen receptor , progesterone receptor , and Ki 67 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : The histological type , ER , PgR , HER 2 , and histological grade were evaluated by needle biopsy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining for ER , progesterone receptor ( PgR ) , HER 2 and epidermal growth factor receptor ( EGFR ) was undertaken . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemically , the tumor cells were positive for cytokeratin , epithelial membrane antigen , HER 2 , and p 53 , but negative for estrogen receptor ( ER ) and progesterone receptor ( PR ) . ^^^ Although the biological behavior of GRCC is difficult to predict in view of the very limited number of case reports , the prognosis of GRCC may be associated with not only histopathological subtype but also other clinicopathological factors , such as size , status of invasion , status of nodal metastasis , nuclear grade , ER , PR , HER 2 , p 53 and so on . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Issues discussed included methods of risk stratification for recurrence ; how biologic markers such as HER 2 status , quantitative estrogen receptor , or genetic markers can be incorporated as prognostic or predictive factors ; and how age , menopausal status , and estrogen receptor levels impact benefits from chemotherapy and endocrine therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : The aim of our study was to assess , by Methylation Specific Polymerase Chain Reaction ( MSP ) , the methylation pattern of the CDH 1 gene and its possible correlation with the expression of E cadherin and other standard immunohistochemical parameters ( Her 2 , ER , PgR , p 53 , and K 67 ) in a series of 79 primary breast cancers ( 71 infiltrating ductal , 5 infiltrating lobular , 1 metaplastic , 1 apocrine , and 1 papillary carcinoma ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
These lesions are estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative , and HER 2 negative ( triple negative ) , and typically express basal cytokeratins , epidermal growth factor receptor ( EGFR ) , and / or c kit . ^^^ We studied 66 cases of high nuclear grade DCIS using antibodies to ER , PR , HER 2 , three basal cytokeratins , EGFR , and c kit to determine the frequency of the triple negative phenotype , and to determine the relationship between the triple negative phenotype and expression of basal cytokeratins and other biomarkers characteristically expressed by invasive basal like carcinomas . ^^^ Four cases ( 6 % ) exhibited the triple negative phenotype ; the remaining cases showed other combinations of ER , PR , and HER 2 expression ( nontriple negative ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This review describes the roles of ( 1 ) hormone related factors ( ER , PgR , phosphorylated ER , ERbeta , aromatase ) , ( 2 ) growth related factors ( HER 2 , Ki 67 , p 53 ) , ( 3 ) ER cofactors ( AIB 1 , NcoR 1 ) , ( 4 ) estrogen dependent genes derived from gene expression profiling ( HDAC 6 , IGFBP4 / 5 ) , and ( 5 ) gene profiling using cDNA microarray . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Potential markers of therapeutic response were evaluated including markers of proliferation , apoptosis , p 21 , HER 2 , estrogen receptor , and progesterone receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Correlations between HER 2 / neu status and age , race and other prognostic histopathologic features revealed : No correlation with age ( or < or = 40 Y vs > 40 Y with a p value of 0 . 552 ) , race ( Saudis vs Non Saudis with a p value of 0 . 133 ) , histopathology subtype ( p=0 . 980 ) , tumor size ( p=0 . 455 ) , number of positive lymph nodes ( p=0 . 660 ) , tumor grade ( p=0 . 062 ) , lymphovascular invasion ( p=0 . 055 ) and progesterone receptor ( PR ) status ( p=0 . 069 ) but positive correlation only with estrogen receptor status ( ER ) ( p=0 . 003 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Histological features , immunohistochemical findings for oestrogen receptor ( ER ) , progesterone receptor ( PgR ) and HER 2 , and clinical outcome and survival after adjuvant chemotherapy were compared between the two groups . ^^^ RESULTS : It was more likely for patients with BLBCs to be found negative for ER ( p < 0 . 0001 ) , PgR ( p < 0 . 0001 ) and HER 2 ( p < 0 . 01 ) than controls . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fifty six per cent of HER 2 amplified samples tested ER positive , while 42 % of ER positive cases showed HER 2 gene amplification , confirming that HER 2 testing should not be confined to ER negative breast cancers . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
EXPERIMENTAL DESIGN : The gene expression levels of KLF 5 , ER , PR , HER 2 , and MKI 67 were quantified in the tumor tissues of 90 patients with breast cancer and correlated with disease free survival and overall survival of the patients . ^^^ The correlations of gene expression between KLF 5 and ER , PR , HER 2 , and MKI 67 were analyzed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Eight markers [ estrogen receptor ( ER ) , progesterone receptor ( PR ) , Bcl 2 , cyclin E , p 53 , MIB 1 , cytokeratin 5 / 6 , and HER 2 ] showed a significant association with survival at 10 years on univariate analysis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Therefore we analyzed gene expression data of pretreatment biopsies of breast cancer patients and compared them with the results of the immunohistochemical receptor expression for ER / PR and Her 2 , as well as FISH testing for HER 2 amplification . ^^^ Samples were characterized according to standard pathology including ER , PR and HER 2 IHC and amount of cancer cells . ^^^ When ER alpha , PR and HER 2 as analyzed by immunohistochemistry were compared to the corresponding mRNA data from gene chips more than 90 % concordance was observed . ^^^ We could observe a switch of receptor expression for ER , PR or HER 2 from positive to negative and vice versa in 16 / 35 cases ( 45 . 7 % ) and 5 / 22 cases ( 22 . 7 % ) respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No significant relationship with age , disease stage , nodal involvement , estrogen receptor or HER 2 status was found . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Many BRCA 1 related tumors have a distinct histological characteristics which together have been called `` basal like . ' ' Typically such tumors are ER , HER 2 and express cytokeratin 5 / 6 , cytokeratin 8 / 18 , EGFR and vimentin . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression levels of the standard clinical markers HER 2 , estrogen receptor ( ER ) , progesterone receptor ( PR ) , and Ki 67 were also assessed on the same cohort . 10 tile software was used to select optimal protein concentration cutpoints and to evaluate the outcome using a training set and a validation set . ^^^ Multivariate analysis of this marker , assessed in a proportional hazards model with tumor size , age , node status , nuclear grade , ER , PR , HER 2 , and Ki 67 , is still highly significant with a hazard ratio of 6 . 8 ( P < 0 . 0001 , 95 % confidence interval , 3 . 1 15 . 1 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Frozen sections of 35 meningiomas were immunostained for HER 2 , estrogen receptor , progesterone receptor , E cadherin , and MIB 1 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
STUDY DESIGN : Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor , progesterone receptor , HER 2 , AKT , and 4EBP1 proteins in 27 atrophic endometria , 31 grade 1 and 24 grade 3 endometrioid endometrial cancers , and 19 malignant mixed mllerian tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical examination was negative for estrogen receptor , progesterone receptor and HER 2 overexpression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Subtype definitions were as follows : luminal A ( ER+ and / or progesterone receptor positive [ PR+ ] , HER 2 ) , luminal B ( ER+ and / or PR+ , HER2+ ) , basal like ( ER , PR , HER 2 , cytokeratin 5 / 6 positive , and / or HER1+ ) , HER2+ / ER ( ER , PR , and HER2+ ) , and unclassified ( negative for all 5 markers ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Therefore , we used the pre treatment core biopsies from 107 patients who were enrolled in the EORTC trial 10902 to analyse tumour characteristics and the oncogenic markers Bcl 2 , p 53 , ER , PgR , HER 2 , and p 21 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Positive to negative change was prominent with intervening endocrine treatment , and it was significant ( p=0 . 015 ) for ER by multiple regression analysis of age , interval of sampling and from prior surgery , intervening chemotherapy , endocrine therapy and human epidermal growth factor receptor 2 ( HER 2 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The assessment of ERa , PgR and HER 2 status is routinely performed today to determine the endocrine responsiveness of breast cancer samples . ^^^ In this study we compared Qrt PCR results for the assessment of mRNA levels of ERa , PgR , and the members of the human epidermal growth factor receptor family , HER 1 , HER 2 , HER 3 and HER 4 . ^^^ The quantitative mRNA expression levels of ERa , PgR and HER 2 also strongly correlated with the respective quantitative protein expression levels prospectively detected by EIA in both laboratories . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We performed immunohistochemical staining for ER , PgR , HER 2 , PCNA ( proliferation cell nuclear antigen ) , Ki 67 , p 53 , and Bcl 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Unfortunately , none of the molecular markers identified in breast tumors is recommended for a use in routine , with the exception of ER and HER 2 respectively predictors of response to hormone therapy and Herceptin . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : To investigate the impact of human epidermal growth factor receptor ( HER ) 1 and HER 2 gene amplification on endocrine therapy responsiveness , a fluorescence in situ hybridization ( FISH ) study was conducted on tumor samples from 305 postmenopausal patients with stage 2 and 3 estrogen receptor ( ER ) positive ( ER > or = 10 % ) breast cancers treated on two independent neoadjuvant endocrine therapy trials . ^^^ CONCLUSION : Neoadjuvant letrozole is clinically effective in ER positive HER 2 FISH positive tumors , indicating sensitivity to short term estrogen deprivation . ^^^ However , continued proliferation despite ongoing letrozole or tamoxifen treatment in the majority of ER positive HER 2 FISH positive samples ( 88 % ) could imply therapeutic resistance that may manifest later in the clinical course of the disease . ^^^ Estrogen independent proliferation is present in estrogen receptor HER 2 positive primary breast cancer after neoadjuvant letrozole . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Chromogenic in situ hybridization to detect HER 2 / neu gene amplification in histological and ThinPrep processed breast cancer fine needle aspirates : a sensitive and practical method in the trastuzumab era . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER , PR , and HER 2 status as well as clinical information regarding treatment and outcome were correlated . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
When eIF4E , histological grade , tumor stage , ER , PR , Her 2 status and the levels of VEGF , IL 8 , MVD were included in a multivariate Cox regression analysis , eIF4E emerged as an independent prognostic factor for breast cancer ( P = 0 . 001 ) , along with stage ( P = 0 . 005 ) , node status ( P = 0 . 046 ) , and MVD ( P = 0 . 004 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HER 2 / neu oncogene protein , epidermal growth factor receptor , progesterone receptor , and estrogen receptor were examined immunohistochemically in specimens of normal and neoplastic endometrium . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
AIMS : Recently , an immunohistochemical panel comprising antibodies against HER 2 , oestrogen receptor ( ER ) , epidermal growth factor receptor ( EGFR ) and cytokeratin ( CK ) 5 / 6 was reported to identify basal like breast carcinomas , as defined by cDNA microarrays . ^^^ Immunohistochemistry with antibodies for HER 2 , ER , EGFR , CK5 / 6 , CK 14 and p 63 was performed according to standard methods . ^^^ All but six cases ( 91 % ) showed the typical immunoprofile of basal like tumours ( ER and HER 2 , EGFR+ and / or CK5 / 6+ ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The distribution of Id 4 signal was assessed in relation to that of estrogen receptor ( ER ) in all samples and correlated with the Her 2 status of the carcinomas . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Breast cancers with brain metastases are more likely to be estrogen receptor negative , express the basal cytokeratin CK5 / 6 , and overexpress HER 2 or EGFR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , overexpression of HER 2 / neu was associated with several poor prognostic features ( younger patient age , premenopause , negative estrogen receptor status , negative progesterone receptor status , and high nuclear grade ) in the subset of IDC combined with DCIS . ^^^ With one exception ( negative estrogen receptor status ) these associations were lost in IDC not combined with DCIS , also suggesting that the role of HER 2 / neu changes during the progression of human breast cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CONCLUSION : Overexpression of HER 2 / neu is associated with poor clinical outcome in a subset of node negative patients with small , ER positive , predominantly invasive tumors and may play a role in resistance to adjuvant chemotherapy . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
High HER 2 / neu expression also was associated with absence of estrogen receptor ( p less than 0 . 005 ) and with increased mortality from cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Therefore , using digital image processing , we compared the correlation between and the prognostic value of ( a ) quantitative immunohistochemical HER 2 / neu protein expression and ( b ) clinical , morphometric , and flow cytometric DNA ploidy features ; histologic grade ; and biochemically assessed estrogen receptor content . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Correlations with estrogen receptor labeling yielded differences significant inversely for both Her 2 / neu protein ( p less than 0 . 02 ) and epidermal growth factor receptor ( p less than 0 . 01 ) . ^^^ There were eight cases positive for both Her 2 / neu protein and epidermal growth factor receptor , four of six cases with negative estrogen receptor , four of six cases with negative estrogen receptor , six of six cases aneuploid , and five of six cases with an elevated S phase . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In contrast , progestins did not change HER 2 / neu mRNA or protein levels in E 2 primed MCF 7 cells that contain high levels of PR ; in T47D cells , which contain low levels of ER and high levels of PR , addition of E 2 or the progestin R 5020 or the antiprogestin RU 38 , 486 had no significant effect on HER 2 / neu mRNA or protein levels over 6 days of treatment . ^^^ In MCF 7 cells , which contain high levels of estrogen receptor and an estradiol ( E 2 ) inducible progesterone receptor ( PR ) , 1 nM E 2 caused a rapid drop in HER 2 / neu mRNA ( 4 . 8 kilobases ) , to 40 % of control values by 6 h , and a more gradual decrease in HER 2 / neu protein , to 50 % by 24 h . ^^^ These characteristics suggest that the observed modulation of HER 2 / neu is an estrogen receptor mediated process . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Ploidy , S phase fraction , Ki 67 staining , estrogen receptor ( ER ) , progesterone receptor ( PR ) , and the expression of HER 2 / neu and epidermal growth factor receptor ( EGFR ) were evaluated in these tumors . ^^^ A higher percentage of comedo invasive carcinomas demonstrated aneuploidy 71 % ; p = 0 . 0158 ) , elevated levels of S phase fraction ( 75 % ; p = 0 . 0016 ) and Ki 67 staining ( 55 % ; p = 0 . 0512 ) , overexpression of HER 2 / neu oncogene ( 47 % ; p = 0 . 0011 ) , and were ER negative ( 35 % ; p = 0 . 0148 ) , PR negative ( 47 % ; p = 0 . 0073 ) when compared to noncomedo invasive carcinomas . ^^^ In invasive tumors , comedo carcinomas are associated with poor prognostic factors , including higher ploidy , S phase fractions , Ki 67 staining , negative ER and PR status , poorer differentiation , larger tumors , and presence of HER 2 / neu oncogene overexpression . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Time resolved immunofluorometric procedures were used to quantify both p 53 protein and PSA in 200 breast tumour extracts , which were also assayed for oestrogen ( ER ) and progesterone receptors ( PGR ) , epidermal growth factor receptors ( EGFR ) , cathepsin D and HER 2 / neu , and characterised for S phase fraction and DNA ploidy . ^^^ Contingency tables indicated significant negative associations between the status of p 53 and that of ER ( P = 0 . 003 ) and PGR ( P = 0 . 001 ) and between PSA and S phase fraction ( P = 0 . 012 ) , and positive associations between p 53 and EGFR ( P = 0 . 017 ) , HER 2 / neu ( P = 0 . 008 ) , S phase fraction ( P = 0 . 001 ) and aneuploidy ( P = 0 . 007 ) , and between PSA and both ER ( P = 0 . 061 ) and PGR ( P = 0 . 010 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It does not appear to express Her 2 / neu protein , estrogen receptor , nor the CA 125 tumor marker . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Increased expression of the HER 2 / neu oncogene in breast cancer correlates with decreased estrogen receptor concentration and seems to be an important prognostic factor . ^^^ Thus , there was a statistically significant correlation of cytolytic effector cell function with HER 2 / neu expression of the tumor ( P = 0 . 003 ) , and HER 2 / neu overexpression correlated with a negative estrogen receptor status ( P = 0 . 005 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
One hundred and nine primary breast cancers were analyzed to assess the presence of the HER 2 / neu gene product ( p 185 ) , the oestrogen ( ER ) and the progesterone ( PR ) receptors , and the total cathepsin D status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In this study we investigated whether tamoxifen administration affects the histopathological characteristics of cervical cancer and the expression of ER , PgR , HER 2 / neu and p 53 protein . ^^^ Pre and post tamoxifen biopsies were evaluated using slides stained with hematoxylin and eosin and immunostained ( ER , PgR , HER 2 / neu , p 53 , PCNA , keratin , heat shock protein 27 , 000 daltons ) . ^^^ No obvious changes were observed in ER , HER 2 / neu and p 53 proteins . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining for p 53 , HER 2 / neu , estrogen receptor , progesterone receptor , and epidermal growth factor receptor was performed on frozen sections from 100 primary endometrial cancers . ^^^ With univariable analysis , race , histologic type , stage , grade , myometrial invasion , estrogen receptor , progesterone receptor , ploidy , p 53 and HER 2 / neu were predictive of the presence of persistent or recurrent disease . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Concentrations of cathepsin D did not correlate with age or with concentrations of HER 2 / neu oncoprotein , estrogen receptor , or epidermal growth factor receptors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fine needle aspirates ( FNA ) from 106 high risk women and 25 low risk women were evaluated for overexpression of estrogen receptor ( ER ) , epidermal growth factor receptor ( EGFR ) , mutant p 53 , and HER 2 / neu by immunocytochemistry , and for aneuploidy by image analysis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : Our purpose was to compare survival , age , tumor size , nodal status , estrogen receptor ( ER ) and progesterone receptor ( PgR ) status , histologic type , S phase fraction , DNA ploidy status , HER 2 / neu protein expression , and p 53 protein status , along with systemic treatment , in a large group of white , black , and Hispanic U . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Estrogen receptor , progesterone receptor , and HER 2 / neu protein in breast cancers from pregnant patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In addition , immunohistochemistry was done for ER , PgR , pS 2 , heat shock protein 27 ( hsp 27 ) , and HER 2 / neu on 12 of the 15 tumors . ^^^ Estrogen receptor , progesterone receptor , and HER 2 / neu protein in breast cancers from pregnant patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HER 2 / neu copy number > or = 3 correlated significantly with pathologic stage of disease , number of axillary nodes with tumor , histologic type , and absence of ER and PgR . ^^^ In Cox multivariate analysis , HER 2 / neu copy number > or = 3 was associated with shorter DFS , independent of nodal status , ER level , and tumor size . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS Reactions in comedo carcinomas were significantly negative for estrogen receptor and progesterone receptor , and positive for p 53 and HER 2 / neu more often than the noncomedo variant . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a prospective pilot study , we performed breast fine needle aspirations ( FNAs ) on 213 high risk and 30 low risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor ( ER ) , epidermal growth factor receptor ( EGFR ) , p 53 and HER 2 / neu . ^^^ Overexpression of ER and HER 2 / neu occurred in 8 % and 19 % , respectively of high risk women ; nc low risk women had these abnormalities . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A logical therapeutic approach for patients who are ER positive and overexpress HER 2 / neu may be to block both the ER and the HER 2 / neu pathways . ^^^ In our study , we used both the MTT tetrazolium dye assay and 3H thymidine incorporation to measure the effects of the anti estrogen Tamoxifen or the 4D5 anti HER 2 / neu antibody alone or in combination on the growth of BT 474 human breast cancer cells which express ER and overexpress HER 2 / neu . ^^^ This simultaneous interruption of both the ER and the HER 2 / neu pathways may be relevant in the clinical treatment of patients who are both ER positive and overexpress HER 2 / neu . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The total cellular p 185 ( HER 2 / neu ) protein ( p 185 ) content was measured by ELISA in 346 invasive primary breast cancers , and the results were compared with those of estrogen ( ER ) and progesterone ( PR ) receptors , pS 2 and Cathepsin D ( Cat D ) content . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The association between the incidence of ALNM and 11 clinical / pathologic factors ( size , lymph / vascular invasion , nuclear grade , S phase , ploidy , palpability , age , estrogen receptor status , progesterone receptor status , HER 2 / neu , and histology ) was analyzed by univariate and , when significant , by multivariate analysis . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no significant correlation of HER 2 / neu amplification with , age , menopausal status , the number of positive nodes , tumor size , estrogen receptor , however , amplification of HER 2 / neu gene was strongly correlated with nodal status ( p = 0 . 0049 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a prospective pilot study , we performed breast fine needle aspirations ( FNAs ) on 224 high risk and 30 low risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor ( ER ) , epidermal growth factor receptor ( EGFR ) , p 53 and HER 2 / neu . ^^^ Overexpression of ER and HER 2 / neu occurred in 7 and 20 % of high risk women but in none of the low risk subjects . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MARY 10 was estrogen receptor , progesterone receptor , Her 2 / neu negative and p 53 , epidermal growth factor receptor positive . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The primary tumors of these cases were then studied using immunohistochemical staining to evaluate the potential prognostic value of tumor markers such as estrogen receptor ( ER ) , progesterone receptor ( PR ) , tumor suppressor gene p 53 , HER 2 / neu oncogene , and multi drug resistance gene ( MDR ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In a prospective random fine needle aspiration ( FNA ) study of women at high risk of development of breast cancer , we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia , as well as abnormalities of several cellular biomarkers ( DNA ploidy ; immunocytochemical expression of p 53 , EGFR , ER , and / or Her 2 / neu ) , were more prevalent in high risk women than in low risk controls . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : An association between the overexpression of proto oncogene HER 2 / neu and resistance to tamoxifen in estrogen receptor ( ER ) positive primary and metastatic breast cancer has been suggested . ^^^ We examine a possible interaction between HER 2 / neu or p 53 expression and tamoxifen effectiveness in patients with ER positive , node positive disease treated with cyclophosphamide , doxorubicin , and fluorouracil in a large adjuvant chemotherapy trial ( Cancer and Leukemia Group B [ CALGB ] 8541 ) . ^^^ PATIENTS AND METHODS : CALGB 8541 assessed HER 2 / neu expression in patients with ER positive disease by immunohistochemistry ( IHC ) and fluorescent in situ hybridization ( FISH ) and amplification by differential polymerase chain reaction ( PCR ) . ^^^ RESULTS : HER 2 / neu status was available for 651 patients with ER positive disease ; 650 , 608 , and 353 patients were assessed by IHC , PCR , and FISH , respectively . ^^^ CONCLUSION : Disease free and overall survival benefit of tamoxifen in patients with ER positive , node positive breast cancer does not depend on HER 2 / neu or p 53 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : To determine the prognostic value of the urokinase plasminogen activation system , contents of uPA , uPAR , and PAI 1 were measured in extracts of endometrial cancer tissue using ELISAs . uPA , uPAR , and PAI 1 levels were determined in 91 , 54 , and 92 extracts , respectively , and correlated with tumor histology , stage , grade , lymph node involvement , prevalence of metastasis , and recurrence as well as with estrogen ( ER ) , progesterone ( PR ) , epidermal growth factor ( EGFR ) receptor and HER 2 / neu contents . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The objective of this study was to assess the degree of expression and prognostic value of estrogen receptors ( ER ) , progesterone receptors ( PR ) , androgen receptors ( AR ) , bcl 2 , p 53 , HER 2 / neu , cyclin D 1 , and MIB 1 in a cohort of male breast carcinoma patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
ER positive or negative status had no significant impact on plasma HER 2 / neu in either ethnic group . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In many studies , the amplification of the HER 2 / neu gene was the most important variable determining outcome , independent of other variables , such as tumor size and estrogen receptor status . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Importantly , this effect was independent of expression levels of p 53 , ERalpha , HER 2 / neu , bag 1 , and BRCA 1 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Many genes have been selected as targets for antisense therapy , including HER 2 / neu , PKA , TGF alpha , EGFR , TGF beta , IGFIR , P 12 , MDM 2 , BRCA , Bcl 2 , ER , VEGF , MDR , ferritin , transferrin receptor , IRE , C fos , HSP 27 , C myc , C raf and metallothionein genes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry was carried out in 58 / 74 carcinomas by using a panel of monoclonal and polyclonal antibodies against estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , Bcl 2 , Bax , Fas and DNA fragmentation factor ( DFF ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The present study aimed to carry out the comparative analysis of the molecular markers expression ( P 53 , Ki 67 , Her 2 / neu , Bcl 2 , Bax , ER , FasL and CD 95 ) at the cytologic and the correspondent histologic samples . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
CONCLUSION : Patients with ER ( + ) and serum HER 2 / neu positive metastatic breast cancer are less likely to respond to hormone treatment and have a shorter duration of response than ER ( + ) and serum HER 2 / neu negative patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no significant difference in estrogen receptor , progesterone receptor or Her 2 / neu status , ploidy , or DNA index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Interestingly , significant associations were found between CTGF expression versus stage , tumor size , lymph node status , and age at diagnosis ; WISP 1 mRNA levels versus stage , tumor size , lymph node , and HER 2 / neu overexpression ; and CYR 61 expression with stage , tumor size , lymph node , age , and estrogen receptor expression . ^^^ Furthermore , multivariate classification tree model analysis showed that stage and lymph node involvement were important for predicting CTGF expression in breast cancers ; the stage , age , and HER 2 / neu status were key factors for WISP 1 expression ; and the stage , age , and estrogen receptor were valuable predictors for CYR 61 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunomicroscopy showed strong reactivity for estrogen receptor ( ER ) , progesterone receptor ( PR ) and gross cystic disease fluid protein 15 ( GCDFP 15 ) , and was negative for Her 2 / neu ( erb 2 ) and cytokeratin 20 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : To determine whether a signet ring carcinoma was a primary malignancy of the gastrointestinal tract metastatic to the breast or vice versa , histochemical analysis was performed for Her 2 / NEU , gross cystic disease fluid protein 15 , estrogen receptor , progesterone , carcinoembryonic antigen , cytokeratin 7 , and cytokeratin 20 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It has been implicated in mammary carcinogenesis through its regulation of HER 2 / neu proto oncogene and estrogen receptor gene The hAP 2gamma gene is located on human chromosome 20q13 . 2 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The authors performed immunohistochemical analysis of estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , and Ki 67 in 25 cases , including 14 from which > 1 tumor was available to perform comparative immunohistochemical analysis . ^^^ Comparative immunohistochemical analysis of separate tumors was equivalent with regard to ER , PR , and HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin embedded blocks of breast cancer tissue biopsies were received from different hospitals and Pathology Laboratories located throughout the island specifically for routine analysis of steroid receptor ( ER / PR ) and / or HER 2 / neu expression . ^^^ CONCLUSIONS : There is a lower prevalence of estrogen receptor in the breast cancer biopsies of women living in Puerto Rico than their USA counterparts , but similar prevalence of progesterone receptor status and HER 2 / neu protein over expression . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Expression levels of HIF 1alpha , HER 2 / neu , estrogen receptor , and progesterone receptor were analyzed in 150 patients with early stage breast carcinoma by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Three phases of tumor progression are described that involve increases in HER 2 / neu expression , de regulation of estrogen receptor expression and increases in apoptosis which in concert determine the phenotype of drug resistance to Tam . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PATIENTS AND METHODS : The expression of HER 2 / neu protein and estrogen receptor ( ER ) in 217 primary breast cancers was assessed immunohistochemically using the HercepTest and an anti ER monoclonal antibody . ^^^ RESULTS : HER 2 / neu ( 3+ ) overexpression and ER expression were seen in 31 . 8 % ( 69 out of 217 ) and 47 . 5 % ( 103 out of 217 ) of the patients , respectively . ^^^ The survival of the HER 2 / neu ( 3+ ) group was significantly lower than other groups ( p = 0 . 0134 ) , especially in the ER ( + ) patients ( p = 0 . 0229 ) . ^^^ However , in the ER ( + ) patients , HER 2 / neu overexpression had no significant effect . ^^^ The effects of HER 2 / neu overexpression and ER expression on the efficacy of the ACT and AET were analyzed by patient survival . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
A close relationship was observed between these 2 assays as applied to the TMA ( 95 . 4 % concordance : 95 % CI , 2 . 2 % to 6 . 8 % ; P < 0 . 0001 ) , and both HER 2 / neu gene amplification and protein overexpression were strongly associated with tumor grade , estrogen receptor status , and progesterone receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 , HER 2 / neu , and Proliferating Cell Nuclear Antigen ( PCNA ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of estrogen receptor , progesterone receptor , Ki 67 , and Her 2 / neu oncogene was analyzed and correlated with Cox 2 status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The results were analyzed for correlations with immunohistochemically determined ER , PR , and HER 2 / neu expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Despite a general inverse association between HER 2 / neu amplification / overexpression and estrogen receptor ( ER ) and / or progesterone receptor ( PR ) expression , a fraction of patients are both HER 2 / neu and hormone receptor ( HR ) positive . ^^^ To better understand the relationship between HER 2 / neu positivity and HR expression , we analyzed HER 2 / neu , ER , and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients . ^^^ METHODS : HER 2 / neu and ER / PR expression was analyzed by enzyme linked immunosorbent assay ( ELISA ) and enzyme immunoassay ( EIA ) , respectively , in 14 human breast cancer cell lines , some of which had been transfected with the HER 2 / neu gene . ^^^ Associations between HER 2 / neu and ER / PR expression were analyzed using Spearman ' s rho correlation and the chi square test , and absolute levels were compared using the Mann Whitney U test . ^^^ RESULTS : HR positive human breast cancer cell lines transfected with the HER 2 / neu gene expressed statistically significantly lower levels of ER and PR than parental lines . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin embedded blocks of the primary tumor were processed for immunohistochemical staining of estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 , cyclin D 1 , and HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Ki S 7 further emerged as an independent predictor of tumour regression ( OR=3 . 34 , CI : 1 . 41 7 . 93 , P=0 . 006 ) , together with tumour size of less than 40 mm ( OR=3 . 82 , CI : 1 . 58 9 . 25 , P=0 . 002 ) and negative oestrogen receptor ( ER ) status ( OR=3 . 35 , CI : 1 . 43 7 . 86 , P=0 . 005 ) , in a multivariate analysis including tumour size , SBR grade , ER and PR status , Ki 67 , p 53 and Her 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This was comprised of a critical histologic review and immunohistochemical evaluation to determine the status of prognostic and predictive markers including estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , Ki 67 , and p 53 . ^^^ Of the 25 patients tested , ER positivity was found in 7 patients , PR positivity was found in 6 patients , HER 2 / neu positivity was found in 7 patients , and p 53 positivity was found in 12 patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin embedded sections were immunohistochemically evaluated for expression of HER 2 / neu , estrogen receptor ( ER ) , progesterone receptor ( PR ) , bcl 2 , cyclin D 1 , Ki 67 , and p 53 . ^^^ Of note , HER 2 / neu expression was correlated with high nuclear grade ( P = 0 . 004 ) , necrosis ( P = 0 . 06 ) , and ER and PR negativity ( P = 0 . 01 and P = 0 . 03 , respectively ) in the combined population . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Signal transduction by growth factor receptors , including HER 2 / neu and epidermal growth factor ( EGF ) receptors , can alter the phosphorylation of estrogen receptor ( ER ) and the biologic activity of ER dependent signaling networks both in the presence and in the absence of estrogenic ligands . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical analysis for estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , C kit , Abl , and PDGFR beta expression were performed . ^^^ Immunohistochemical analyses revealed that 24 % expressed ER or PR , 19 % expressed HER 2 / neu , and none expressed C kit . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The estrogen receptor and HER 2 / neu were among the earliest targets investigated , ultimately leading to the widespread use of tamoxifen and trastuzumab , respectively , in the treatment of breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We identified 69 ER negative and 19 ER positive breast cancer cases with concurrent immunohistochemical prognostic panels ( ER , PR , HER 2 / neu , Ki 67 , and p 53 ) ; immunohistochemical analysis was performed for AR using standard techniques . ^^^ In ER negative tumors , AR was associated with increased age ( P = . 02 ) , postmenopausal status ( P < . 001 ) , tumor grade ( P = . 03 ) , tumor size ( P = . 03 ) , and HER 2 / neu overexpression ( P = . 003 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Correlations involving HER 2 / neu status , estrogen receptor ( ER ) and progesterone receptor ( PR ) status , tumor grade , patient age , lymph node involvement , and tumor size were evaluated using the Mantel Haenszel chi square test and the Spearman correlation . ^^^ RESULTS : HER 2 / neu overexpression was correlated significantly with negative ER ( P = 0 . 0001 ) and PR status ( P = 0 . 0001 ) , Grade 3 ( G 3 ) lesions ( P = 0 . 0001 ) , and young age ( P = 0 . 006 ) . ^^^ The likelihood of HER 2 / neu positivity in a patient with positive ER and PR status and G1 / G2 disease was approximately 6 . 1 % . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Serum concentration of soluble her 2 / neu was correlated with tumor size ( P < 0 . 05 ) , but not with axillary lymph nodes nor estrogen receptor status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Paraffin embedded tumor specimens from the chest wall recurrences were available for 43 patients and were constructed into tissue microarrays for immunohistochemical staining of estrogen receptor , progesterone receptor ( PR ) , p 53 , HER 2 / neu , and cyclin D . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
No correlation was noted between FAS overexpression and estrogen receptor ( ER ) or progesterone receptor ( PR ) status , whereas a positive correlation was found between high levels of FAS expression and the amplification and / or overexpression of HER 2 / neu oncogene . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
HER 2 / neu expression was related to axillary lymph node metastasis ( P=0 . 014 ) , inflammatory infiltrates ( P=0 . 004 ) , and the absence of oestrogen ( ER ) ( P=0 . 0026 ) and progesterone ( P=0 . 01 ) receptors ( PR ) . p 53 expression was related to lymph node involvement ( P=0 . 03 ) , necrosis ( P=0 . 036 ) , absence of ER ( P=0 . 028 ) and PR ( P=0 . 065 ) . p 53 was not associated with outcome . ^^^ ER positive patients treated with adjuvant tamoxifen had shorter DFS and OS when they were HER 2 / neu positive . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An immunohistochemical analysis was performed to determine estrogen receptor and progesterone receptor expression and p 53 and HER 2 / neu overexpression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In both the ovarian surface and inclusion cyst epithelia , the percentage of cells was determined that stained positively for Ki 67 , p 21 , p 27 , p 53 , cyclin A , cyclin D 1 , bcl 2 and the presence of HER 2 / neu , oestrogen ( ER alpha ) and progesterone receptors ( PR ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The expression status of the estrogen receptor alpha ( ERalpha ) and that of the epidermal growth factor receptor Her 2 / neu frequently correlate inversely in breast cancers . ^^^ While ERalpha dependent cancers respond to antiestrogen therapy , Her 2 / neu overexpressing cancers typically display resistance to antiestrogens and poor prognosis . ^^^ In this report we have explored the mechanism linking the loss of expression of ERalpha in breast cancer cells with overexpression of Her 2 / neu , which signals constitutively via a phosphatidylinositol 3 kinase ( PI3K ) / Akt kinase pathway . ^^^ Thus , FOXO3a represents an important intracellular mediator of ERalpha expression , suggesting possible therapeutic intervention strategies for Her 2 / neu overexpressing refractory breast tumors . . ^^^ Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her 2 / neu / phosphatidylinositol 3 kinase / Akt signaling pathway . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
These include estrogen receptor ( ER ) , heat shock proteins : 70 and 90 , Apaf 1 , Her 2 / neu , and paxillin . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical staining was performed for ER alpha , estrogen receptor ER beta , progesterone receptor ( PR ) , pS 2 and her 2 / neu in 59 cases of ductal carcinoma in situ ( DCIS ) . ^^^ Estrogen receptor alpha and beta , progesterone receptor , pS 2 and HER 2 / neu expression delineate different subgroups in ductal carcinoma in situ of the breast . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Menopausal status , estrogen receptor status , progesterone receptor status [ absent ( 0 % of the cells positive ) versus expressed ] , clinical tumor size , histologic grade , Ki 67 , Her 2 / neu expression , and type and route of chemotherapy were considered . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An association of reduced PTEN expression with shorter relapse free survival and disease specific survival in stage 1 patients was still observed after stratification by stage , axillary lymph node status , tumor size , grade , and expression of ER alpha , progesterone receptor , and Her 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Third , we explore the role that FAS exhibits in cancer evolution by specifically regulating cancer related proteins such as Her 2 / neu oncogene and estrogen receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : Seven out of eight ESCC were negative for estrogen receptor as well as for HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical analysis was used to identify the presence of estrogen receptor ( ER ) and progesterone receptor and the overexpression of HER 2 / neu oncogene . ^^^ Compared with controls , OR estimates for breast cancer by parity and age at first birth were significantly associated with ER and / or HER 2 / neu tumor status by Wald test ( P < 0 . 05 ) . ^^^ Our findings support the hypothesis that some breast cancer risk factors differ by ER and HER 2 / neu tumor marker subtypes . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
On this basis the authors performed immunohistochemical staining for estrogen receptor ( ER ) alpha and ER beta , progesterone receptor ( PR ) , pS 2 , her 2 / neu , and AR in 59 cases of DCIS ( 24 low grade , 5 intermediate grade , 30 high grade ) . ^^^ The authors conclude that AR expression in DCIS is not correlated with nuclear grading and with the expression of other known endocrine related markers such as ER alpha and beta , PR , pS 2 , and her 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Histologic and nuclear grades , presence of tumor necrosis and angiolymphatic invasion ( ALI ) , and estrogen receptor ( ER ) , progesterone receptor ( PR ) , and HER 2 / neu expression were assessed in core biopsies of 55 patients with invasive carcinomas . ^^^ Higher histologic and nuclear grades , ER , PR status , and HER 2 / neu overexpression were not associated with pCR . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tumor cells were positive for bcl 2 , neuron specific enolase , synaptophysin , CAM 5 . 2 and cytokeratin AE1 / 3 , but negative for LCA , CD 30 , HMB 45 , chromogranin A , estrogen receptor , progesterone receptor , Her 2 / neu and CD 99 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RON+ / MET+ and RON / MET+ tumors resulted in a large risk increase for 10 year disease free survival after adjusting for tumor size , histologic grade , estrogen receptor , bcl 2 , HER 2 / neu , and p 53 status by multivariate Cox analysis ( risk ratio , 5 . 3 ; P = 0 . 001 and risk ratio , 3 . 76 ; P = 0 . 005 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Comparison of HER 2 / neu , ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma . ^^^ We attempted to compare the pattern of HER 2 / neu , ER and PCNA in premenopausal and postmenopausal patients with breast carcinoma to identify potential biological differences . ^^^ Five hundred and forty eight samples from 318 premenopausal and 230 postmenopausal women with invasive ductal carcinoma of the breast were evaluated for HER 2 / neu , ER and PCNA expression by immunohistochemistry . ^^^ In contrast , HER 2 / neu expression was found to be significantly associated with ER negativity in the two groups ( p < 0 . 05 in premenopausal , p < 0 . 001 in postmenopausal patients ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Using pretreatment biopsy materials , immunohistochemical studies were performed for estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , p 53 , and Ki 67 . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Receptors for ER , PR and HER 2 / neu were analysed by immunohistochemistry ( IHC ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The primary objective of this study was to evaluate the relative prevalence of estrogen receptor negative contralateral breast cancer to the first primary cancer and to assess the correlation between the relative overexpression of HER 2 / neu in the first primary cancer and contralateral breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
RESULTS : Hormone receptor negative breast cancers were more often HER 2 / neu positive than hormone receptor positive cancers , both for ER ( 28 . 7 % 5 6 . 8 % ) and PR ( 19 . 9 % 5 5 . 9 % ) . ^^^ In multivariate analysis , both ER , PR , and tumour grade were independently associated with HER 2 / neu . ^^^ CONCLUSIONS : ER , PR , and tumour grade are independent predictors for HER 2 / neu overexpression in women with primary operable breast cancer . ^^^ ER and PR are negatively associated with HER 2 / neu , whereas tumour grade is positively associated with HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We compared patient age , tumor size , axillary lymph node status , and the expression of estrogen receptor ( ER ) , progesterone receptor ( PR ) , deleted in colon cancer ( DCC ) , HER 2 / neu , and p 53 . ^^^ Compared with the non mucinous type , mucinous carcinoma specimens have more DCC expression ( 100 % vs 48 . 7 % ; p = 0 . 0027 ) and more ER expression ( 90 . 9 % vs 26 . 9 % ; p = 0 . 0023 ) , but less HER 2 / neu overexpression ( 0 % vs 38 . 1 % ; p = 0 . 0302 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of our study was to assess , by immunohistochemistry , COX 2 expression in ductal carcinoma in situ ( DCIS ) and its possible correlation with HER 2 / neu , vascular endothelial growth factor ( VEGF ) expression and other common immunohistochemical parameters ( p 53 , ER , PGR , Ki 67 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
PURPOSE : HER 2 / neu and estrogen receptor ( ER ) are critical in the biology of breast carcinoma , and both are validated therapeutic targets . ^^^ EXPERIMENTAL DESIGN : ER positive , HER 2 / neu overexpressing BT 474 human breast carcinoma cells were cultured in the presence of the anti HER 2 / neu therapeutic antibody trastuzumab ( Herceptin ) , the antiestrogen tamoxifen , or both . ^^^ These results suggest that combined inhibition of ER and HER 2 / neu signaling may represent a powerful approach to the treatment of breast cancer . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The purpose of this study was to determine if any relationship exists between Her 2 / neu gene amplification and estrogen receptor ( ER ) , progesterone receptor ( PR ) , MIB 1 , grade , size and age in female breast cancer . ^^^ Her 2 / neu gene was amplified in 37 ( 10 % ) out of 379 ER positive cases and in 39 ( 28 % ) out of 139 ER negative cases . ^^^ Comparison of these frequencies using chi square test revealed statistically significant correlation between Her 2 / neu amplification and ductal versus lobular carcinoma ( p < 0 . 0003 ) , ER ( p=0 . 0001 ) and PR ( p < 0 . 0001 ) negative tumors , over expression of MIB 1 ( p < 0 . 0005 ) and high tumor grade ( p=0 . 0009 ) , while size of the tumor ( p=0 . 08 ) and age of the patients ( p=0 . 67 ) were not statistically significant . ^^^ Correlation was found between Her 2 / neu amplification and tumor type , high histological grade , ER and PR negative tumors , and high proliferative MIB 1 index . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We studied the immunohistochemical expression of HER 2 / neu , epidermal growth factor receptor ( EGFR ) , vascular endothelial growth factor ( VEGF ) , cyclooxygenase 2 ( COX 2 ) , estrogen receptor ( ER ) , and progesterone receptor ( PR ) in uterine cervical small cell and large cell neuroendocrine carcinomas ( SCNECs and LCNECs ) from 24 patients seen at The University of Texas M . ^^^ Expression of HER 2 / neu , epidermal growth factor receptor , vascular endothelial growth factor , cyclooxygenase 2 , estrogen receptor , and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix : a clinicopathologic and prognostic study . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Thus far , there is no specific therapy for the ER negative and HER 2 / neu resistant groups , which are among the subset of aggressive tumors . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
COX was inversely correlated with estrogen receptor ( P = 0 . 045 ) and progesterone receptor ( P = 0 . 028 ) , and positively correlated with HER 2 / neu ( P = 0 . 003 ) . ^^^ Positive COX correlated with other markers of poor outcome , including a shorter time to local relapse , negative estrogen receptor / progesterone receptor , and positive Her 2 / neu status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We have assessed a wider spectrum of tumour markers ( ER , progesterone receptor ( PgR ) , p 53 , Ki 67 and HER 2 / neu ) and compared extent and staining intensities at the primary tumour and the involved ALN on specimens of 22 cases with invasive ductal breast cancer . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Their mean disease free interval was 28 . 5 months , HER 2 / neu and ER and / or PgR positive was shown in 2 and 8 cases , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Fourteen samples of human infiltrating ductal breast cancer arising from a background of ductal carcinoma in situ ( DCIS ) were analyzed for LEF 1 , estrogen and progesterone receptor ( ER and PR ) and her 2 / neu expression . in vitro , the effect of estradiol on LEF 1 protein expression was examined in several breast cancer cell lines . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The following data for each patient were collected : age , tumor size , histological grade , axillary lymph node status , overall survival , estrogen ( ER ) , progesterone ( PR ) receptor expression as well as expression of bcl 2 , Ki 67 , nm 23 , HER 2 / neu , and p 53 . ^^^ The correlation of prognostic groups according to the NPI with other prognostic and predictive factors such as age , ER , PR , p 53 , bcl 2 , Ki 67 , nm 23 , Ki 67 , Cathepsin D and HER 2 / neu on overall survival was analyzed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
There was no significant difference between the 2 groups with respect to tumor size , presence of lymphovascular invasion , estrogen receptor ( ER ) / progesterone receptor ( PR ) and HER 2 / neu status , type of breast surgery , margin status , or nuclear grade . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The data suggest estrogenic activities of E 2 and tamoxifen at ER alpha regulated pS 2 and c myc genes are in part mediated by HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
This xenograft was ER , PR , Her 2 / neu negative and p 53 , EGFR positive . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We investigated the association of estrogen receptor , progesterone receptor , Bcl 2 , HER 2 / neu , p 53 , and Ki 67 with clinicopathologic features and outcome in young women with breast cancer . ^^^ Positive expression of estrogen receptor , progesterone receptor , bcl 2 , HER 2 / neu , p 53 , and Ki 67 were 42 . 7 % , 48 . 5 % , 35 . 6 % , 28 . 0 % , 36 . 9 % , and 39 . 7 % , respectively . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The established method in prognosis of breast cancer includes detection of molecular markers , such as the estrogen receptor ( ER ) , progesterone receptor ( PR ) , and HER 2 / neu . ^^^ Flow cytometric analysis was used for the detection of ER , PR , HER 2 / neu , epidermal growth factor receptor ( EGFR ) , and E cadherin . ^^^ ER , PR , and HER 2 / neu demonstrated a weakly positive expression pattern when compared with E cadherin . ^^^ MCF10A had weak positive to almost negative expression values of ER , PR , HER 2 / neu , and E cadherin , which ranged from 3 to 13 % . ^^^ We found that ER , PR , and HER 2 / neu marker expressions in 5 out of 5 cell lines were consistent with established expression patterns . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Age , T stage , estrogen receptor status , HER 2 / neu status , grade , angiolymphatic invasion , lobular histology , tubular / mucinous histology , and the number of SLNs resected were assessed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
It is concluded that only Ki 67 , ER , PR and Her 2 / neu may be recommended for clinical use . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
MATERIALS AND METHODS : To investigate this , pre treatment biopsies from 517 patients with locally advanced breast cancer were analyzed for expression of estrogen receptor [ ER ] , progesterone receptor [ PgR ] , Her 2 / neu , epidermal growth factor receptor [ EGF R ] , p 53 , Bcl 2 and MIB 1 by immunohistochemistry [ IHC ] , and these data were compared to the pathological response after preoperative epirubicine / cyclophosphamide [ EC ] chemotherapy ( + / radiotherapy ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The most commonly used markers in clinical practice are the estrogen receptor , progesterone receptor and HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Survival was significantly greater in patients with estrogen receptor ( ER ) positive primary ( P = . 02 ) and metastatic ( P < . 004 ) tumors , Her 2 / neu positive metastases ( P = . 02 ) , < / =2 hepatic metastases ( P < . 002 ) , and age > 50 years at metastasectomy ( P = . 02 ) . ^^^ CONCLUSIONS : The ER status of the primary tumor and ER and Her 2 / neu status of hepatic metastases , in addition to other clinical factors , may help select patients who would benefit from hepatic metastasectomy . . ^^^ The utility of estrogen receptor , progesterone receptor , and Her 2 / neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemical analysis of expression of VEGF , estrogen ( ER ) and progesterone receptor ( PR ) , HER 2 / neu , and Ki 67 was performed in 233 breast cancers . ^^^ In postmenopausal patients tumors with a higher expression of VEGF were associated not only with ER negative but also with HER 2 / neu positive tumor cells . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Immunohistochemistry was carried out by using antibodies against estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , p 53 and cathepsin D . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Breast tissue specific and at the same time oncologically important immunohistochemical markers : estrogen and progesterone receptors ( ER , PR ) , oncoprotein HER 2 / neu , protein PS 2 , markers of angiogenesis CD 31 and mitotic activity Ki 67 were investigated . ^^^ In the 1 group of the estrogen and progesterone receptors ( ER , PR ) and protein PS 2 was lower , in contrast to the expression of HER 2 / neu , CD 31 and Ki 67 were higher then in the elder group . ^^^ Expression of the estrogen and progesterone receptors ( ER , PR ) and protein PS 2 markers was increasing with the patient age , and significant decrease of the HER 2 / neu , CD 31 and Ki 67 was observed . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An immunohistochemical ( IHC ) study of ER , PR and Her 2 / neu was conducted , followed by fluorescent in situ hybridization ( FISH ) validation for Her 2 / neu gene amplification in cases initially scored as positive 2+ with IHC . ^^^ CONCLUSION : Her 2 / neu positivity may activate ER expression through signaling kinases , and the combined target of mitogenic estrogen plus the monoclonal antibody therapy against Her 2 / neu overexpressing tumors expand chances of survival for patients in developing countries such as Kenya . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression patterns of ER alpha , PR , HER 2 / neu , and EGFR in different cell origin subtypes of high grade and non high grade ductal carcinoma in situ . ^^^ Here we refine the relationships between these 3 subtypes and the expression patterns of estrogen receptor alpha ( ER alpha ) , progesterone receptor ( PR ) , HER 2 / neu , and epidermal growth factor receptor ( ERFR ) in 53 cases of non high grade and 46 cases of high nuclear grade DCIS . ^^^ Using a panel of antibodies to ER alpha , PR , HER 2 / neu , and EGFR , along with cytokeratin ( CK ) markers ( CK5 / 6 , CK 8 , CK 14 , CK 17 , and CK 18 ) , we found that all 3 cell origin subtypes can express ER alpha and PR , and their expression is higher in non high grade DCIS than in high grade DCIS ; the expression of HER 2 / neu is associated with luminal subtype only in non high grade DCIS , but can be seen in all 3 subtypes in high grade DCIS ; the expression of EGFR is low and is present only in luminal cell subtypes in both high and non high grade DCIS . ^^^ In conclusion , the expression patterns of ER alpha , PR , HER 2 / neu , and EGFR are markedly different in different cell origin subtypes of both high grade and non high grade DCIS , suggesting that cell origin subtypes as well as nuclear grade contribute to the biological and molecular heterogeneity of DCIS . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor ( ER ) , progesterone receptor ( PR ) , p 53 , Her 2 / neu ( HER ) , tumor characteristics , type of surgery , use of radiation or tamoxifen , and site of recurrence . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
IH included estrogen receptor ( ER ) , progesterone receptor ( PR ) , Her 2 / neu and Ki 67 ( MIB 1 ) in all 13 cases . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Pathological findings were as follows : invasive ductal carcinoma ( scirrhous type ) , 2 . 2 cm in size , histological grade 3 , positive invasion to the lymphatic and blood vessels , negative nodal status ( 0 / 11 ) , negative ER / PgR status , and overexpression of HER 2 / neu . ^^^ Pathological findings were as follows : invasive ductal carcinoma ( scirrhous type ) , 1 . 8 cm in size , histological grade 2 , positive invasion to the lymphatic and blood vessels , negative nodal status ( 0 / 5 ) , positive ER and uncertain PgR status , and overexpression of HER 2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Carcinomas induced by neu in ovariectomized rats had down regulated estrogen receptor and progesterone receptor , while those induced by ras had only down regulated progesterone receptor . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Response rate was reduced in the presence of neu from 50 to 17 % for ER+ cases and from 26 to 0 % for ER cases . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To elucidate the frequency and biological significance of the expression of estrogen receptor ( ER ) , progesterone receptor ( PR ) , and neu oncogene in breast carcinoma , ER , PR and neu proteins were examined by immunohistochemical assay in 74 Taiwanese patients with breast carcinoma . ^^^ The neu oncoprotein was expressed in 25 . 7 % of breast carcinomas , but did not correlate with ER and PR status , tumor size , tumor grade , lymphoid infiltration , or axillary node status . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
An association between the proportion of nodes affected and the intensity of neu amplification in estadiol receptor negative ( ER ) BC was found ( P = 0 . 028 ) , which was confirmed by the multi factor analysis of variance ( P = 0 . 05 ) . ^^^ It is concluded that ( 1 ) the combination ER with neu amplification might define a new group of more aggressive BC , as is suggested by their associated nodal involvement ; ( 2 ) the linkage of myc amplifications with ER BC and high grade of neu amplification might reflect a trait of tumor aggressivity . . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Both neu gene overexpression and loss of estrogen receptor ( ER ) expression have been found to correlate with a poor prognosis in human breast cancer . ^^^ Studies of breast tumor specimens have suggested that these two factors are not independent , leading us to hypothesize that there is a causal relationship between loss of ER and overexpression of neu . ^^^ In this report , we confirm that ER can negatively regulate the expression of the neu gene protein product , p185neu , in two ER positive but not an ER negative breast cancer cell line ( s ) . ^^^ We demonstrate that the expression of ER in these cell lines is sufficient to confer the ability to respond to estradiol by down regulating neu expression at both the protein and RNA levels . ^^^ Utilizing neu promoter chloramphenicol acetyltransferase constructs in transient cotransfection assays , we have also shown that this regulation occurs at the transcriptional level and requires the presence of both ER and estradiol . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Surprisingly , a relatively stronger Rb reaction was seen in some high nuclear grade tumors . p 53 positivity was found in 23 % of cases and was a significant predictor of Rb loss . p 53 also was correlated with poorly differentiated ( nuclear grade 3 ) neoplasms and neu expression but not with negative ER status . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The authors studied multiple clinical and histopathologic features , estrogen receptor ( ER ) and progesterone receptor ( PR ) status , DNA flow cytometric characteristics , and the expression of c myb , H ras , and neu oncogenes . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Several prognostic factors may help in identifying poor prognostic subgroups of stage 1 patients , including ER and PR status , flow cytometry data , nuclear grade , neu oncogene expression , and perhaps haptoglobin related protein , Cathepsin D , and Ki 67 expression . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The biologic profile of 907 infiltrating breast carcinomas was determined considering estrogen receptor ( ER ) and progesterone receptor ( PR ) , proliferation index ( PI ) and c erbB 2 / Neu expression . ^^^ In 907 infiltrating breast carcinomas , the quantitation of ER , PR , an PI was obtained with an image analysis system ( CAS 200 , Becton Dickinson Cell Analysis Systems , San Jose , CA ) ; Neu was evaluated semiquantitatively . ^^^ Seventy seven percent of tumors were ER positive , 70 % were PR positive , 58 % had a high PI , and 35 % were Neu positive . ^^^ The overall analysis indicated a direct correlation between ER and PR ( Spearmans ' rho [ rs ] = 0 . 47 , P < 0 . 001 ) and an inverse correlation between PI and ER ( rs = 0 . 39 , P < 0 . 001 ) , PI and PR ( rs = 0 . 32 , P < 0 . 001 ) , Neu and ER ( rs = 0 . 20 , P < 0 . 001 ) , and Neu and PR ( rs = 0 . 21 , P < 0 . 001 ) . ^^^ Cluster analysis , performed based on the biologic profile ( ER , PR , PI , c erbB 2 / Neu expression ) , identified two final groups of tumors with different pathologic features . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
In 50 in situ breast cancers an immunohistochemical study , evaluating estrogen ( ER ) and progesterone ( PR ) receptors , Proliferation Index ( PI ) , c erbB 2 / Neu and p 53 expression was performed . ^^^ For ER , PR , Neu and p 53 , 10 % of the positive area was used as cut off value ; 13 % was used for PI . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Proposed biomarkers to be studied include : ( a ) markers associated with neoplastic phenotypes , e . g . , excessive proliferation , alternations of nuclear morphology and angiogenesis ; ( b ) proteins likely to be required for response to the putative chemopreventive agents , e . g . , estrogen receptor , nuclear retinoid receptors ; ( c ) markers indicative of intact downstream response pathways , e . g . , progesterone receptors ; ( d ) oncogenes and tumor suppressor genes regulated by the proposed chemopreventive agents , e . g . , neu , TGF beta ; and ( e ) potential novel markers of genetic instability that could be studied in randomly obtained needle aspirates , i . e . , random chromosomal gains and losses in high risk mammary epithelium . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The present study attempts to clarify the specific contribution of cathepsin D ( CD ) and pS 2 to the progression of breast cancer ( BC ) by examining the relationship between these two factors and TNM status , tumour grade , estradiol receptors ( ER ) and the prognosis factors epidermal growth factor receptor ( EGFR ) and neu amplification in a group of 270 BC patients . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
While Western blot analysis initially indicated that GI 101A was ER , analysis of ER mRNA by RT PCR and RPA have demonstrated the expression of ER ( as well as EGF receptor and neu oncogene ) transcripts . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
STUDY DESIGN : In 99 in situ ( ISC ) and 2718 infiltrating breast carcinomas ( IC ) , biologic markers ( estrogen receptor [ ER ] , progesterone receptor [ PR ] proliferation index , cerbB 2 / NEU , p 53 , bcl 2 and DNA ploidy ) were evaluated with an image analysis system ( CAS 200 / 486 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To investigate whether adult patterns of ER and PR expression are established in mid pubertal female cynomolgus monkeys , we labeled neuroendocrine ( NEU ) neurons by microinjection of retrograde tracer into the median eminence , and then identified ER and PR by specific immunostaining in separate sets of hypothalamic sections . ^^^ ER and PR appeared in the cytoplasm and nuclei of cells identified exclusively as neurons , and retrograde tracer remained clearly visible in the cytoplasm of NEU neurons after immunostaining . ^^^ Numbers of NEU and related neurons expressing ER or PR were quantified in principal hypothalamic regions . ^^^ In the supraoptic nucleus , almost all neurons analyzed ( n = 580 ) contained ER ( 94 % ) with many also NEU ( 73 % ER + NEU ) , while lesser amounts of the neurons examined ( n = 214 ) expressed PR ( 75 % ) and were NEU ( 53 % PR + NEU ) . ^^^ In the paraventricular nucleus , most of the neurons analyzed ( n = 302 ) contained ER ( 90 % ER ; 54 % ER + NEU ) , but few of the neurons studied ( n = 269 ) contained PR ( 34 % PR ; 19 % PR + NEU ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Prognostic significance of c erbB 2 / neu amplification and epidermal growth factor receptor ( EGFR ) in primary breast cancer and their relation to estradiol receptor ( ER ) status . ^^^ The aim of this study is to evaluate the prognostic significance of c erbB 2 / neu amplification and epidermal growth factor receptor ( EGFR ) expression in primary breast cancer ( BC ) and their prognostic implications when combined with estradiol receptor ( ER ) status . ^^^ Neu , EGFR , estradiol and progesterone receptors ( ER and PR ) had a marked influence on disease free survival ( DFS ) in univariate analysis . ^^^ The EGFR + / neu / phenotype represented a sub group with an even worse prognosis with respect to DFS ( p = 0 . 0034 ) as well as EGFR + / ER tumors ( p = 0 . 005 ) . ^^^ Moreover , neu + / ER patients also had a high probability of relapse ( p = 0 . 0000 ) and death ( p = 0 . 006 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
METHODS : Estrogen and progesterone receptors ( ER and PR ) , proliferation index ( PI ) , and p 53 and neu expression were studied by immunohistochemical technique and measured by quantitative image analysis in 99 pure in situ carcinomas ( ISCp ) ; in 105 mixed invasive / in situ carcinomas , with a separate analysis of in situ ( ISCm ) and invasive ( ICm ) components ; and in 373 invasive carcinomas < or =1 cm ( IC ) . ^^^ Younger women ( < or =40 years ) with invasive carcinoma had worse biologic profiles , with lower ER ( P < 0 . 001 ) and higher PI ( P=0 . 021 ) , neu ( P=0 . 008 ) , and p 53 ( P=0 . 040 ) . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
We used Cox and log normal step wise regression to assess the multivariate effects of the following factors on DFS : age , tumor size , nodal status , histology , tumor and nuclear grade , lymphovascular and perineural invasion ( LVPI ) , ductal carcinoma in situ ( DCIS ) type , DCIS extent , DCIS at edge of tumor , ER and PgR , ERICA , adjuvant systemic therapy , ki 67 , S phase , DNA index , neu oncogene , and pRb . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
To examine the effect of removing estrogen receptor alpha ( ERalpha ) signaling on the ability of an MMTV neu / erbB2 transgene to induce mammary tumors , the neu transgene was expressed in the ERalpha knockout ( alphaERKO ) mouse , which lacks functional ERalpha . ^^^ MMTV neu females that lacked ERalpha still developed mammary tumors ; however , tumor onset was significantly delayed . ^^^ This study indicates that ERalpha is not required for mammary tumor induction by overexpression of neu / erbB2 , but plays a role in the rate of tumor onset . ^^^ Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2 / neu . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The aim of this study was to extend our previous observations on the soy modulation of biochemical parameters in 7 , 12 dimethylbenz [ a ] anthracene ( DMBA ) induced rat mammary tumors , by simultaneously investigating the expression of estrogen receptor alpha ( ERalpha ) , estrogen receptor beta ( ERbeta ) , progesterone receptor ( PR ) , apoptosis , neu , and markers of cell proliferation , such as proliferating cell nuclear antigen ( PCNA ) by immunohistochemistry . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
The following factors were examined for their univariate and multivariate effects on time to recurrence outside the breast ( DFI ) and survival from breast cancer ( DSS ) : age , weight , tumour size , estrogen receptor , progesterone receptor , histologic type , tumour grade , nuclear grade , lymphovascular invasion , overexpression of neu oncoprotein , DNA ploidy , % cells in S phase , and adjuvant therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Cell growth and apoptosis were examined in several NSCLC lines that express varying amounts of ERbeta , EGFR , and Neu but no full length ERalpha . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Loss of Pten or gain of Ras mutations during the evolution of tumors in Wnt 1 TG mice has no effect on the expression of ER , but overexpression of Neu or loss of p 53 leads to ER negative tumors . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Tests for estrogen receptor ( ER ) , progesterone receptor ( PR ) and Her2 / neu protein were performed on paraffin sections . ^^^ Among the GCC cases , ER , PR and Her2 / neu were positive in 2 ( 18 . 1 % ) , 1 ( 9 . 1 % ) and 5 ( 45 . 4 % ) cases , respectively . ^^^ Glassy cell carcinoma of the cervix : cytologic features and expression of estrogen receptor , progesterone receptor and Her2 / neu protein . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Pathology : 0 . 6 cm poorly differentiated ER , PR , and Her 2 / Neu negative IDC . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Expression of cyclooxygenase 2 ( COX 2 ) , receptors for estrogen ( ER ) , and progesterone ( PR ) , p 53 , ki 67 , and neu protein in endometrial cancer . ^^^ METHODS : Immunohistochemistry was performed on paraffin embedded sections by using rabbit polyclonal antiserum against human COX 2 , anti ER ( clone 1D5 ) , and anti PR ( clone 1A6 ) monoclonal antibodies , anti ki 67 ( clone MIB 1 ) and p 53 ( clone DO 7 ) , and polyclonal antibody anti human c erbB2 / neu . ^^^ RESULTS : There was no difference in the distribution of COX 2 , p 53 , and neu positive cases according to ER or PR positivity , while the percentage of ki 67 positive endometrial tumors was significantly higher in ER negative versus ER positive tumors ( 54 . 5 % versus 31 . 6 % , P value = 0 . 044 ) . ^^^ CONCLUSIONS : We showed that COX 2 expression is not correlated with ER , PR , p 53 , and neu , thus suggesting that COX 2 mediated activities may follow independent pathways . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
Factors used in these investigations were age , weight , tumor size , histology , tumor grade , nuclear grade , lymphovascular invasion , estrogen receptor ( ER ) , progesterone receptor ( PR ) , combined ER / PR receptor , overexpression of neu oncoprotein , DNA ploidy , S phase , and adjuvant therapy . ^^^
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA
Interacting proteins: P04626 and P03372	Pubmed	SVM Score :0.0
NA